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PREFACE 
The current thesis presents data obtained during my PhD research project, developed at 
Instituto de Medicina Molecular (iMM Lisboa) in the period of January 2012 to April 2015, under the 
supervision of Professor Doutor João Pedro Simas (Faculdade de Medicina, Universidade de 
Lisboa). My PhD work was inserted into the project «Pathogenesis of Kaposi’s sarcoma 
herpesvirus LANA», in the scope of Harvard Medical School-Portugal (HMS-PT) Program in 
Translational Research and Information, from Fundação para a Ciência e a Tecnologia (FCT). This 
was a project involving three research teams: Prof. Kenneth M. Kaye Laboratory (Harvard Medical 
School, USA), Prof. Mª Arménia Carrondo and Dr Colin E. McVey Laboratory (Instituto de 
Tecnologia Química e Biológica, Universidade Nova de Lisboa, Portugal), and Prof. J. Pedro 
Simas Laboratory (Instituto de Medicina Molecular, Faculdade de Medicina da Universidade de 
Lisboa, Portugal), the coordinator of the project. The work presented in chapter 5 of this thesis was 
performed in strict collaboration with Dr Min Tan from Prof. K.M. Kaye Lab and results presented in 
Figure 5.4 were obtained by him. In addition, the work performed in chapter 6 was developed in 
collaboration with Dr Imre Berger (European Molecular Biology Laboratory, Grenoble, France), who 
received me in his laboratory for two weeks during June 2012, where the results presented in 
Figures 6.3 and 6.4 were generated by me. 
 
This thesis is organized in eight chapters, which are preceded by a summary written in 
Portuguese and an abstract. Before the description of the results, an introductory review of the 
subject is provided in chapter 1, followed by the aims of the work. In chapters 2, 3, 4, 5 and 6 the 
original data obtained during this research project are presented and discussed. Final 
considerations, which integrate the results presented in previous chapters as well as future 
directions, are presented in chapter 7. Finally, chapter 8 concerns the description of the materials 
and methodologies employed to carry out the presented work. The publications that resulted from 
the research carried out throughout the duration of this project are included in appendix 1 and 2. 
 
 
Data presented in this dissertation were purely the result of work carried out by me, 
except for results presented in Figure 5.4, and it is clearly acknowledged in the text 
whenever data or reagents produced by others were utilized. This work has not been 
submitted for any degree at this or any university. 
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Correia, B.*, Cerqueira, S.A.*, Beauchemin, C., Pires de Miranda, M., Li, S., Ponnusamy, R., 
Rodrigues, L., Schneider, T.R., Carrondo, M.A., Kaye, K.M., Simas, J.P., and McVey, C.E. (2013). 
Crystal structure of the gamma-2 herpesvirus LANA DNA binding domain identifies charged 
surface residues which impact viral latency. PLoS Pathog. 9, e1003673. *shared first authorship 
 
Construction of recombinant viruses and all animal experiments presented in this publication 
(Figure 5 and Table 4) were performed by me.  
 
This article was published back to back with two other articles from independent teams, led by Prof. 
Thomas F. Schulz (Hellert et al., 2013) and Prof. Paul M. Lieberman (Domsic et al., 2013). 
 
 
 
Appendix 2 
Cerqueira, S.A.*, Tan, M.*, Li, S., Juillard, F., McVey, C.E., Kaye, K.M., and Simas, J.P. LANA E3 
ubiquitin-ligase activity impacts gammaherpesvirus latent infection. In preparation. *shared first 
authorship 
 
Data presented in Figures 4, 5 and 7, and Tables 1 and 2 were obtained by me. The MuHV-4 
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These publications result from the work performed by the consortium in the scope of the 
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RESUMO 
A principal característica dos herpesvírus é a sua capacidade de estabelecerem infeções 
latentes que persistem durante toda a vida do hospedeiro. Os gamaherpesvírus, em particular, são 
importantes agentes com potencial oncogénico que estabelecem latência em linfócitos, 
especialmente células B. Para persistirem no hospedeiro, os gamaherpesvírus exploram o ciclo de 
vida normal da célula B, induzindo a proliferação de células B latentemente infetadas em centros 
germinativos e a sua posterior diferenciação em células B de memória de longa duração. Durante 
a latência, o genoma viral é mantido sob a forma de um epissoma circular extracromossomal no 
núcleo da célula hospedeira e a expressão de proteínas virais é limitada. Assim, é necessário que 
os epissomas virais repliquem em sincronia com a divisão celular e que sejam segregados para os 
núcleos-filhos após a mitose, de modo a persistirem em células em proliferação. Este processo é 
controlado por proteínas de manutenção do epissoma, codificadas pelos gamaherpesvírus. Os 
gama-2-herpesvírus, como o vírus associado ao sarcoma de Kaposi (KSHV) ou o herpesvirus de 
murganho-4 (MuHV-4), expressam uma proteína associada à latência (LANA) que medeia a 
persistência do epissoma, através da ligação a repetições terminais (TRs) presentes no genoma 
viral. LANA regula também a transcrição celular através da sua atividade de ubiquitina-ligase E3. A 
estrutura cristalina do domínio de ligação ao DNA (DBD) de LANA foi recentemente resolvida, 
revelando várias características estruturais que se encontram associadas a funções específicas da 
proteína. O estudo dos mecanismos subjacentes às funções de LANA é de extrema importância, 
uma vez que esta proteína é essencial para o estabelecimento e manutenção da infeção latente in 
vivo. Contudo, a contribuição individual de cada uma das funções atribuídas a LANA no decorrer 
da infeção natural do hospedeiro encontra-se ainda pouco caracterizada. 
A estrita especificidade de hospedeiro dos gamaherpesvírus humanos, o vírus Epstein-Barr 
(EBV) e o vírus KSHV, tem limitado os estudos in vivo. O gamaherpesvírus MuHV-4 é um parasita 
natural de roedores selvagens, geneticamente relacionado com os gamaherpesvírus humanos e 
que, à semelhança destes, infeta latentemente células B, induzindo a sua proliferação em centros 
germinativos e posterior diferenciação em células B de memória, como estratégia para persistir 
durante toda a vida do hospedeiro. Além disso, a proteína LANA de MuHV-4 (mLANA) apresenta 
homologia aminoacídica, estrutural e funcional com a proteína LANA de KSHV (kLANA), 
representando assim um modelo para o estudo da patogénese de LANA in vivo, usando um 
modelo de infeção animal. Esta tese teve como principal objetivo avaliar o papel de determinadas 
funções de LANA no contexto da infeção latente in vivo por gamaherpesvírus, recorrendo à 
infeção de ratinhos de laboratório com o vírus MuHV-4 como modelo experimental. Com este 
propósito, foram construídos vírus MuHV-4 recombinantes contendo mutações baseadas na 
estrutura do DBD de mLANA, de modo a interferir com interfaces específicas da proteína. A 
capacidade destes recombinantes estabelecerem e manterem uma infeção latente foi analisada 
após infeção intranasal de ratinhos.  
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A estrutura cristalina do DBD de mLANA permitiu identificar uma interface de ligação ao DNA, 
a qual possibilita a interação de mLANA com as sequências TRs do DNA viral. Para avaliar a 
importância desta interação no contexto da infeção latente in vivo, construiu-se um vírus 
recombinante contendo mLANA incapaz de se ligar às TRs, devido a mutações específicas na 
interface de ligação ao DNA. Seguidamente, procedeu-se à infeção intranasal de ratinhos com o 
vírus recombinante e analisou-se o comportamento do mesmo durante o estabelecimento e 
manutenção da latência. Os resultados obtidos demonstraram que a ligação de mLANA às TRs do 
DNA viral é essencial para a expansão da latência em células B do centro germinativo, bem como 
para a persistência do vírus no hospedeiro. Estas experiências validam assim a importância da 
ligação de mLANA ao DNA viral durante a infeção latente in vivo, indicando ainda que a 
incapacidade do vírus amplificar a latência em células B dos centros germinativos tem 
consequências severas na manutenção da infeção latente a longo termo, o que suporta o modelo 
proposto para a infeção por gamaherpesvírus. 
No lado oposto à interface de ligação ao DNA de mLANA encontra-se uma região extensa de 
resíduos carregados positivamente, designada região positiva dorsal. Para investigar o papel 
funcional desta região na infeção latente in vivo, foram construídos vírus MuHV-4 recombinantes 
contendo mutações na periferia ou na zona central da região positiva dorsal de mLANA. Os vírus 
foram administrados intranasalmente a ratinhos e o efeito das mutações introduzidas em mLANA 
no estabelecimento e na manutenção da latência foi avaliado. Os resultados obtidos 
demonstraram que a região positiva dorsal, particularmente a zona periférica, é necessária para a 
eficiente expansão da latência em células B do centro germinativo. As mutações na zona central 
tiveram um impacto menor na latência. Embora estudos anteriores tenham demonstrado que a 
região positiva dorsal de mLANA está envolvida na ligação à proteína celular Brd4, os resultados 
obtidos neste estudo não permitiram estabelecer uma relação entre os fenótipos observados e a 
perda de ligação a Brd4. Deste modo, o mecanismo através do qual a região positiva dorsal de 
mLANA exerce a sua função permanece desconhecido. 
Estudos anteriores realizados no nosso laboratório demonstraram que mLANA promove a 
formação de um complexo de ubiquitina-ligase através do recrutamento das proteínas celulares 
ElonguinaB/C e Culina5, de modo a promover a poli-ubiquitinação e consequente regulação de 
dois fatores de transcrição celulares: o fator nuclear kappa B (NF-κB) e Myc. A interação de 
mLANA com a ElonguinaB/C e com a Culina5 é mediada pelo motivo supressor da sinalização por 
citocinas (SOCS-box), presente em mLANA, o qual se localiza perpendicularmente à interface de 
ligação ao DNA. Para esclarecer a relevância biológica da atividade de ubiquitina-ligase de 
mLANA, foram construídos vírus MuHV-4 recombinantes contendo mutações na SOCS-box de 
mLANA. Estas mutações foram introduzidas tendo em conta a estrutura do DBD, de modo a inibir 
a função de ubiquitina-ligase de mLANA sem interferir com a sua função de manutenção do 
epissoma viral. Os vírus recombinantes foram administrados intranasalmente a ratinhos e o seu 
fenótipo foi depois analisado durante o estabelecimento e manutenção da latência. As mutações 
introduzidas resultaram numa atenuação dos níveis de latência no baço, demonstrando que a 
atividade de ubiquitina-ligase de mLANA contribui para a amplificação da latência viral in vivo. 
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Embora não tenha sido possível inibir completamente a atividade de ubiquitina-ligase de mLANA, 
o facto de uma inibição parcial desta função ter sido suficiente para reduzir os níveis de latência 
sugere que a SOCS-box poderá ser um alvo farmacológico para inibir a atividade de ubiquitina-
ligase de mLANA e, consequentemente, controlar a infeção viral. 
Durante o estudo do impacto da atividade de ubiquitina-ligase de mLANA in vivo, foi 
identificado um vírus recombinante capaz de expandir a latência em ratinhos apesar de conter 
mutações em mLANA que comprometiam severamente a ligação às TRs do DNA viral, eliminando 
assim a persistência do epissoma. Tendo em conta que, conforme demonstrado no presente 
estudo, a ligação de mLANA às TRs é fundamental para o estabelecimento e manutenção da 
latência in vivo, equacionou-se a hipótese de que este mutante, mLANAV199A/L202A, seria capaz de 
mediar a manutenção do epissoma, mas o ensaio usado para testar esta função não seria 
suficientemente sensível, devido à presença de um número de cópias de TRs inferior ao número 
de cópias presente no genoma viral completo. Para determinar se o mutante mLANAV199A/L202A 
seria capaz de mediar a persistência do epissoma no contexto do genoma viral completo, 
estabeleceram-se linhas celulares latentemente infetadas com um vírus MuHV-4 deficiente em 
ORF50, o qual é incapaz de replicação lítica, contendo as mutações V199A/L202A em mLANA 
(vORF50-mLANAV199A/L202A). A presença de epissomas foi posteriormente analisada em gel 
Gardella. Os resultados obtidos revelaram a presença de epissomas em todas as linhas celulares 
infetadas com vORF50-mLANAV199A/L202A, demonstrando que mLANA é capaz de mediar a 
persistência do epissoma na presença de mutações que reduzem consideravelmente a sua 
ligação às TRs, dependendo do número de cópias de TRs existentes nos epissomas. Estes 
resultados sugerem que a ligação de mLANA a múltiplas cópias de TRs poderá compensar perdas 
consideráveis na capacidade de ligação ao DNA, de modo a manter eficazmente o epissoma.  
Além dos estudos de patogénese anteriormente referidos, no âmbito desta tese testou-se 
também a possibilidade de expressão de mLANA na sua forma completa em células de inseto, 
usando baculovírus. Os resultados mostraram que bons níveis de expressão de mLANA podem 
ser obtidos recorrendo a este sistema de expressão. Esta descoberta poderá contribuir para a 
futura resolução da estrutura cristalina de mLANA na forma completa, uma vez que apenas a 
estrutura do seu DBD C-terminal é conhecida, facilitando assim o estudo de outras funções de 
mLANA in vivo, com base em dados estruturais. 
Globalmente, os resultados apresentados nesta tese validam o papel essencial de LANA na 
infeção latente por gamaherpesvírus, evidenciando ainda a vantagem da realização de estudos de 
patogénese baseados em informação estrutural. Assim, este estudo sugere que a inibição 
farmacológica de determinadas funções de LANA, usando como alvo características estruturais 
associadas a funções específicas da proteína, poderá ser uma estratégia para controlar a infeção 
latente por gamaherpesvírus e as patologias relacionadas.  
 
 
Palavras-chave: gamaherpesvírus; proteína associada à latência; manutenção do epissoma; 
região positiva dorsal; ubiquitina-ligase  
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ABSTRACT 
The hallmark of herpesviruses is the establishment of lifelong latent infections in specific cell 
types. Gammaherpesviruses, a herpesvirus subfamily with causative roles in several malignancies, 
drive proliferation of latently infected B cells in germinal centres (GCs) to expand latency and to 
achieve long-term persistence in memory B cells. During latency, the viral genome is maintained as 
a non-integrated circular episome within the host cell nucleus, and viral protein expression is highly 
restricted. To persist in proliferating cells, viral episomes must replicate in step with normal cell 
division and segregate to newly formed nuclei after mitosis. This process is mediated by 
gammaherpesvirus episome maintenance proteins. In particular, gamma-2-herpesviruses encode a 
latency-associated nuclear antigen (LANA), which has been shown to mediate episome 
persistence and is also known as a cellular transcription modulator, including through E3 ubiquitin-
ligase activity. Remarkably, the crystal structure of LANA DNA binding domain has been solved 
and revealed several structural features that are associated with specific LANA functions. 
The aim of this thesis was to address the role of particular LANA functions in the context of 
gammaherpesvirus latent infection in vivo, using infection of laboratory mouse with murid 
herpesvirus-4 (MuHV-4) as an experimental model. To this end, MuHV-4 recombinant viruses 
harbouring structure-based mutations targeting specific MuHV-4 LANA (mLANA) interfaces were 
engineered, and the ability of these recombinants to establish and maintain latent infection was 
analysed upon intranasal infection of mice. These experiments demonstrated that mLANA binding 
to terminal repeat (TR) elements in viral DNA is essential for latency expansion in GC B cells and 
persistence in the host. Interestingly, mLANA was capable of mediating episome persistence 
despite mutations that resulted in considerably reduced TR DNA binding, depending on TR 
elements number present in episomes. This work also showed that the novel mLANA dorsal 
positive patch, opposite to the DNA binding interface, is required for efficient latency expansion in 
GC B cells. In addition, recombinants bearing mutations in mLANA suppressor of cytokine 
signalling (SOCS)-box, which lies within a loop protruding perpendicular to the DNA binding 
interface, exhibited an attenuation of latency levels in spleen, demonstrating that mLANA E3 
ubiquitin-ligase activity contributes to latency amplification.  
Overall, these findings validate LANA as an essential player in gammaherpesvirus latent 
infection and reveal the advantage of performing pathogenesis studies guided by structural data. 
Hence, this study constitutes a primer for pharmacological inhibition of LANA functions, through 
targeting of specific structural features, as a putative strategy to control gammaherpesvirus latent 
infection and associated pathologies. 
 
 
Keywords: gammaherpesvirus; latency-associated nuclear antigen; episome maintenance; dorsal 
positive patch; E3 ubiquitin-ligase 
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3 
Introduction 
Gammaherpesviruses, such as the human viruses Epstein-Barr virus and Kaposi´s sarcoma-
associated herpesvirus, establish lifelong latent infections in B lymphocytes and exert causative 
roles in several malignancies. During latency, the viral genome is maintained as a non-integrated 
circular episome within the host cell nucleus, and viral protein expression is highly restricted. To 
persist in proliferating cells, viral episomes must replicate in step with normal cell division and 
segregate to newly formed nuclei after mitosis. This process is mediated by gammaherpesvirus 
episome maintenance proteins. Gamma-2-herpesviruses, a genus of gammaherpesvirus, encode a 
latency-associated nuclear antigen (LANA), which mediates episome persistence. In addition, 
LANA proteins have been described as cellular transcription modulators. Since LANA is essential 
for latent infection, understanding the mechanisms underlying its functions offers an opportunity to 
control gammaherpesvirus infection and associated pathologies. This introductory chapter will 
mainly focus on the current knowledge on gammaherpesvirus latency and LANA structure and 
function. 
 
 
1.1. Herpesvirus 
 
1.1.1. General properties  
 
Herpesviridae is a family of enveloped viruses containing large linear double-stranded DNA 
genomes (>100 kb) with a vast coding capacity. Herpesviruses are widely disseminated in 
vertebrate species, with a large spectrum of animals harbouring at least one of these viruses. 
However, each herpesvirus exhibits a very narrow host range. Herpesviruses are remarkably well-
adapted to their hosts, probably due to a long co-evolutionary history. Thus, herpesvirus infection 
of a natural immunocompetent host is rarely fatal, promoting virus transmission (Barton et al., 
2011; Davison, 2002; Wu et al., 2010). 
 
The hallmark of herpesviruses is the establishment of latent infections which persist for the life 
of the host. During latency, herpesviruses persist as a non-infectious form, from which they 
periodically reactivate to disseminate to new hosts. Most herpesvirus infections are asymptomatic 
or cause a mild illness, but effects can be devastating in immunocompromised hosts (Barton et al., 
2011; Wu et al., 2010). 
 
Herpesviruses have biphasic life cycles consisting of a lytic and a latent phase. Upon 
transmission to a naïve host, the virus establishes a productive acute infection at the site of 
infection, usually the epithelium of a mucosal surface. During this lytic phase, there is a sequential 
order of viral gene expression and the viral genome is replicated several times, leading to the 
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production of infectious virion progeny and the death of the infected cell. This primary infection is 
rapidly resolved by the host immune system and results in effective immunity against reinfection 
(Stoopler, 2005; Wu et al., 2010). 
 
The lytic infection is followed by a lifelong latent infection in a specific type of cells. The 
targeted cell type is herpesvirus specific and is usually different from the cell type harbouring the 
productive infection. During latency, limited gene expression occurs. No virions are produced and 
viral genome is maintained as a non-integrated circular episome in the nucleus of the infected cell, 
being replicated by host DNA polymerase and equally distributed to daughter cells, when the 
latently infected cell divides during the course of cellular growth. The expression of viral proteins is 
severely reduced to those required for maintenance of viral genome, manipulation of host cell 
function and evasion of the host immune system. By expressing few proteins during latency, the 
virus limits the amount of antigen produced, thereby reducing the chance of being detected by the 
host immune system. A critical aspect of latency is the ability of the virus to sporadically reactivate 
in response to specific signals, ensuring the transmission of infectious virions to new hosts, as well 
as reinfection and establishment of latent infection in more cells of the same individual, thereby 
establishing a reservoir of infection for life (Barton et al., 2011; Wu et al., 2010). 
 
Herpesviridae family is divided into three subfamilies: Alphaherpesvirinae, Betaherpesvirinae 
and Gammaherpesvirinae. Alphaherpesviruses establish latency mainly in neurons, 
betaherpesviruses in myeloid cells, and gammaherpesviruses in lymphocytes. Humans are the 
natural hosts of eight herpesviruses: herpes simplex virus (HSV)-1, HSV-2, and varicella-zoster 
virus (VZV) (Alphaherpesvirinae); human cytomegalovirus (HCMV), human herpesvirus (HHV)-6, 
and HHV-7 (Betaherpesvirinae); Epstein-Barr virus (EBV), and Kaposi’s sarcoma-associated 
herpesvirus (KSHV), also known as HHV-8 (Gammaherpesvirinae) (Davison, 2002; Stevenson et 
al., 2009; Wu et al., 2010). Since the work presented in this thesis is focused on the pathogenesis 
of gammaherpesvirus latent infection, only this subfamily will be described in detail in the following 
sections. 
 
 
1.1.2. The subfamily Gammaherpesvirinae 
 
Members of the subfamily Gammaherpesvirinae are lymphotropic viruses, with the majority 
establishing latency in B lymphocytes. Gammaherpesviruses drive the proliferation of latently 
infected lymphocytes, in order to establish and maintain a large reservoir of latent viral genomes, 
and thus efficiently colonize the host. However, virus-driven lymphoproliferation is associated with 
the development of lymphoproliferative diseases, as well as several lymphoid and non-lymphoid 
cancers, since several gammaherpesviruses are able to induce neoplasia in natural or 
experimental hosts (Barton et al., 2011; Damania, 2004; Stevenson, 2004). 
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Gammaherpesvirinae subfamily is further subdivided into four genera, based on DNA 
homology and genomic organization, being Lymphocryptovirus and Rhadinovirus the two main 
genera. Lymphocryptoviruses (or gamma-1-herpesviruses) have only been identified in primates, 
whereas Rhadinoviruses (or gamma-2-herpesviruses) infect a wide range of mammalian species, 
including primates (Barton et al., 2011; Davison et al., 2009; Simas and Efstathiou, 1998). 
 
Gammaherpesviruses exhibit a very narrow host tropism, limiting the study of the human 
gammaherpesviruses EBV and KSHV. For this reason, there has been considerable interest in 
developing animal models to investigate the pathogenesis of human gammaherpesviruses. In 
particular, infection of laboratory mice with murid herpesvirus-4 (MuHV-4) has proved to be a good 
model system (Barton et al., 2011; Nash et al., 2001; Simas and Efstathiou, 1998). The following 
sections of this thesis will focus on the two known human gammaherpesviruses and then on 
MuHV-4 as an experimental model for the study of gammaherpesvirus pathogenesis. 
 
 
 
1.2. Epstein-Barr virus (EBV) 
 
Epstein-Barr virus (EBV), a gamma-1-herpesvirus, was discovered more than 50 years ago in 
cultured tumour cells derived from Burkitt’s lymphoma tissue (Epstein et al., 1964). This was the 
first human tumour virus ever described (Thorley-Lawson and Allday, 2008). EBV prevalence in the 
normal population is extremely high, reaching over 95% of the adult population worldwide (Kutok 
and Wang, 2006; Lieberman, 2014). Primary EBV infection generally occurs in the first decade of 
life and is usually asymptomatic. However, if the infection is acquired during adolescence or later, it 
can result in infectious mononucleosis, a self-limiting lymphoproliferative disease (Henle et al., 
1968; Kutok and Wang, 2006). After primary infection, which is rapidly controlled by both cellular 
and humoral immune mechanisms, EBV persists in a quiescent state in resting memory B 
lymphocytes that circulate in the peripheral blood for the life of healthy carriers (Babcock et al., 
1998; Hislop et al., 2007; Kutok and Wang, 2006). Persistent infection is characterized by stable 
low levels of latently infected memory B cells, as a consequence of the dynamic equilibrium 
between virus-driven B cell proliferation and host immune control. A low level of active viral 
replication continues asymptomatically in EBV carriers, leading to virus secretion into the saliva 
and transmission from one human to another through the oral route (Hislop et al., 2007; Kutok and 
Wang, 2006).  
 
Although EBV infection is benign and uneventful in the majority of humans, EBV has been 
associated with a number of diseases, particularly autoimmunity and cancer. Immunocompromised 
individuals are at risk for EBV lymphomas that are aggressive and often fatal (Table 1.1). However, 
EBV-associated malignancies can also develop in immunocompetent individuals (Table 1.1) (Kutok 
and Wang, 2006; Thorley-Lawson and Gross, 2004). 
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Table 1.1. EBV-associated diseases (adapted from Kutok and Wang, 2006). 
Non-malignant 
disease 
 Infectious mononucleosis 
Chronic active infection 
Oral hairy leukoplakia 
Malignant 
disease 
Immunocompromised 
host 
Acquired immunodeficiency syndrome (AIDS)-associated B cell 
lymphomas 
Post-transplant lymphoproliferative disorder 
Severe combined immunodeficiency-associated B cell lymphomas 
X-linked lymphoproliferative disorder-associated B cell 
lymphomas 
Immunocompetent 
host 
Burkitt’s lymphoma 
Classical Hodgkin’s lymphoma  
T cell lymphomas 
Lymphoepithelioma-like carcinoma (salivary, thymus, lungs, 
stomach) 
 
 
 
1.2.1. Germinal centre (GC) model of EBV infection  
 
EBV is the best studied gammaherpesvirus and a biological model of EBV infection has been 
proposed, the germinal centre (GC) model. This model, described below, reveals strategies of 
infection which are believed to be common to all gammaherpesviruses that persist in B 
lymphocytes. 
 
The GC model (Figure 1.1), proposed by Thorley-Lawson and co-workers, defends that EBV 
persists by exploiting normal B cell biology (Thorley-Lawson, 2001). This implies that new latently 
infected B cells pass through a series of differentiation stages, each employing a discrete viral 
gene transcription programme. Following oral transmission, EBV establishes a lytic infection in 
permissive cells of the oropharynx, leading to high levels of virus shedding in saliva. It is thought 
that both squamous epithelial cells and locally infiltrating B cells support this lytic infection. 
Thereafter, the virus colonises the general B cell system via growth-transforming latent infection of 
B cells in local lymphoid tissue such as the tonsil. According to the GC model, EBV directly infects 
naïve B cells, activating them into proliferating latently infected blasts. At this stage, EBV expresses 
its latency III or growth transcription programme (Table 1.2), which is characterized by the 
expression of the full repertoire of viral latent proteins: EBV nuclear antigens (EBNAs) 1, 2, 3A, 3B, 
3C and LP, and latent membrane proteins (LMPs) 1, 2A and 2B. These proteins have all the 
necessary activities to push B cells to become activated blasts without external signalling (Babcock 
et al., 2000; Joseph et al., 2000; Thorley-Lawson, 2005). In culture, EBV immortalises human 
resting B cells by expressing the growth programme, driving the establishment of continuously 
proliferating lymphoblastoid cell lines (growth transformation or immortalisation) (Thorley-Lawson 
and Mann, 1985). 
 
Introduction 
 
 
7 
 
Figure 1.1. Normal B cell response and the parallel with the GC model of EBV persistence. (A) Normal B 
cell response. The epithelium of the tonsil continuously samples antigens entering the mouth. Underneath the 
epithelium, naïve B cells that encounter cognate antigen become activated and migrate into a follicle where 
they receive further activation signals from dendritic cells and helper T cells, and establish a GC reaction. In 
the GC, the blast undergoes repeated rounds of cell division, proliferating rapidly, in association with somatic 
hypermutation (SHM) and class switch recombination (CSR), followed by interaction with follicular dendritic 
cells and T cells to select those blasts that have the highest affinity for the antigen. The later receive further 
survival and differentiation signals, while the other cells die by apoptosis. The surviving ones differentiate into 
either a plasma cell or a memory B cell and leave the GC. Upon re-challenge with the antigen, memory B cells 
are quickly activated and differentiate into antibody producing plasma cells. (B) GC model of EBV persistence. 
EBV traverses the epithelium and infects a naïve B cell, activating it into a proliferating latently infected blast, 
as though the cell was responding to antigen, through expression of all nine known latent proteins, the growth 
transcription programme. These cells migrate to the follicle where the viral transcription programme changes 
to the more restricted default programme and a GC reaction is established. Subsequently the latently infected 
cells differentiate into memory B cells that leave the follicle. In the periphery, all viral protein expression is shut 
down, the latency programme, and the latently infected cells are maintained as normal memory B cells. These 
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memory B cells can occasionally divide to maintain the pool of latently infected cells and so express the 
genome tethering protein EBNA1, the EBNA1 only programme. At any time a small subset of latently infected 
memory B cells initiates lytic replication in association with terminal differentiation signals. Reactivation leads 
to the production of infectious virus and cell death. These virions can either replicate at a secondary tissue, 
where they are amplified and shed into saliva for transmission to new hosts, or infect new naïve B cells, thus 
restarting the cycle of infection (adapted from De Silva and Klein, 2015, Thorley-Lawson, 2005 and Thorley-
Lawson et al., 2013). 
 
 
Table 1.2. Patterns of EBV latent gene expression in normal B cells and tumours (adapted from 
Thorley-Lawson, 2005).  
Transcription 
programme 
Genes expresseda 
Infected normal B 
cell type 
Function 
Infected tumour 
type 
Growth 
(Latency III) 
EBNA1, 2, 3A, 3B, 
3C and LP 
LMP1, 2A and 2B 
Naïve  B cell activation 
Immunoblastic 
lymphoma 
Default 
(Latency II) 
EBNA1, LMP1 and 
LMP2A 
Germinal centre 
Differentiation of 
activated B cell into 
memory 
Hodgkin’s disease 
EBNA1 
(Latency I) 
EBNA1 Dividing memory 
Cellular division of 
latently infected 
memory B cells 
Burkitt’s lymphoma 
Latency 
(Latency 0) 
None Resting memory 
Allows lifetime 
persistence 
 
Lytic All lytic genes Plasma cell 
Viral replication in 
plasma cell 
 
aDoes not include the non-coding EBER and BART RNAs. 
 
 
Proliferating latently infected blasts then migrate into a follicle to participate in the GC reaction. 
Here, EBV expresses the latency II or default transcription programme (Table 1.2), consisting of a 
more restricted pattern of latent proteins: EBNA1, LMP1 and LMP2A. EBNA1 is required for 
replication and maintenance of the viral episome, mediating the association of viral genomes with 
host mitotic chromosomes, whereas LMP1 and LMP2A proteins provide the necessary surrogate 
signals to drive the differentiation of latently infected B cells into memory B cells that leave the GC 
and enter the peripheral circulation (Babcock et al., 2000; Caldwell et al., 1998; Casola et al., 2004; 
Gires et al., 1997; He et al., 2003; Marechal et al., 1999; Panagopoulos et al., 2004; Roughan and 
Thorley-Lawson, 2009; Sears et al., 2003; Thorley-Lawson, 2001; Yates et al., 1985).   
 
In latently infected memory B cells, EBV expresses either EBNA1 transcription programme 
(latency I) or latency transcription programme (latency 0) (Table 1.2). During EBNA1 transcription 
programme, EBV only expresses the viral genome tethering protein EBNA1, so that viral episomal 
DNA is maintained and segregated when B cells divide. In contrast, in the latency transcription 
programme no viral proteins are expressed at all. The memory compartment has been considered 
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the site of long-term persistence, since the virus is quiescent and hence invisible to the immune 
response (Babcock et al., 2000; Hochberg et al., 2004; Thorley-Lawson, 2001).  
 
In addition to latent proteins, EBV expresses several non-coding RNAs and microRNAs 
(miRNAs) during latency (Kang and Kieff, 2015). EBV-encoded RNA (EBER) 1 and 2 are small 
non-coding RNAs abundantly expressed in latently infected cells (Lerner et al., 1981). EBV-
encoded miRNAs are expressed from two regions of EBV genome: BART and BHRF1. The EBV 
genome transcribes at least 25 pre-miRNAs and more than 40 mature miRNAs (Kang and Kieff, 
2015; Lopes et al., 2013). Similarly to latent proteins, EBV-encoded miRNAs exhibit distinct 
patterns of expression according to the EBV latency programme (Qiu et al., 2011). 
 
At any time, a small subset of latently infected memory B cells can reactivate and initiate lytic 
replication, which is thought to occur in response to the normal physiologic signals that drive 
terminal differentiation of memory B cells into plasma cells. Reactivation of EBV is subdivided into 
three phases: immediate early, when the transcription factors initiating viral replication are 
expressed, early, when the proteins involved in viral DNA replication are produced, and late, when 
viral DNA and structural proteins are assembled into virions. A crucial role for epithelial cells in 
amplifying the amount of infectious virus before shedding has been proposed. Released infectious 
virus can then be shed into saliva for viral spread to new hosts, or infect new naïve B cells, thus 
completing the cycle (Hadinoto et al., 2009; Laichalk and Thorley-Lawson, 2005; Thorley-Lawson 
et al., 2013).  
 
Each stage of the cycle of EBV infection has been demonstrated experimentally (Babcock et 
al., 1998; Babcock et al., 2000; Laichalk and Thorley-Lawson, 2005) and, with the exception of the 
memory compartment, is potentially regulated by the host immune response (Hislop et al., 2007). 
The GC model of EBV infection remains the only experimentally validated model that accounts for 
all the latent and lytic stages of the virus, providing an explanation for the origin and pathogenesis 
of EBV-associated lymphomas (Thorley-Lawson et al., 2013). However, a quantitative analysis of 
viral persistence and an understanding of the dynamic interactions between the different 
components of the GC model and how their regulation by the immune system produces the EBV 
pattern of persistence has been lacking. Recently, a mathematical description of the GC model has 
been developed that successfully recapitulates persistent EBV infection, correctly predicting the 
observed patterns of cytotoxic T lymphocytes (CTLs) regulation and the size of the infected GC 
and memory B cell populations (Delgado-Eckert and Shapiro, 2011; Hawkins et al., 2013). 
Importantly, this mathematical model predicts that it is the cycle of infection that explains 
persistence and provides the stability that allows EBV to persist at extremely low levels, rather than 
viral quiescence in the memory B cell compartment. This moves the focus away from a single 
infected stage, the memory B cell compartment, to the entire cycle of infection.  
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1.3. Kaposi’s sarcoma-associated herpesvirus (KSHV) 
 
Kaposi’s sarcoma-associated herpesvirus (KSHV) was first discovered in 1994 by Chang and 
colleagues, from patients with Kaposi’s sarcoma (KS) (Chang et al., 1994). KSHV, also known as 
human herpesvirus-8 (HHV-8), is a gamma-2-herpesvirus with an etiologic role in KS, the most 
prevalent tumour among human immunodeficiency virus (HIV)/acquired immunodeficiency 
syndrome (AIDS) patients worldwide (Achenbach et al., 2011). KSHV is also associated with other 
two human malignancies: primary effusion lymphoma (PEL) and multicentric Castleman’s disease 
(MCD) (Cesarman et al., 1995; Soulier et al., 1995). KS tumours are comprised of KSHV-infected 
cells of endothelial origin, whereas PEL and MCD are of B cell origin. Furthermore, KSHV was 
recently associated with an inflammatory cytokine syndrome (Uldrick et al., 2010). 
 
Unlike EBV virus, KSHV is not ubiquitous. Among the general population, the seroprevalence 
of KSHV infection in northern Europe, Asia and America is less than 10%, but it reaches 30% in 
Mediterranean regions and over 50% in most of sub-Saharan Africa. The association between the 
incidence of KSHV-associated malignancies and KSHV seroprevalence is high. However, the 
presence of KSHV DNA alone in healthy individuals is not sufficient to cause disease, and the 
existence of cofactors as HIV infection or drug-induced immunosuppression are important for 
KSHV-associated disease progression. The transmission mode of KSHV has not been completely 
clarified yet. It is currently thought that KSHV is mainly transmitted through saliva, although 
transmission through organ transplants, blood and sexual fluids have also been documented (Cai 
et al., 2010; Edelman, 2005; Mesri et al., 2010; Uldrick and Whitby, 2011; Uppal et al., 2014).  
 
Being a herpesvirus, KSHV exhibits two distinct phases of infection: lytic replication and 
latency. Latency is characterized by limited gene expression without virion production, and it 
represents the main strategy used by the virus to escape host immune system, while maintaining 
its genome in infected cells. Periodically, the latent virus reactivates to enter lytic replication, during 
which the viral genes are fully expressed in a cascade manner (immediate early, early and late 
genes), leading to the production of infectious particles and transmission to new hosts. Little is 
known about KSHV primary infection, but there is evidence that it is benign in immunocompetent 
individuals, and it results in lifelong latency (Wang et al., 2001; Wu et al., 2012).  
 
 
1.3.1. KSHV latency 
 
During latency, KSHV genome is maintained as a circular episome within the host cell nucleus 
with highly restricted protein expression, in order to maintain the genome in the dividing cells and to 
limit host immune responses, while enhancing cell survival and virus persistence (Uppal et al., 
2014). Only a small portion of the viral genome is actively transcribed during latency. The major 
latency locus includes four viral genes, encoding KSHV latency-associated nuclear antigen 
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(kLANA)/ORF73, vCyclin/ORF72, viral Fas-associated death domain-like interleukin-1β-converting 
enzyme-inhibitory protein (vFLIP)/ORF71, and K12/Kaposin family (Kaposin A, B and C), as well as 
twelve viral pre-miRNAs (Cai et al., 2005; Dittmer et al., 1998). kLANA is the viral episome 
maintenance protein and, in addition, it exerts transcriptional regulatory activities and affects cell 
growth, through interaction with several cell proteins (Ballestas and Kaye, 2011). vCyclin, the viral 
homolog of cellular cyclin D, regulates cell cycle and proliferation, whereas vFLIP, the viral 
homolog of cellular FLIP, has a role in inhibition of apoptosis (Uppal et al., 2014). The kLANA 
promoter controls the expression of kLANA, vCyclin and vFLIP, while the Kaposin promoter drives 
the expression of the three Kaposin transcripts, a bicistronic transcript for vCyclin and vFLIP, and 
the twelve viral pre-miRNAs which can be processed to yield mature miRNAs (Dittmer et al., 1998; 
Pearce et al., 2005). The major latency locus is abundantly and consistently transcribed in all 
latently infected cells (Speck and Ganem, 2010). Additionally, PEL cells, but not KS cells, express 
a second latency locus encoding viral interferon regulatory factor-3 (vIRF-3), also known as LANA-
2, indicating that some latency genes may be lymphoid specific (Rivas et al., 2001; Speck and 
Ganem, 2010). More recently, a third latency locus encoding K1 protein has been identified 
(Chandriani and Ganem, 2010). Other viral genes expressed during latency, although at low levels, 
include viral interleukin-6 (vIL-6) and K15 (Giffin and Damania, 2014). 
 
In vivo, KSHV has been detected in endothelial cells, epithelial cells, B cells and monocytes 
(Ambroziak et al., 1995; Blasig et al., 1997; Dupin et al., 1999; Pauk et al., 2000). However, the 
main targets of KSHV long-term latent infection are B cells, particularly the subset expressing the 
lambda (λ) light chain of B cell receptor (Chadburn et al., 2008; Hassman et al., 2011). KSHV 
infection drives proliferation of primary B cells (Hassman et al., 2011) and individual KSHV latent 
genes, specifically the ones encoding kLANA and vFLIP, induce B cell proliferative phenotypes in 
transgenic mice (Ballon et al., 2011; Sin et al., 2010). B cell specific expression of multiple KSHV 
latent proteins, including kLANA, vFLIP, vCyclin and Kaposin, as well as the viral miRNAs, leads to 
sustained hyperplasia, lymphoma and hyper-responsiveness to antigen stimulation in transgenic 
mice (Sin and Dittmer, 2013). 
 
The mechanisms by which KSHV establishes and maintains latency are not as well 
understood as for EBV. However, the overall strategy is believed to be the same: subversion of 
normal B cell developmental pathways to induce cell proliferation and achieve long-term 
persistence. A putative model of KSHV B cell pathogenesis has been proposed (Dittmer and 
Damania, 2013). According to this model, the primary infection event drives the infected cell into an 
activated state. In non-permissive cell subtypes the virus is rapidly lost or the cell dies. In contrast, 
in cells permissive to the establishment of latency, the virus persists and confers a survival 
advantage to the infected cell. The molecular nature of this advantage and the exact complement 
of viral genes which confer it are not well defined. This model suggests that the establishment of 
KSHV latent infection is analogous to that of EBV, which starts with expressing a more extensive 
set of genes and then contracts to latency I or latency 0 transcription programmes.  
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1.4. Murid herpesvirus-4 (MuHV-4) 
 
A major limitation to the study of the human gammaherpesviruses is the absence of a robust 
small animal model in which to investigate viral pathogenesis, due to the very narrow host tropism 
exhibited by EBV and KSHV (Barton et al., 2011; Simas and Efstathiou, 1998). The identification of 
murid herpesvirus-4 (MuHV-4) (archetypal strain murine gammaherpesvirus-68 (MHV-68)) 
(Blaskovic et al., 1980), a naturally occurring rodent pathogen, offered the possibility of developing 
a mouse model of gammaherpesvirus pathogenesis. 
 
MuHV-4 was originally isolated from bank voles (Myodes glareolus) in Slovakia (Blaskovic et 
al., 1980). Later studies indicated that this virus is endemic in wood mice (Apodemus sylvaticus) in 
the United Kingdom, suggesting that this may be the natural host species (Blasdell et al., 2003). 
Like KSHV, MuHV-4 is a gamma-2-herpesvirus. Its genome consists of 118 kb of unique DNA 
sequence with a G+C content of 46%, flanked by a variable number of 1.2 kb terminal repeat (TR) 
regions (Efstathiou et al., 1990). It is estimated that MuHV-4 genome contains approximately 80 
protein-coding open reading frames (ORFs), the majority of which are collinear and homologous to 
those of other gammaherpesviruses, particularly KSHV (Virgin et al., 1997). However, MuHV-4 
genome harbours a number of genes unique to the virus (M1-14). 
 
MuHV-4 readily infects laboratory mice (Mus musculus), in which it establishes a lifelong latent 
infection (Simas and Efstathiou, 1998). Similarly to EBV, MuHV-4 causes an acute infectious 
mononucleosis syndrome and exploits the normal B cell biology to colonize the host, driving 
proliferation of latently infected B cells in GC reactions to persist in memory B cells (Barton et al., 
2011; Doherty et al., 1997; Flano et al., 2002). Furthermore, persistent infection with MuHV-4 has 
been associated with increased frequencies of malignancies in mice with defective immune 
systems, mainly B cell lymphomas (Lee et al., 2009; Sunil-Chandra et al., 1994; Tarakanova et al., 
2005). MuHV-4 also provides an in vivo infection model in which host immune evasion 
mechanisms are preserved (Stevenson et al., 2009). In addition, MuHV-4 genome can be readily 
manipulated, thereby allowing the generation of mutant viruses whose phenotype can be assessed 
in the mouse (Adler et al., 2000). Therefore, MuHV-4 constitutes a unique experimental model for 
the study of gammaherpesvirus pathogenesis.  
 
 
1.4.1. MuHV-4 model of infection 
 
Following intranasal infection of laboratory mice, the primary site of productive virus replication 
is the lung, specifically alveolar epithelial cells (Figure 1.2) (Sunil-Chandra et al., 1992a). MuHV-4 
host entry is co-operative, as virion binding to heparan-expressing alveolar epithelial cells licenses 
alveolar macrophages infection, and this in turn licenses epithelial cells infection (Lawler et al., 
2015). Acute infection in the lung is resolved within 10 to 12 days post-infection (dpi) by host 
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immune system and is followed by lifelong latent infection in lymphoid tissue. Latency is 
established predominantly in B cells (Marques et al., 2003; Sunil-Chandra et al., 1992b), but is also 
established in macrophages, dendritic cells and lung epithelial cells (Flano et al., 2000; Stewart et 
al., 1998). Latent infection in the spleen is characterized by an initial proliferation of infected B cells 
and consequent amplification of the latent virus, reaching maximum levels around 14 dpi and 
decreasing thereafter to low levels, which remain stable throughout the entire life of the host 
without overt disease (Cardin et al., 1996; Marques et al., 2003; Simas and Efstathiou, 1998; Sunil-
Chandra et al., 1992b).  
 
 
Figure 1.2. Model of MuHV-4 infection. After intranasal (i.n.) infection of inbred mice, MuHV-4 establishes a 
productive infection in the respiratory tract that peaks at around 4-7 dpi and is cleared to undetectable levels 
by 10-12 dpi. From the lung, the virus disseminates to the lymphoid tissue, with latent virus being first detected 
in the lymph nodes and subsequently in the spleen, mainly in B cells. During latent infection in the spleen 
there is an amplification of latent virus that reaches maximum levels at around 14 dpi and afterwards 
decreases to reach low steady-state levels of latently infected cells that persist for the lifetime of the host. 
From the spleen, the virus further disseminates to other sites, probably via infected memory B cells (adapted 
from (Stevenson et al., 2002)). p.i., post-infection. 
 
 
The peak of latent infection is accompanied by a transient splenomegaly and 
lymphadenopathy (Sunil-Chandra et al., 1992a), due to the proliferation of latently infected B cells 
and to a large increase in CD4+ and CD8+ T cell numbers, dependent on CD4+ T cells (Ehtisham et 
al., 1993; Usherwood et al., 1996a). This phase of infection is also accompanied by high levels of 
non-virus-specific antibodies and CD8+ T cells in peripheral blood, thus resembling the infectious 
mononucleosis caused by EBV (Blackman et al., 2000; Tripp et al., 1997).  
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In agreement to what has been proposed for EBV, the establishment of MuHV-4 latent 
infection does not require a prior productive infection. In fact, latency is established in lung B cells 
as early as 3 days after respiratory inoculation, supporting the hypothesis that infection of B cells is 
a concurrent event with the ongoing lytic infection of the mucosal epithelium. Moreover, 
recombinant viruses that cannot undergo lytic replication still establish latency in mice. However, 
lytic replication is required for virus trafficking and establishment of latency in the spleen (Flano et 
al., 2005; Moser et al., 2006). 
 
In vitro, MuHV-4 productively infects epithelial cells and fibroblasts from a variety of species, 
ranging from chickens to primates (Svobodova et al., 1982), and latently infects murine B cell lines 
(Sunil-Chandra et al., 1993). MuHV-4-positive B cell lines have been established from tumours of 
infected mice, of which S11 is the best characterized (Usherwood et al., 1996b). Infection of 
primary B cells with MuHV-4 results in their activation and increased proliferation, however the cells 
do not become transformed and usually die within two weeks (Dutia et al., 1999; Stevenson and 
Doherty, 1999). MuHV-4 has been shown to immortalize only foetal B cells in vitro (Liang et al., 
2011). 
 
 
1.4.2. MuHV-4 latency 
 
MuHV-4 enters new hosts via the olfactory neuroepithelium (Milho et al., 2012) or genital tract 
(Francois et al., 2013), dendritic cells take it to lymph nodes (Gaspar et al., 2011), and from there it 
reaches the spleen. This epithelial/myeloid/lymphoid MuHV-4 infection pathway (Frederico et al., 
2012) is thus quite different from the epithelial cell/B cell exchange proposed for EBV (Borza and 
Hutt-Fletcher, 2002). Then, MuHV-4 enters the spleen by infecting marginal zone (MZ) 
macrophages, which provide a conduit to MZ B cells. These cells relocate to the white pulp, 
allowing virus transfer to follicular dendritic cells, which appear to transfer the virus without 
becoming infected (analogous to their presentation of immune complexes to GC B cells), and from 
there the virus reaches GC B cells to establish persistent infection. Therefore, MuHV-4 exploits the 
normal splenic immune communication routes to spread by serial myeloid/lymphoid exchange 
(Frederico et al., 2014a).  
 
Early in latency, MuHV-4 infection is found in naïve, GC, memory and plasma B cells (Collins 
et al., 2009; Flano et al., 2002; Marques et al., 2003; Willer and Speck, 2003), as well as in 
macrophages and dendritic cells (Flano et al., 2000). However, at the peak of latent infection, the 
majority of latently infected cells correspond to B cells proliferating in GCs. This proliferation leads 
to the amplification of the pool of latently infected cells, which reaches maximal levels at 2 to 3 
weeks post-infection (Cardin et al., 1996; Marques et al., 2003; Simas and Efstathiou, 1998). 
Subsequently, most GCs regress and there is a consequent decline in the latent load to a low 
steady state that persists for the lifetime of the host. Hence, latency in naïve and GC B cells, as 
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well as in non-B cell reservoirs, wanes as time progresses, and at late times post-infection viral 
latency is predominantly maintained in isotype-switched memory B cells (Flano et al., 2002; Willer 
and Speck, 2003). GC B cell proliferation and differentiation into memory B cells are critical for 
maintenance of MuHV-4 long-term persistence (Kim et al., 2003; Moser et al., 2005). In fact, 
although several B cell subsets can be initially infected by the virus, only the ones that access a 
GC and differentiate into memory B cells are capable of maintaining long-term viral latent infection. 
Thus, MuHV-4 exploits the normal B cell developmental pathways, taking advantage of the GC 
reaction to expand the pool of latently infected cells, and later to induce their differentiation into 
long-lived memory B cells, similarly to what has been proposed for EBV latency.  
 
MuHV-4-driven activation, proliferation and differentiation of latently infected B cells are 
dependent on CD4+ T cell help (Collins and Speck, 2014; Stevenson and Doherty, 1999; 
Usherwood et al., 1996a), CD40 ligand (Brooks et al., 1999) and CD40 (Kim et al., 2003), implying 
that MuHV-4 relies on normal T cell help to enter the GC reaction and differentiate into a memory B 
cell. In the absence of CD4+ T cells, infected B cells exhibit impaired proliferation in GCs, latency 
amplification is reduced and splenomegaly is not observed. In addition to CD4+ T cell help, host 
colonization also requires T cell-independent survival signals provided by the B cell-activating 
factor (BAFF) receptor (BAFF-R) (Frederico et al., 2014b).  
 
Little is known about how MuHV-4 reactivates from latency and re-enters the lytic cycle. 
However, similarly to EBV and KSHV, plasma cell differentiation seems to be linked to MuHV-4 
reactivation from latently infected B cells, and it has been proposed that the M2 latency-associated 
protein is involved in this process (Liang et al., 2009; Rangaswamy and Speck, 2014).  
 
A restricted number of MuHV-4 ORFs are transcribed during the establishment of latency in 
the spleen, including the ones encoding M1, M2, M3, M4, M8, M9, M11 (or vBcl-2), K3, ORF72 (or 
vCyclin), ORF73 (or MuHV-4 latency-associated nuclear antigen, mLANA) and ORF74 (Marques et 
al., 2003). Moreover, the pattern of transcription in B cells is selective and dependent on the 
differentiation stage of the B cell, raising the possibility that, like EBV, MuHV-4 has different latency 
programmes. 
 
Similarly to EBV and KSHV, MuHV-4 encodes at least 15 miRNAs at the left end of its 
genome, which are expressed both in lytically and latently infected cells in vitro (Pfeffer et al., 2005; 
Zhu et al., 2010). Recent studies have demonstrated that these miRNAs are dispensable for viral 
acute replication, but contribute to the establishment of latency and to reactivation in vivo (Feldman 
et al., 2014). MuHV-4 miRNAs are located downstream of viral transfer-RNA (tRNA)-like elements 
(Pfeffer et al., 2005; Zhu et al., 2010). These uncharged viral tRNAs are expressed in the spleens 
of latently infected mice and have been used as a marker for latent infection (Bowden et al., 1997; 
Simas et al., 1999).  
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Research conducted in our laboratory has focused on the latent phase of MuHV-4 infection. 
We have been particularly interested in characterizing the biological functions of mLANA and M2 
latent proteins, by dissecting the basic molecular mechanisms by which these proteins contribute to 
the establishment of latency and host colonization, and by clarifying the impact of those 
mechanisms in vivo, using an animal model of infection. 
 
mLANA, also known as ORF73, exhibits homology in sequence, structure and function to 
KSHV kLANA. In fact, mLANA was shown to mediate viral episome maintenance, and to regulate 
cellular transcription through E3 ubiquitin-ligase activity (Correia et al., 2013; Fowler et al., 2003; 
Habison et al., 2012; Hellert et al., 2013; Rodrigues et al., 2009; Rodrigues et al., 2013). Since the 
work presented in this thesis is focused on the pathogenesis of mLANA on latent infection, the 
functions of this viral protein will be described in detail in section 1.5.2. 
 
The M2 protein has been shown to function as a modulator of B cell signalling, exhibiting 
functional homology to EBV LMP2A and KSHV K1 and K15. Biochemical research carried out in 
our laboratory has identified several intracellular targets of M2, namely Fyn, Lyn, Vav1, NCK1, 
PLCγ2, PI3K and SHP2, and demonstrated that this viral protein promotes the assembly of B cell 
signalling complexes downstream of the B cell receptor (BCR) (Pires de Miranda et al., 2008; Pires 
de Miranda et al., 2013; Rodrigues et al., 2006). Importantly, M2 modulation of B cell signalling was 
shown to be critical for the efficient entry of latently infected B cells in GC reactions in vivo 
(Herskowitz et al., 2008; Pires de Miranda et al., 2008). Recent studies performed by our research 
group have shown that M2 promotes the formation of conjugates between the B cell and the helper 
CD4+ T cell, possibly conferring a competitive advantage to the infected B cell in acquisition of T 
cell help and initiation of a GC reaction, hence host colonization (Fontinha et al., 2015). 
Additionally, recent studies from other laboratories have suggested that M2 has also a role in viral 
reactivation from latently infected B cells, specifically by manipulating plasma cell differentiation 
(Liang et al., 2009; Rangaswamy and Speck, 2014). 
 
Persistence of gammaherpesviruses relies on a dynamic balance between virus-driven B cell 
proliferation and control by CD8+ cytotoxic T lymphocytes (CTLs) (Stevenson et al., 2009). Virus-
specific CD8+ CTLs recognize viral epitopes through their T cell receptor (TCR). These epitopes 
are derived from the intracellular processing of viral proteins, and are displayed on the surface of 
infected cells by major histocompatibility complex (MHC) class I glycoproteins (Tortorella et al., 
2000). M2 contains an MHC H2Kd haplotype-restricted epitope that is recognized by CD8+ CTLs 
from infected BALB/c (H2d) mice (Husain et al., 1999). A study conducted in our laboratory 
demonstrated that, in these mice, the absence of the M2 epitope results in uncontrolled long-term 
virus-driven proliferation of latently infected cells in GCs. Therefore, M2 H2Kd-restricted CD8+ CTL 
epitope, in the appropriate host MHC haplotype, renders M2 indirectly responsible for setting the 
long-term viral load (Marques et al., 2008). Furthermore, a recent work carried out in our group 
showed that CD8+ CTL control of latency amplification in GC B cells is critically dependent on 
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strong epitope binding to MHC class I molecules. In contrast, infection control is effective over a 
broader range of CD8+ CTL functional avidities for the epitope, showing relatively good tolerance 
for sub-optimal TCR engagement. Therefore, this study identified critical MHC class I and CD8+ T 
cell engagement thresholds for in vivo CD8+ CTL control of virus-driven B cell proliferation, which is 
fundamental for the development of successful immunotherapies and vaccines (Godinho-Silva et 
al., 2014).  
 
Another study performed in our laboratory aimed to clarify the role of BCR specificity in B cell 
susceptibility to MuHV-4 latency and how this is related to B cell activation. This study 
demonstrated that although viral latency is not restricted to virus-specific B cells, the establishment 
of latency in B cells is not a stochastic event in terms of BCR specificity, relying on mechanisms 
that remain to be identified (Decalf et al., 2014). 
 
 
 
1.5. Latency-associated nuclear antigen (LANA) 
 
1.5.1. KSHV LANA (kLANA) 
 
KSHV latency-associated nuclear antigen (kLANA), encoded by ORF73 gene, is one of the 
few proteins expressed during KSHV latency. kLANA is approximately 1,162 amino acids in length 
(Figure 1.3). A large repetitive region of acidic and glutamine-rich repeats is contained in the middle 
of the protein, separating the N- and C-terminal regions. Heterogeneity in the length of this internal 
repeat region of kLANA has been noted among KSHV isolates. The N-terminal region of kLANA 
contains a proline-rich region and binds to many chromatin-associated proteins. The C-terminal 
region contains a unique leucine-rich domain and another repeat region, followed by unique 
sequence, and associates with a number of host cell proteins and chromosomes. The unique C-
terminal region self-associates to bind DNA and recognizes a specific DNA sequence within the TR 
region of the KSHV genome (Ballestas and Kaye, 2011).  
 
In tumours and latently infected cells, the KSHV genome (~200 kb) persists as a multi-copy 
(10-50 copies per cell), covalently closed circular extrachromosomal plasmid (episome). To persist 
in proliferating cells, episomes must segregate to newly formed nuclei after mitosis. kLANA is 
critical for this process, by simultaneously binding host cell mitotic chromosomes and viral TR DNA 
sequences, and thus mediating viral episome maintenance in daughter cells (Ballestas et al., 1999; 
Ballestas and Kaye, 2001, 2011). Binding to TR DNA is mediated by C-terminal kLANA (Kelley-
Clarke et al., 2007b). N-terminal kLANA is the dominant chromosome association region (Kelley-
Clarke et al., 2009), binding to histones H2A/H2B (Barbera et al., 2006). However, C-terminal 
kLANA can also bind to chromosomes, with concentration at pericentromeric and peritelomeric 
regions (Kelley-Clarke et al., 2007a). Interestingly, a number of kLANA-associated proteins localize 
Chapter 1 
 
 
18 
in pericentromeric regions of chromosomes or are heterochromatin-associated proteins, including 
MecP2, Brd4, NuMA, CenpF and Bub1 (Matsumura et al., 2010; Ottinger et al., 2006; Si et al., 
2008; Xiao et al., 2010; You et al., 2006), some of which associate with C-terminal kLANA. These 
interactions are thought to contribute to kLANA tethering of viral genomes to mitotic chromatin.  
 
Another fundamental aspect during proliferation of latently infected cells is the replication of 
viral episome prior to each cell division, in order to avoid a loss in episome copy number per cell, 
which would eventually lead to the complete loss of the KSHV genome from proliferating cells. 
Replication of the KSHV genome is carried out by host cell DNA replication machinery, and kLANA 
was shown to play an important role in this process (Ballestas and Kaye, 2011; Uppal et al., 2014). 
C-terminal kLANA binds cooperatively to two adjacent LANA binding sites (LBS) located within 
each TR unit, a high-affinity site and a low-affinity site (Garber et al., 2002). Near these two binding 
sites is a 32 bp GC-rich element, and together they form the minimal kLANA DNA replication 
element (Hu and Renne, 2005). kLANA also recruits host replication factors, including origin 
recognition complex (ORC) subunits (ORC1-6), mini-chromosomal maintenance proteins (MCMs), 
topoisomerase IIβ and replication factor C (RFC), to the viral replication element (Purushothaman 
et al., 2012; Stedman et al., 2004; Sun et al., 2014; Verma et al., 2006). Thus, kLANA mediates 
replication of the KSHV genome in latently infected cells. Importantly, epigenetic modifications, 
including DNA methylation, chromatin modifications and nucleosome positioning, control kLANA-
mediated KSHV DNA replication during latency (Uppal et al., 2014). Nonetheless, recent studies 
have suggested that DNA replication can initiate throughout the KSHV genome and that the 
replication origin of the TRs only exhibits a slight preference for their usage, indicating that kLANA-
dependent origin at the TRs plays only a limited role in genome replication (Verma et al., 2011).  
 
kLANA is also known to modulate host cell gene expression by interacting with different 
transcription factors and chromatin regulatory proteins, and through direct binding to the regulatory 
regions of the cellular genes (Uppal et al., 2014). In particular, kLANA associates with the Mediator 
complex, a multi-subunit transcriptional co-activator complex for RNA polymerase II, suggesting 
that the viral protein can recruit the RNA polymerase II transcriptional machinery to activate 
transcription (Roupelieva et al., 2010). Consistent with this observation is the association of kLANA 
with transcriptional activators, including CBP, CREB2, c-jun, KLIP, Myc, Sp1, SRF, Stat3 and Rb 
(An et al., 2004; Bubman et al., 2007; Lim et al., 2001; Lim et al., 2000; Liu et al., 2007; Muromoto 
et al., 2006; Pan et al., 2003; Radkov et al., 2000; Roupelieva et al., 2010; Verma et al., 2004). 
Transcriptional repressors like CIR, I-mfa, Sap30a and Sin3a also interact with kLANA (Krithivas et 
al., 2000; Kusano and Eizuru, 2010). It has been proposed that these interactions have effects on 
viral persistence, cellular transcription and growth transformation. However, the actual impact of 
the association of kLANA with the plethora of reported transcriptional activators and repressors in 
the context of KSHV life cycle needs to be further elucidated. In addition, kLANA was shown to 
associate with the promoter region of several cellular genes (Lu et al., 2012), but it remains unclear 
whether this is sufficient to modulate host gene expression, and coordination with other factors may 
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be required (Mercier et al., 2014). kLANA also associates with several viral promoters to regulate 
transcription of viral genes. For instance, kLANA represses the promoter of Rta/ORF50, the KSHV 
lytic transactivator protein (Lukac et al., 1999), to inhibit its expression, as a mechanism to repress 
initiation of the viral lytic cycle and thus maintain latency (Lan et al., 2004). kLANA can also auto-
regulate its expression by inducing transcription from the kLANA promoter (Jeong et al., 2004). 
 
Control of cell cycle checkpoints and inhibition of apoptosis are hallmarks of proliferating 
tumour cells, including PEL cells and KS spindle cells. The association of kLANA with many 
proteins involved in cell cycle regulation suggests that it promotes cell survival. Furthermore, data 
gathered from protein interaction studies support the role of kLANA in cellular transformation, as 
certain kLANA-associated proteins can affect cell growth (Ballestas and Kaye, 2011). For example, 
kLANA represses Brd4-induced activation of the cyclin E promoter, promoting cell cycle 
progression (Ottinger et al., 2006). In addition, kLANA associates with the tumour suppressors Rb 
and p53, thereby activating E2F-dependent genes and modulating p53-dependent pathways to 
prevent cell cycle arrest and apoptosis (An et al., 2005; Cai et al., 2007; Friborg et al., 1999; 
Katano et al., 2001; Radkov et al., 2000; Si and Robertson, 2006; Wong et al., 2004). kLANA is 
also an activator of human telomerase reverse transcriptase (hTERT), the enzymatic subunit of 
telomerase, which has been shown to be an important determinant for cell immortalization (Verma 
et al., 2004). Moreover, kLANA stabilizes Myc by blocking glycogen synthase kinase-3 (GSK-3)-
mediated phosphorylation of Myc at T58 residue and thus its degradation, while independently 
stimulating extracellular signal-regulated kinase 1 (ERK1)-mediated phosphorylation at S62 
residue, an event that stabilizes Myc, thereby promoting its transcriptional activity and growth 
transformation properties (Liu et al., 2007). Other signalling pathways associated with cancer, such 
as Notch and Wnt pathways, are affected by kLANA (Fujimuro and Hayward, 2003; Fujimuro et al., 
2003; Wang et al., 2014). kLANA effects on cell growth may also be mediated by increases in 
survivin expression, an inhibitor of apoptosis (Lu et al., 2009). Finally, B cell-specific expression of 
kLANA in a transgenic mouse model resulted in follicular hyperplasia, increased GC formation, and 
lymphomas, suggesting that kLANA is a key player in KSHV-associated lymphomagenesis 
(Fakhari et al., 2006). 
 
In summary, kLANA is a multifunctional protein critical for KSHV latency, with a role in viral 
episome replication and persistence, regulation of host and viral transcription, and control of cell 
growth and proliferation. To accomplish this, kLANA interacts with a plethora of host cellular 
proteins, which are involved in diverse cellular processes. Hence, understanding kLANA role in 
modifying or adapting host cell protein function may provide an opportunity to control KSHV latent 
infection and related oncogenesis. 
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1.5.2. MuHV-4 LANA (mLANA) 
 
Like KSHV, MuHV-4 encodes a latency-associated nuclear antigen (mLANA), which is the 
product of ORF73 gene. mLANA is 314 amino acids in length, which is considerably smaller than 
the 1,162-amino acid kLANA (Figure 1.3) (Virgin et al., 1997). Most of the difference in size is due 
to the absence of the internal acidic and glutamine-rich repeat elements in mLANA. The N-terminal 
region of mLANA contains a proline-rich region and it was shown to interact with some host cell 
proteins (Rodrigues et al., 2013). The C-terminal region of mLANA has amino acid homology to the 
kLANA DNA binding domain (DBD) and, similarly to the latter, it self-associates to bind DNA and 
recognizes a specific DNA sequence within the TR region of the MuHV-4 genome (Correia et al., 
2013; Grundhoff and Ganem, 2003; Habison et al., 2012; Hellert et al., 2013; Paden et al., 2012).  
 
 
Figure 1.3. Schematic diagram of KSHV LANA (kLANA) and MuHV-4 LANA (mLANA). The proline-rich 
region (P) and the C-terminal region harbouring the DNA binding domain (DBD) shared by both proteins are 
indicated. DBD also mediates dimerization and interdimer association of LANA proteins. In kLANA, residues 5 
to 13 mediate chromosome association through binding to histones H2A/H2B. The internal region of kLANA, 
which is absent from mLANA, comprises aspartate-glutamate (DE), glutamine (Q), and glutamine-glutamate 
(EQE) regions, and also a putative leucine zipper (LZ) region. All these contain repeat elements. The internal 
unique region of kLANA comprising amino acids 262 to 320 is required for episomal replication (adapted from 
Ponnusamy et al., 2015). 
 
 
In contrast to kLANA, mLANA functions can be directly assessed in a mouse model of 
infection. Previous studies showed that a mLANA-null MuHV-4 virus exhibits a severe latency 
deficit in splenocytes from infected animals, particularly in GC B cells, thereby demonstrating that 
mLANA has a critical role in the establishment of latency and virus persistence in the host (Fowler 
et al., 2003; Moorman et al., 2003).  
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The role of mLANA in lytic replication is controversial. A study reported that mLANA-null virus 
displayed normal lytic replication both in vitro and in vivo (Fowler et al., 2003). In contrast, an 
independent study found that mLANA-null virus exhibited a modest defect in acute replication in the 
lungs of infected mice, suggesting that mLANA might play a role in lytic replication in vivo 
(Moorman et al., 2003). Differences in virus inoculum and in mouse strain may account for the 
divergence between the two published works. Afterwards, a third study reported a multiplicity of 
infection (MOI)-dependent requirement for mLANA in viral replication in fibroblasts (Forrest et al., 
2007), indicating that mLANA might also be involved in lytic replication in vitro, which again was not 
consistent with the work of Fowler et al. Possible explanations for the observed discrepancies 
include differences in the MOI and in the cell line used. Overall, these studies demonstrate that 
mLANA may have a role in lytic replication in vitro and in vivo, depending on the virus inoculum and 
the host. Some authors have speculated that either some aspect of mLANA function is required for 
virus replication in vivo (e.g. a function modulating the innate immune response to MuHV-4 
infection), or the establishment of latency in some cell type(s) followed by reactivation contributes 
to acute virus replication in vivo (Moorman et al., 2003). Nonetheless, the exact contribution of 
mLANA for acute virus replication is unknown, and it is well established that mLANA have a 
predominant role in latency. 
 
Like the other gammaherpesviruses, the MuHV-4 genome persists as a multi-copy, 
circularized, extrachromosomal episome in latently infected cells (Usherwood et al., 1996b). 
mLANA was reported to be required for efficient viral episome maintenance in vitro (Fowler et al., 
2003). This conclusion was based on the observation that a B cell line infected with the mLANA-
null MuHV-4 virus exhibited a significant decrease in viral episomes content compared to the same 
B cell line infected with the wild-type virus. Furthermore, analysis of viral genome-positive 
splenocytes from mice infected with the mLANA-null virus revealed the absence of viral episomes, 
implying that the viral genome was either integrated into the host chromosomes or maintained in a 
linear state (Paden et al., 2010). Thus, these data suggested that mLANA was involved in the 
formation and/or maintenance of an extrachromosomal viral episome in vivo. However, it was not 
until recently that the mechanism by which mLANA allows episome persistence was beginning to 
be elucidated and found to be reminiscent of kLANA-mediated KSHV episome persistence 
(Habison et al., 2012). In fact, this study demonstrated that mLANA acts on TR DNA sequences of 
the MuHV-4 genome to mediate viral episome persistence. Moreover, mLANA is broadly 
distributed throughout the nucleus in interphase and over mitotic chromosomes in episome-
deficient cells, but concentrates at dots both in interphase nuclei and along mitotic chromosomes in 
episome-containing cells. Hence, these dots likely correspond to sites where viral episomes are, 
supporting the hypothesis that mLANA directly tethers MuHV-4 episomes to mitotic chromosomes 
to efficiently segregate viral DNA into daughter nuclei, similarly to the tethering mechanism of 
kLANA. Future work is necessary to clarify the exact molecular mechanism underlying this process 
and to better understand the similarities and differences between mLANA and kLANA-mediated 
episome persistence. Unbiased mutagenesis of mLANA revealed a putative DBD, which was 
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shown to be required for the interaction of mLANA with viral TR DNA in vitro and for the 
establishment of latency in vivo (Paden et al., 2012). However, only the determination of the crystal 
structure of mLANA DBD allowed the identification of specific residues of mLANA involved in 
binding to DNA (section 1.6.3). The engineering of MuHV-4 recombinant viruses bearing mutations 
in these residues and the analysis of these DNA binding-deficient mutants in the mouse, thereby 
combining the structural data with the mouse model of infection, are necessary to provide an 
unequivocal evidence of the impact of mLANA DNA binding and episome maintenance in vivo. 
 
In addition to the episome maintenance function, mLANA is also able to modulate cellular 
transcription. Research conducted in our laboratory has demonstrated that mLANA assembles an 
E3 ubiquitin-ligase complex to mediate poly-ubiquitination of host transcription factors nuclear 
factor-kappa B (NF-κB) and Myc. mLANA promotes the poly-ubiquitination of nuclear p65/RelA, a 
member of the NF-κB family, targeting it to proteasomal degradation and thereby suppressing NF-
κB transcriptional activity (Rodrigues et al., 2009). Hence, mLANA mimics the GC physiological 
inhibition of NF-kB that prevents premature differentiation of GC B cells (Basso et al., 2004; Heise 
et al., 2014; Shaffer et al., 2001), suggesting that mLANA promotes the development of MuHV-4-
driven GC reactions to expand the host pool of latently infected cells (Rodrigues et al., 2009). In 
contrast, mLANA stabilizes Myc through heterotypic poly-ubiquitination, thereby prolonging its half-
life. Consequently, mLANA increases Myc transcriptional activity and expression of Myc target 
genes, which are involved in cellular growth and proliferation, thus promoting cell divisions during 
the expansion of MuHV-4 infected B cells in GCs. Stabilization of Myc by mLANA was 
demonstrated to be critical for MuHV-4-driven lymphoproliferation, as infected cells exhibit 
increased expression of Myc target genes and the virus amplifies exclusively in GC B cells 
containing intact Myc (Rodrigues et al., 2013). Interestingly, mLANA was also found to interact with 
bromodomain and extra-terminal (BET) proteins, particularly Brd2 and Brd4, to associate with 
cellular chromatin and activate BET-responsive promoters of G1/S cyclins, thus promoting cell 
cycle progression (Ottinger et al., 2009). Recent studies have demonstrated that mLANA 
interaction with BET proteins is important for the establishment of MuHV-4 latency in mice (Hellert 
et al., 2013). Notably, mLANA is required for MuHV-4 immortalization of murine foetal liver-derived 
B cells in vitro (Liang et al., 2011).  
 
In summary, mLANA exhibits functional homology to kLANA, mediating viral episome 
persistence and regulating cellular transcription. Therefore, mLANA represents a good model to 
study LANA pathogenesis in vivo, using a mouse model of infection. 
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1.6. Crystal structure of the DNA binding domain (DBD) of 
gammaherpesvirus episome maintenance proteins 
 
As mentioned before, during latent infection, gammaherpesvirus genome persists as a multi-
copy extrachromosomal plasmid (episome). To ensure episome persistence in proliferating latently 
infected cells, gammaherpesviruses encode episome maintenance proteins, which are critical for 
efficient segregation of episomes into daughter nuclei. Gammaherpesvirus episome maintenance 
proteins include EBV EBNA1, KSHV kLANA and MuHV-4 mLANA. 
 
Episome maintenance proteins must contain a DNA binding domain (DBD) that allows them to 
bind viral DNA. In fact, the crystal structures of EBV EBNA1, KSHV kLANA and MuHV-4 mLANA 
DBDs have been solved, and found to exhibit common structural features (Bochkarev et al., 1996; 
Bochkarev et al., 1995; Correia et al., 2013; Domsic et al., 2013; Hellert et al., 2015; Hellert et al., 
2013; Ponnusamy et al., 2015). The resolution of the crystal structure of DBDs provides 
advantages for pathogenesis studies, enabling the rational design of mutations in the DNA binding 
interface of episome maintenance proteins that may result in loss of DNA binding and episome 
persistence properties, with consequent elimination of viable virus in the host.  
 
 
1.6.1. Crystal structure of EBNA1 DBD 
 
The crystal structure of EBNA1 DBD was solved at 2.5 Å resolution (Bochkarev et al., 1995). 
Subsequently, the crystal structure of EBNA1 DBD bound to an 18 bp palindromic binding site was 
solved at 2.4 Å resolution (Bochkarev et al., 1996). These structural studies revealed that EBNA1 
DBD binds to its 18 bp palindromic binding site on viral DNA as a dimer. The EBNA1 dimer 
comprises two domains, the flanking and the core domains. The flanking domain of each monomer 
(amino acid residues 461-503) includes an α-helix that projects into the major groove of DNA and 
an extended chain that travels along the minor groove and mediates several sequence-specific 
contacts with the viral DNA. The core domain (amino acid residues 504-607) comprises the 
dimerization interface and also has a direct role in DNA recognition (Cruickshank et al., 2000). The 
structure of EBNA1 core domain contains an eight-stranded anti-parallel β-barrel, which is 
comprised of four strands from each monomer, and the β-strands in each monomer are connected 
by two α-helices on the outside of the barrel. The β-barrel is the scaffold of protein and is 
responsible for the marked stability of the EBNA1 dimer. In addition, EBNA1 is proposed to bend 
and distort the DNA at the origin of replication (oriP), which contains multiple copies of the 18 bp 
EBNA1 binding site (Bochkarev et al., 1996; Hsieh et al., 1993).  
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1.6.2. Crystal structure of kLANA DBD 
 
The crystal structure of kLANA C-terminal DBD was not solved until recently (Domsic et al., 
2013; Hellert et al., 2013). Interestingly, the structure shares the overall fold of EBNA1 DBD, 
despite the very little amino acid sequence homology shared between the two proteins. A central, 
anti-parallel β-sheet forms a hydrophobic core through which two protein subunits form a dimer. 
kLANA dimers are stabilized by an eight-stranded anti-parallel β-barrel to which each monomer 
contributes four β-strands. In addition to the stabilization by the hydrogen bonding network of the β-
barrel, hydrophobic amino acid side chains project into the core and form a tightly packed 
hydrophobic cluster. The β-barrel is flanked by two α-helices of each monomer, α2 and α3. The N-
terminal helix, α1, is packed against the two other helices and is not in direct contact with the 
central β-barrel. Remarkably, the crystal structure of kLANA DBD revealed a higher-ordered 
assembly comprised of five dimers interacting end-to-end, forming a decameric ring with an 
exterior DNA binding surface. The inter-dimer interactions are mediated by helices α1 and α3 
facing the equivalent helices in the second dimer. The oligomeric interface between kLANA dimers 
is dispensable for single site DNA binding, but is required for cooperative DNA binding, replication 
function, and episome maintenance. The crystal structure also identified an N-terminal arm, which 
is crucial for DNA interaction and, based on homology to EBNA1, likely wraps around the minor 
groove of the cognate DNA, providing for high affinity binding.  
 
Opposite to the DNA binding site, kLANA DBD harbours a characteristic lysine-rich positively 
charged surface patch (Domsic et al., 2013; Hellert et al., 2013), which is absent in EBNA1. This 
lysine patch contains key residues involved in interactions with cellular BET proteins Brd2 and 
Brd4, which have been shown to mediate kLANA function in chromosome binding, transcription 
regulation and cell cycle control (Ottinger et al., 2006; Viejo-Borbolla et al., 2005). A recent 
published work has demonstrated that the lysine patch exerts a key role in kLANA-mediated DNA 
replication and consequent episome persistence, likely acting through a host cell partner(s) other 
than a BET protein or by inducing specific structures or complexes (Li et al., 2015).  
 
Previous experiments demonstrated that kLANA cooperatively binds to two sites within the 
KSHV TR DNA, LBS1 and LBS2 (Garber et al., 2002). However, a third kLANA binding site, LBS3, 
was recently described (Hellert et al., 2015). All three sites are located in a region of the KSHV TR 
subunit previously recognized as a minimal replicator. LBS1 is a high-affinity site, whereas LBS2 
and LBS3 correspond to low-affinity sites. The crystal structure of kLANA DBD in complex with 
LBS1 has also been solved (Hellert et al., 2015), providing the basis for a plausible model to 
describe the arrangement of three kLANA dimers on the KSHV minimal replicator. In contrast to 
EBNA1, kLANA binds to the minimal replicator in an asymmetric manner. Binding of three kLANA 
dimers is facilitated by the presence of three kLANA binding sites and, in this assembly, the protein 
complex presumably follows the shape of a semicircle, with the lysine patches of the individual 
dimers oriented towards the centre. One helix α2 per dimer interacts with the major groove of DNA. 
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Intriguingly, it was shown that kLANA DBD can coat DNA of arbitrary sequence by virtue of its 
characteristic lysine patch, assembling into supermolecular spirals around DNA by self-association 
of kLANA (Hellert et al., 2015). It has been proposed that the KSHV minimal replicator may act as a 
structural template for the nucleation of kLANA spirals in trans. Such spirals may assemble on 
remote sites in the viral genome that are not directly defined by their DNA sequence. Once formed, 
this nucleator complex may recruit more free and/or LBS-bound kLANA dimers to cooperatively 
assemble a spiral of unknown length. Functionally, this self-assembly of kLANA oligomers may be 
involved in the formation of the latent subnuclear KSHV microdomains (kLANA speckles), which 
can be visualized by fluorescence microscopy and are a hallmark of KSHV latency (Gao et al., 
1996; Kedes et al., 1996; Simpson et al., 1996). These microdomains possibly also contain a 
plethora of cellular proteins, many of which are known to directly interact with kLANA (Hu et al., 
2014; Kaul et al., 2007). In addition, an oligomer might also incorporate kLANA binding sites in the 
host genome, which would further contribute to the physical link between virus and host chromatin 
(Mercier et al., 2014). Alternatively, the minimal replicator may induce kLANA spiral assembly 
directly on unspecific host DNA, which would have a similar effect. 
 
Another crystal form of kLANA DBD was shown to form dimer and bent tetramer assemblies 
(Ponnusamy et al., 2015). Interestingly, kLANA tetramer is intrinsically bent both in the free and 
bound state to LBS1-2 DNA. This bent conformation is driven by the core of hydrophobic residues 
in kLANA that are located at one end of both helices α1 and α3 at the dimer-dimer interface. 
kLANA DBD bent tetramer can adopt different bend angles, thereby facilitating kLANA cooperative 
binding and bending of DNA. This rotational flexibility is conferred by a hydrophobic pivot point 
located at the dimer-dimer assembly interface. The LBS1 and LBS2 sites are each expected to 
bind one kLANA dimer, hence formation of tetramer is required for binding with LBS1-2 DNA. In 
solution, kLANA maintains a bent conformation when bound to LBS1-2, but additionally assembles 
into an octamer ring with two LBS1-2 bound. Alterations in the arrangement of LBS within TR or at 
the tetramer assembly interface have a drastic effect on the ability of kLANA binding.  
 
In summary, the studies on kLANA DBD crystal structure have demonstrated that kLANA 
oligomerizes into different assemblies: a dimer, a tetramer, an octameric or decameric ring, and an 
infinitive number of dimers joined to form a spiral conformation. These assemblies may each have 
designated functions for KSHV, and the versatility of kLANA functions may be attributed to the 
different observed quaternary structures (Ponnusamy et al., 2015). 
 
 
1.6.3. Crystal structure of mLANA DBD 
 
The crystal structure of mLANA C-terminal DBD was recently solved by our consortium in the 
scope of the Harvard Medical School-Portugal (HMS-PT) Program (Correia et al., 2013), and by 
others (Hellert et al., 2013). Reminiscent of EBNA1, the tertiary structure of mLANA DBD exhibits 
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an α+β ferredoxin-like fold which assembles to form a dimeric eight-stranded anti-parallel β-barrel 
that is central to its functional architecture. Each monomer contributes an anti-parallel four-
stranded β-sheet ‘‘half-barrel’’ from which helices α2 and α3 pack onto the plaited sheet with their 
axis parallel to the strands of the sheet. The core of the barrel is occupied by large hydrophobic 
surface that contributes to the stability of mLANA. The flanking helix α1 caps this helical 
arrangement and lies perpendicular to the central β-barrel. mLANA DBD dimer forms a tetramer to 
cooperatively bind adjacent TR DNA binding sites. mLANA dimers pack so that the DNA-binding 
flanking helix α1 in each dimer is in position to interact with both the flanking helix α1 and helix α3 
from the adjacent dimer. 
 
Similarly to kLANA, mLANA DBD exhibits an electrostatic surface with a ventral (top) and a 
dorsal (bottom) face, corresponding to the opposite sides of the β-barrel core (Correia et al., 2013; 
Hellert et al., 2013). A representation of mLANA ventral and dorsal faces is shown in the 
introductions of chapter 2 (Figure 2.1) and chapter 3 (Figure 3.1), respectively. The ventral face of 
mLANA DBD contains a cluster of positively charged residues and was identified as the DNA 
binding interface, since disruption of targeted residues on the ventral surface abolishes DNA 
binding. Helix α2 is the predicted DNA recognition helix. Similarly to kLANA, mLANA cooperatively 
binds to two adjacent high and low-affinity TR DNA binding sites, MuHV-4 LANA binding site 1 
(mLBS1) and mLBS2, respectively. mLANA tetramers and octamers bound to mLBS1-2 have been 
described, but not rings or spiral-like structures (Ponnusamy et al., 2015). Remarkably, mLANA 
oligomers adopt a rigid linear conformation upon binding to DNA, rather than the bent conformation 
of kLANA tetramer. Interestingly, regardless of the binding modes, both kLANA and mLANA bind to 
reciprocal DNA, suggesting that it might be feasible to substitute mLANA with kLANA within MuHV-
4 virus in order to explore kLANA function in a mouse model of infection.  
 
Protruding perpendicular to the ventral face of mLANA DBD lies a partially disordered β2-β3 
loop (amino acid residues 199-215) that harbours a motif required for the interaction of mLANA 
with the components of the E3 ubiquitin-ligase complex (Correia et al., 2013; Rodrigues et al., 
2009). In addition, electrostatic surface analysis of mLANA DBD revealed an extensive positive 
patch on its dorsal side, opposite to the DNA binding interface, which is present in kLANA but 
absent in EBNA1 (Correia et al., 2013; Hellert et al., 2013). This dorsal face encompasses the 
identified 226QAKKLK231 motif that is involved in binding to BET proteins, particularly Brd2 and Brd4 
(Ottinger et al., 2009).  
 
In conclusion, MuHV-4 mLANA shares not only functional homology (section 1.5.2) but also 
structural homology to KSHV kLANA, emphasising the use of mLANA as a model for the study of 
kLANA pathogenesis in the mouse and even for testing pharmacological inhibitors of LANA 
functions through targeting of key structural features of the DNA binding domain.  
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1.7. E3 ubiquitin-ligase complexes assembled by LANA proteins 
 
In addition to their critical function in episome persistence, LANA proteins are able to 
assemble E3 ubiquitin-ligase complexes to modulate ubiquitination and thus control cellular 
pathways. Ubiquitination is a post-translational modification in which the small protein ubiquitin is 
attached to a protein substrate (Kerscher et al., 2006). Ubiquitin is covalently attached to a 
substrate lysine and one ubiquitin molecule is conjugated to the next through one of its seven 
lysines, leading to the formation of different types of poly-ubiquitin chains (Berndsen and 
Wolberger, 2014). The tagging of substrates with particular types of poly-ubiquitin chains 
determines their fate in the cell (Komander and Rape, 2012). Thus, ubiquitination is an essential 
regulatory mechanism in eukaryotes, controlling a wide range of cellular pathways. Ubiquitination 
occurs through a three-enzyme cascade (Figure 1.4), involving an E1 ubiquitin-activating enzyme, 
an E2 ubiquitin-conjugating enzyme and an E3 ubiquitin-ligase enzyme (Berndsen and Wolberger, 
2014). First, ubiquitin is activated by the E1 activating enzyme, in an adenosine triphosphate 
(ATP)-dependent reaction, resulting in the formation of a thioester bond between the E1 active site 
cysteine and the ubiquitin C-terminus. Ubiquitin is then transferred to the active site cysteine of the 
E2 conjugating enzyme, yielding an E2~ubiquitin thioester intermediate. Finally, the E3 ubiquitin-
ligase binds to the E2~ubiquitin intermediate and the substrate, catalysing the transfer of ubiquitin 
to the substrate target lysine (or, in some cases, to the substrate N-terminus). Distinct classes of 
E3 ubiquitin-ligases have been identified, including really interesting new gene (RING) E3s, which 
catalyse the direct transfer of ubiquitin from the E2 enzyme to the substrate, in a one-step reaction. 
In particular, Cullin5-RING E3 ubiquitin-ligases (CRL5), also known as 
ElonginBC/Cullin5/suppressor of cytokine signalling (SOCS) (EC5S) E3 ubiquitin-ligases, are 
multisubunit complexes containing a scaffold protein (Cullin5) attached to a RING finger protein 
(Rbx) (Cullin5-Rbx module), an adaptor heterodimer (ElonginB/C), and a substrate recognition 
protein (SOCS-box protein). The latter component bridges the substrate of ubiquitination to the E3 
ubiquitin-ligase complex, by interacting with ElonginB/C and Cullin5 through its SOCS-box 
(Lydeard et al., 2013; Skaar et al., 2013; Yoshimura et al., 2007).  
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Figure 1.4. The ubiquitination cascade. The ubiquitination cascade begins with ATP-dependent charging of 
the E1 activating enzyme and results in formation of a thioester bond between the ubiquitin C-terminus and 
the E1 active site cysteine. Ubiquitin is then transferred to the active site cysteine of the E2 conjugating 
enzyme in a transthioesterification reaction. An E3 ubiquitin-ligase catalyses the transfer of the ubiquitin from 
the active site cysteine of the E2 to a primary amine on a lysine side chain or protein N-terminus. There are 
three classes of E3 ubiquitin-ligases: the really interesting new gene (RING), the homology to E6AP C-
terminus (HECT) and the RING-between-RING (RBR). RING E3s bind to both E2~Ub thioester and substrate, 
catalysing the attack of the substrate lysine on the thioester. HECT and RBR E3s both have active site 
cysteines and catalyse substrate ubiquitination in a two-step reaction involving formation of a thioester with the 
HECT or RBR E3, followed by attack of the substrate lysine or N-terminus on the E3~Ub thioester to form an 
isopeptide (or peptide) linkage between the ubiquitin C-terminus and lysine (or the protein N-terminus) 
(adapted from Berndsen and Wolberger, 2014). 
 
 
kLANA assembles an E3 ubiquitin-ligase complex by recruiting ElonginB/C and Cullin5, 
through an unconventional SOCS-box motif, in order to target the tumour suppressors p53 and von 
Hippel-Lindau (VHL) for degradation, potentially providing a favourable environment for cell growth 
(Cai et al., 2006). Recent studies have demonstrated that the E3 ubiquitin-ligase complex 
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assembled by kLANA also targets the NF-κB family member p65/RelA for degradation, resulting in 
a reduction of interleukin-8 (IL-8) expression and neutrophil chemotaxis (Li et al., 2011). However, 
the relevance of kLANA E3 ubiquitin-ligase activity within the physiological context of KSHV latent 
infection in vivo remains to be clarified. 
 
Similarly to kLANA, mLANA assembles an E3 ubiquitin-ligase complex, EC5SmLANA, by 
recruiting ElonginB/C and Cullin5 (Figure 1.5), through an unconventional SOCS-box motif (amino 
acid residues 199-206) present in mLANA C-terminal domain (Rodrigues et al., 2009). mLANA also 
acts as the substrate recognition component of the EC5SmLANA complex, interacting with cellular 
substrates through motifs independent of the SOCS-box, as yet unidentified (Rodrigues et al., 
2009; Rodrigues et al., 2013). Two cellular targets of mLANA E3 ubiquitin-ligase activity are known: 
NF-κB and Myc. mLANA mediates poly-ubiquitination-dependent proteasomal degradation of the 
NF-κB family member p65, thus inhibiting NF-κB transcriptional activity (Rodrigues et al., 2009). In 
contrast, mLANA stabilizes Myc through heterotypic poly-ubiquitination, thus increasing Myc 
transcriptional activity (Rodrigues et al., 2013). Mutation of four key residues on mLANA SOCS-box 
(199VSCLPLVP206, underlined residues mutated to alanine) prevents mLANA binding to ElonginC, 
therefore abrogating mLANA E3 ubiquitin-ligase activity, and a recombinant MuHV-4 virus 
containing these mutations (vSOCS) exhibits a severe latency deficit, being unable to expand in 
GC B cells and persist in mice (Rodrigues et al., 2009). However, recent unpublished results 
demonstrated that the four mutations introduced in mLANA SOCS-box disrupt not only mLANA E3 
ubiquitin-ligase activity but also its ability to bind viral TR DNA and to mediate episome persistence 
(Tan et al., unpublished data). Therefore, the severe latency deficit of vSOCS recombinant virus 
cannot be exclusively attributed to the suppression of mLANA E3 ubiquitin-ligase activity, and the 
contribution of this function of mLANA for latent infection remains to be elucidated. 
 
 
Figure 1.5. E3 ubiquitin-ligase complex assembled by mLANA (EC5SmLANA). mLANA recruits ElonginB/C 
and Cullin5, through a SOCS-box motif, to assemble an E3 ubiquitin-ligase complex. In addition, mLANA is 
also the substrate recognition component of the complex, interacting with p65 and Myc through motifs 
independent of the SOCS-box. EC5SmLANA complex mediates poly-ubiquitination-dependent proteasomal 
degradation of the NF-κB family member p65, thus inhibiting NF-κB transcriptional activity. In contrast, 
EC5SmLANA stabilizes Myc through heterotypic poly-ubiquitination, thus increasing Myc transcriptional activity. 
EloB, ElonginB; EloC, ElonginC, Cul5, Cullin5; Ub, ubiquitin.   
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1.8. Aims 
 
During latency, the gammaherpesvirus genome is maintained as a non-integrated circular 
episome within the host cell nucleus. To persist in proliferating cells, viral episomes must replicate 
in step with normal cell division and segregate to newly formed nuclei after mitosis. LANA protein 
has been shown to mediate episome persistence, through binding to the TR sequences in viral 
genome. In addition, LANA regulates cellular transcription, including through E3 ubiquitin-ligase 
activity. Remarkably, the crystal structure of LANA DNA binding domain has been solved and 
revealed several structural features that are associated with specific LANA functions. The study of 
the mechanisms underlying LANA functions is crucial, since this protein is essential for the 
establishment and maintenance of latent infection in vivo. However, the individual contribution of 
each function assigned to LANA during the natural infection remains largely uncharacterized. 
 
As mentioned in the preface, this work was inserted into the project «Pathogenesis of Kaposi’s 
sarcoma herpesvirus LANA» of the HMS-PT Program from FCT, gathering the expertise of three 
research teams in KSHV LANA (Prof. K.M. Kaye group), structural biology (Prof. M.A. Carrondo 
and Dr C.E. McVey group) and in the murine model of MuHV-4 infection (Prof. J.P. Simas group). 
The aim of this thesis was to address the role of particular LANA functions in the context of 
gammaherpesvirus latent infection in vivo, combining LANA structural data, obtained by Carrondo 
and McVey group, with the animal model of infection with MuHV-4, in which our group is expert. 
MuHV-4 LANA, mLANA, was used as a model to investigate LANA pathogenesis in mice. To this 
end, MuHV-4 recombinant viruses harbouring structure-based mutations targeting specific mLANA 
interfaces were engineered, and the ability of these recombinants to establish and maintain latent 
infection was analysed upon intranasal infection of mice. 
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mLANA binding to TR DNA is essential for gammaherpesvirus 
latency expansion in GC B cells and persistence in the host 
 
2.1. Introduction 
 
During expansion of latency in GC B cells, MuHV-4 genomes (episomes) must replicate in 
step with normal cell division and segregate to daughter nuclei, in order to persist in proliferating 
cells. mLANA mediates viral episome persistence by binding to TR DNA sequences of the MuHV-4 
genome and tethering viral episomes to mitotic chromosomes, thus ensuring segregation of the 
viral DNA into daughter nuclei (Habison et al., 2012). 
 
The crystal structure of C-terminal mLANA DBD was recently solved by Prof. M.A. Carrondo 
and Dr C.E. McVey laboratory, and by others (Correia et al., 2013; Hellert et al., 2013). The 
structure uncovered an electrostatic surface with a ventral and a dorsal face. The ventral face 
contains a cluster of positively charged residues, identified as the DNA binding interface (Figure 
2.1, panel A). The structural basis for DNA recognition was inferred from the observed phosphate 
binding pattern, which revealed that five of the seven phosphate ions located at the surface of 
mLANA DBD are situated on the ventral face. This analysis demonstrated that histidine (H) 186 
and lysine (K) 187 residues, in the predicted DNA recognition helix α2 (Figure 2.1, panel B), are 
involved in interactions with phosphate ions of DNA. Notably, mutations at these residues 
(mLANAH186D/K187E) disrupt mLANA binding to TR DNA (Correia et al., 2013). 
 
To validate in vivo the DNA binding structural data, a MuHV-4 recombinant virus containing 
mLANA mutations H186D/K187E (vmLANAH186D/K187E) was engineered in the scope of this thesis. 
This recombinant virus was intranasally administered to C57BL/6 mice and its phenotype was 
analysed during the establishment and maintenance of latency by three independent, although 
complementary assays. Ex vivo reactivation assays were performed in total splenocytes to 
determine latent load in spleen. Limiting dilution coupled to real-time PCR to detect viral DNA-
positive cells (Marques et al., 2003) was applied to quantify the frequency of infection in total 
splenocytes and in GC B cells. Finally, in situ hybridization of splenic sections with viral 
tRNAs/miRNAs (Bowden et al., 1997; Simas et al., 1999) was performed to identify infected cells 
within the spleen.  
 
Data presented in this chapter is included in the publication in Appendix 1 (Correia et al., 
2013), in which I am first co-author. During the development of this work, two independent teams 
led by Prof. Thomas F. Schulz (Hellert et al., 2013) and Prof. Paul M. Lieberman (Domsic et al., 
2013) were also working on LANA structure. For this reason, the three articles were published back 
to back. 
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Figure 2.1. The ventral face of mLANA DBD. (A) Electrostatic surface potential representation showing the 
ventral side of mLANA dimer DBD. The five phosphate binding sites that trace DNA interactions are 
highlighted. The surface potentials displayed scale from -0.5 V (red, negatively charged) to +0.5 V (blue, 
positively charged) (Correia et al., 2013). (B) Ribbon representation of mLANA dimer in the same orientation 
as in (A). Residues H186 and K187, in the predicted DNA recognition helix α2, are highlighted. This panel was 
kindly provided by Dr Rajesh Ponnusamy from Dr C.E. McVey’s laboratory (Instituto de Tecnologia Química e 
Biológica (ITQB), Universidade Nova de Lisboa, Portugal). 
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2.2. Results 
 
2.2.1. Generation of a MuHV-4 recombinant virus harbouring mutations on 
mLANA ventral face 
 
To evaluate the importance of mLANA binding to viral TR DNA in MuHV-4 latent infection, a 
recombinant virus containing mLANA residues histidine (H) 186 and lysine (K) 187 substituted by 
aspartate (D) and glutamate (E), respectively, was engineered (vmLANAH186D/K187E virus).  
 
The MuHV-4 recombinant was generated by mutagenesis of the viral genome cloned as a 
bacterial artificial chromosome (BAC) (Adler et al., 2000), as described in detail in Materials and 
Methods, section 8.2.5. This technique allows the maintenance of the viral genome as a BAC in 
Escherichia coli and the site-directed mutagenesis of the genome by homologous recombination 
(Adler et al., 2003). Verification of the introduced mutations was carried out by sequencing across 
ORF73 gene in the BAC vector. The genomic structure of generated virus was verified by 
examination of restriction enzyme digestion profiles of E. coli-derived BAC DNA. 
 
Infectious viruses were reconstituted by transfection of BAC DNA into baby hamster kidney 
(BHK)-21 fibroblasts. Since MuHV-4 containing BAC sequences is attenuated in vivo compared to 
the wild-type virus (Adler et al., 2001), these sequences were removed by propagating the viruses 
in NIH-3T3 fibroblasts expressing Cre recombinase (Stevenson et al., 2002). In MuHV-4 BAC, the 
BAC sequences are flanked by loxP sites and the expression of Cre recombinase from the cellular 
genome results in efficient excision of the BAC sequences during growth.  
 
The stability of the introduced mutations was checked in viruses recovered from latently 
infected spleens, by sequencing ORF73 gene in viral high molecular weight (HMW) DNA extracted 
from frozen-thawed splenocyte suspensions of infected mice. This analysis confirmed the retention 
of the engineered point mutations following in vivo infection. 
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2.2.2. vmLANAH186D/K187E recombinant virus displays normal lytic replication 
kinetics in vitro and in vivo 
 
In vitro lytic replication kinetics of vmLANAH186D/K187E recombinant virus was compared to that 
of the vWT virus by a multi-step growth curve in permissive BHK-21 fibroblasts. Cells were infected 
at a low MOI and virus titres were determined at 0, 24, 48, 72, 96 and 120 hours post-infection. 
vmLANAH186D/K187E replicated to higher levels than vWT for the first 48 hours post-infection, followed 
by a growth plateau, while vWT virus reached a slightly higher growth plateau at 96 hours post-
infection (Figure 2.2, panel A). Despite these differences, the lytic replication kinetics in vitro was 
essentially preserved for vmLANAH186D/K187E virus. 
 
The course of MuHV-4 infection upon intranasal inoculation is characterized by the 
establishment of a productive infection in alveolar epithelial cells that peaks at 4 to 7 dpi and is then 
resolved to undetectable levels by 10 to 12 dpi (Sunil-Chandra et al., 1992a). In vivo acute phase 
replication kinetics of vmLANAH186D/K187E recombinant virus was determined and compared to that 
of vWT virus in lung tissue of infected C57BL/6 mice. Following intranasal inoculation of C57BL/6 
mice, lungs were removed at 3, 7 and 14 dpi, and the titre of infectious viruses was determined in 
frozen-thawed lung homogenates by plaque assay. At the peak of lytic infection, vmLANAH186D/K187E 
virus exhibited a deficit of about 10-fold compared to vWT virus (Figure 2.2, panel B). However, the 
lytic replication kinetics of vmLANAH186D/K187E in vivo was similar to that of vWT, with peak titres at 
around 7 dpi and clearance by day 14 (Figure 2.2, panel B).  
 
Taken together, these results demonstrate that vmLANAH186D/K187E recombinant virus displays 
normal lytic replication kinetics in vitro and in vivo, consistent with mLANA having a predominant 
role in latency (Fowler et al., 2003; Marques et al., 2003). 
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Figure 2.2. vmLANAH186D/K187E recombinant virus displays normal lytic replication kinetics in vitro and 
in vivo. (A) Multi-step growth curves were constructed by infection of BHK-21 cells with the indicated viruses 
at low MOI (0.01 plaque forming units (PFU)/cell). At the indicated times post-infection, samples were 
harvested and virus titres were determined by plaque assay of frozen-thawed samples. (B) C57BL/6 mice 
were intranasally infected with 104 PFU of the indicated viruses. At 3, 7 and 14 days post-infection, lungs were 
removed and infectious viruses were titrated by plaque assay of frozen-thawed lung homogenates. Each point 
shows the titre of an individual mouse. Horizontal lines indicate arithmetic means. The dashed line represents 
the limit of detection of the assay.  
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2.2.3. mLANA binding to viral TR DNA is required for the establishment and 
maintenance of MuHV-4 latency 
 
Following lytic replication in the lung, MuHV-4 disseminates to the lymphoid tissue, namely the 
spleen and lymph nodes, where it establishes a latent infection (Sunil-Chandra et al., 1992a). 
Latent infection in the spleen is characterized by an initial proliferation of infected B cells and 
consequent amplification of the latent virus, reaching maximum levels around 14 dpi and 
decreasing thereafter to low levels, which remain stable throughout the entire life of the host 
(Cardin et al., 1996; Flano et al., 2003; Marques et al., 2003; Simas and Efstathiou, 1998; Sunil-
Chandra et al., 1992b). 
 
To evaluate the importance of mLANA binding to viral TR DNA in MuHV-4 latent infection, 
C57BL/6 mice were intranasally infected with vmLANAH186D/K187E recombinant virus and latent load 
in spleen was determined by quantification of ex vivo reactivation-competent viruses in total 
splenocytes by infectious centre assay. For comparative purposes, vWT virus, expressing a fully 
functional mLANA, was also included in the experiments.  
 
Infectious centre assay (Marques et al., 2003; Sunil-Chandra et al., 1992a), also known as ex 
vivo reactivation assay, is a well-established assay in which single cell suspensions are prepared 
from the harvested spleens, serially diluted and co-cultured with permissive fibroblast cells. The 
presence of latent virus in the splenocyte population is revealed by the observation of cytopathic 
effect (cpe) – plaques of cell lysis – in fibroblast monolayers. Viral plaques are counted and 
infectious centres titre is expressed as the number of plaque forming units (PFU) per spleen, 
considering that a viral plaque is originated by a single PFU. Unless preformed infectious viruses 
are present at the time of harvest, cpe can only result from viral reactivation from latency. Thus, to 
confirm that the results obtained for each virus truly reflect latent infection, spleen samples must 
also be analysed for the presence of preformed infectious viruses. To this end, replicate samples 
are subjected to freeze-thawing to disrupt the cells and, consequently, any possibility of 
reactivation from latency, without inactivating preformed infectious virus. Replicating viruses are 
then detected by incubation with permissive cells, which are later examined for the presence of 
cpe. 
 
vmLANAH186D/K187E recombinant virus was examined at 14 and 21 dpi for its ability to establish 
and expand latent infection in the spleen, and at 50 dpi for its ability to maintain long-term 
persistence. The results obtained are shown in Figure 2.3, panel A. vWT virus presented the 
expected peak of infection at 14 dpi, with latent infection subsiding at 21 dpi to reach low long-term 
latency levels at 50 dpi (Figure 2.3, panel A). In contrast, vmLANAH186D/K187E virus exhibited a 
marked defect in ex vivo reactivation assay, being barely detectable beyond the limit of detection of 
the assay as soon as 14 dpi (Figure 2.3, panel A). Analysis of vmLANAH186D/K187E infection at 21 
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and 50 dpi revealed that virus persistence in mice was severely compromised (Figure 2.3, panel 
A). 
 
Not every latently infected cell necessarily reactivates its virus ex vivo. Therefore, the ex vivo 
reactivation assay was complemented with limiting dilution coupled to real-time PCR to detect viral 
DNA-positive cells (Marques et al., 2003), as a second measure of the frequency of infection of 
total splenocytes.  
 
To this end, C57BL/6 mice intranasally infected with vWT or vmLANAH186D/K187E viruses were 
analysed at 14, 21 and 50 dpi. Total splenocytes were subjected to 2-fold serial dilutions, with 8 
replicates per dilution, and lysed. Cell lysates were then analysed by real-time PCR for the 
presence of viral genomes, using the fluorescent TaqMan methodology with primers and probe 
specific for MuHV-4 M9 gene. Further details are described in Materials and Methods, section 
8.2.10. 
 
The results obtained are in agreement with results from ex vivo reactivation assay. At 14 dpi, 
the peak of latency amplification, the frequency of vmLANAH186D/K187E DNA-positive total 
splenocytes was two orders of magnitude lower in comparison with vWT infection (Figure 2.3, 
panel B and Table 2.1). The incapability of vmLANAH186D/K187E to amplify latency resulted in a 
severe deficit of virus persistence at 21 and 50 dpi when compared to vWT (Figure 2.3, panel B 
and Table 2.1). 
 
Altogether, these data demonstrate that mLANA binding to viral TR DNA is required for the 
establishment and maintenance of MuHV-4 latency. 
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Figure 2.3. mLANA binding to viral TR DNA is required for the establishment and maintenance of 
MuHV-4 latency. (A) Quantification of latent infection in spleen by ex vivo reactivation assay. C57BL/6 mice 
were intranasally infected with 104 PFU of the indicated viruses. At days 14, 21 and 50 post-infection, latent 
viruses in spleens were titrated by infectious centre assay (closed circles). Titres of preformed infectious 
viruses were determined in frozen-thawed splenocyte suspensions (open circles). Each circle represents the 
titre of an individual mouse. Horizontal bars show arithmetic means. The dashed line represents the limit of 
detection of the assay. (B) Quantification of viral DNA-positive cells in total splenocytes. C57BL/6 mice were 
intranasally infected with 104 PFU of the indicated viruses. At days 14, 21 and 50 post-infection, reciprocal 
frequencies of viral infection in total splenocytes were determined by limiting dilution and real-time PCR. Data 
were obtained from pools of five spleens per group. Bars represent the frequency of viral DNA-positive cells 
with 95% confidence intervals. 
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Table 2.1. Frequency of MuHV-4 latent infection in total splenocytesa. 
Virus Dpi Reciprocal frequencyb of viral DNA+ cells (95% CI) 
vWT 
14 310 (198-707) 
21 2243 (1405-5545) 
50 4976 (3220-10952) 
vmLANAH186D/K187E 
14 17377 (11229-38406) 
21 30949 (20094-67314) 
50 25919 (16901-55571) 
aData were obtained from pools of 5 spleens. 
bFrequencies were calculated by limiting dilution coupled to real-time PCR, with 95% confidence intervals (CI). 
 
 
 
2.2.4. mLANA binding to viral TR DNA is essential for MuHV-4 latency 
expansion in GC B cells 
 
During the establishment of latent infection in the spleen, MuHV-4 colonizes multiple cell 
types. However, the main target of latent infection is B lymphocytes (Flano et al., 2000; Marques et 
al., 2003). To assess whether the deficit in the establishment of latency exhibited by 
vmLANAH186D/K187E recombinant virus reflected a phenotype in GC B cells, the frequency of viral 
DNA-positive cells in this subpopulation was determined by limiting dilution combined with real-time 
PCR (Marques et al., 2003). 
 
C57BL/6 mice were intranasally infected with vWT or vmLANAH186D/K187E viruses and spleens 
were harvested at 14 dpi. Splenocyte suspensions were prepared and stained with three cell 
surface markers: anti-CD19, anti-CD95 and anti-GL7 T and B cell activation marker. GC B cells 
were purified by flow activated cell sorting (FACS), through enrichment for CD19+CD95hiGL7hi cells. 
The purity of the sorted GC B cell population was higher than 95%. Purified GC B cells were 2-fold 
serially diluted and 8 replicates of each dilution were analysed by real-time PCR for the presence of 
viral genomes, using a set of primers and probe specific for MuHV-4 M9 gene. Further details are 
described in Materials and Methods, section 8.2.10. 
 
The results obtained are shown in Figure 2.4 and Table 2.2. The frequency of 
vmLANAH186D/K187E infection in GC B cells at 14 dpi was three orders of magnitude lower comparing 
to vWT infection. This result shows that the severe latency deficit in spleen reported earlier for 
vmLANAH186D/K187E recombinant virus (section 2.2.3) reflects a marked impairment in the ability of 
the virus to drive latency expansion in GC B cells.  
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Figure 2.4. mLANA binding to viral TR DNA is essential for MuHV-4 latency expansion in GC B cells. 
Quantification of viral DNA-positive cells in GC B cells. C57BL/6 mice were intranasally infected with 104 PFU 
of the indicated viruses. At day 14 post-infection, reciprocal frequencies of viral infection in FACS-purified GC 
B cells (CD19+CD95hiGL7hi) were determined by limiting dilution and real-time PCR. Data were obtained from 
pools of five spleens per group. Bars represent the frequency of viral DNA-positive cells with 95% confidence 
intervals. 
 
 
 
Table 2.2. Frequency of MuHV-4 latent infection in GC B cellsa. 
Virus Dpi Reciprocal frequencyb of viral DNA+ cells (95% CI) 
vWT 
14 
6 (4-14) 
vmLANAH186D/K187E 3079 (2006-6619) 
aData were obtained from pools of 5 spleens. The purity of sorted cells was determined by FACS analysis and 
was always greater 95%. 
bFrequencies were calculated by limiting dilution coupled to real-time PCR, with 95% confidence intervals (CI). 
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2.2.5. Loss of mLANA-mediated TR DNA binding abolishes MuHV-4 
colonization of splenic follicles 
 
To complement the data of frequencies of infection in GC B cells during acute virus-driven 
lymphoproliferation, the ability of vmLANAH186D/K187E virus to colonize splenic follicles and to induce 
latency expansion in GCs was assessed by in situ hybridization, using a probe specific for MuHV-4 
tRNAs and miRNAs (Bowden et al., 1997; Pfeffer et al., 2005). These transcripts are abundantly 
expressed in the GC and constitute an important marker for latency, allowing the analysis of the 
colonization and expansion of latent infection in GCs (Bowden et al., 1997; Simas et al., 1999). 
C57BL/6 mice were intranasally infected with vWT or vmLANAH186D/K187E viruses and at 14 dpi 
spleens were dissected, fixed and paraffin-embedded. Spleen sections were made and processed 
for in situ hybridization with viral tRNAs/miRNAs specific riboprobes (details in Materials and 
Methods, section 8.2.11). Three spleens and six sections per spleen were analysed per virus. 
Pictures of representative spleen sections from each group of animals were taken. 
 
Mice infected with vWT virus exhibited the typical large clusters of infected cells within GCs at 
14 dpi (Figure 2.5, panel a) (Simas et al., 1999). These clusters correspond to cellular proliferation 
and consequent expansion of the latently infected cell pool. In contrast, in situ hybridization showed 
that vmLANAH186D/K187E virus had a severe impairment in GC colonization, with consequent 
abolishment of the proliferation of latently infected cells within splenic follicles (Figure 2.5, panel b). 
 
In situ hybridization results are consistent with the previous data, demonstrating that loss of 
mLANA-mediated TR DNA binding during latent infection severely compromises host GC 
colonization. 
 
 
Figure 2.5. Loss of mLANA-mediated TR DNA binding abolishes MuHV-4 colonization of splenic 
follicles. C57BL/6 mice were intranasally infected with 104 PFU of the indicated viruses. At 14 days post-
infection, spleens were dissected and processed for in situ hybridization with a viral tRNA/miRNA-specific 
riboprobe. Panels show representative spleen sections from each group of animals. Dark staining indicates 
cells positive for virally encoded tRNAs/miRNAs. All sections are magnified x200 and counterstained with 
haematoxylin. 
 
vmLANA: WT H186D/K187E
14 dpi
a b
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2.2.6. Phenotypic changes in vmLANAH186D/K187E recombinant virus are intrinsic 
to ORF73 locus and not the consequence of mutations elsewhere in 
MuHV-4 genome  
 
To ensure that the phenotypic alterations observed in vmLANAH186D/K187E recombinant virus 
were due to the mutations introduced in mLANA, which disrupted binding to viral TR DNA, and not 
the consequence of mutations introduced elsewhere in MuHV-4 genome during mutagenesis, a 
revertant virus (vmLANAH186D/K187E-R) was generated. In this revertant virus, the ORF73 locus was 
restored to the wild-type status, by mutagenesis of the viral genome cloned as a BAC (Adler et al., 
2000), as described in detail in Materials and Methods, section 8.2.5.   
 
C57BL/6 mice were intranasally infected with vWT virus or vmLANAH186D/K187E-R revertant 
virus and latent load in spleen was determined by quantification of ex vivo reactivation-competent 
viruses in total splenocytes by infectious centre assay. 
 
vmLANAH186D/K187E-R revertant virus was examined at 14 dpi for its ability to establish and 
expand latent infection in the spleen. Infectious centre assay showed that vmLANAH186D/K187E-R 
virus established normal latency levels in spleen (Figure 2.6).  
 
These results demonstrate that vmLANAH186D/K187E phenotype is reverted to the wild-type 
phenotype when ORF73 locus is restored to the wild-type status. Thus, these data confirm that the 
phenotypic changes observed with vmLANAH186D/K187E recombinant virus result from the mutations 
in mLANA which disrupted DNA binding, and not from mutations elsewhere in the viral genome. 
 
 
Figure 2.6. Phenotypic changes in vmLANAH186D/K187E recombinant virus are intrinsic to ORF73 locus 
and not the consequence of mutations elsewhere in MuHV-4 genome. Quantification of latent infection in 
spleen by ex vivo reactivation assay. C57BL/6 mice were intranasally infected with 104 PFU of the indicated 
viruses. At day 14 post-infection, latent viruses in spleens were titrated by infectious centre assay (closed 
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circles). Titres of preformed infectious viruses were determined in frozen-thawed splenocyte suspensions 
(open circles). Each circle represents the titre of an individual mouse. Horizontal bars show arithmetic means. 
The dashed line represents the limit of detection of the assay.  
 
 
 
2.3. Discussion 
 
This work demonstrates the essential role of mLANA DNA binding interface in 
gammaherpesvirus latent infection, as a MuHV-4 recombinant virus containing mLANA abolished 
for DNA binding was severely compromised in its ability to establish latent infection in mice.  
 
mLANA binding to viral TR DNA was shown to be required for the establishment of MuHV-4 
latency. At 14 dpi, the peak of viral latent infection (Cardin et al., 1996; Marques et al., 2003), 
vmLANAH186D/K187E recombinant virus harbouring mLANA abolished for DNA binding exhibited a 
severe deficit in latency levels in the spleen, as assessed by ex vivo reactivation assay and 
quantification of the frequency of infection in total splenocytes. This deficit resulted from a marked 
impairment of virus-driven latency expansion in GC B cells, which severely compromised the 
colonization of splenic follicles. Hence, mLANA binding to viral TR DNA is critical for viral 
persistence in proliferating GC B cells. These data validate earlier studies with mLANA-null virus, 
which reported a requirement of mLANA for efficient viral episome maintenance in vitro (Fowler et 
al., 2003) and for the maintenance of an extrachromosomal viral episome in vivo (Paden et al., 
2010). In addition, these results are consistent with the finding that virus containing mLANA 
incapable of binding DNA was highly deficient for establishment of latency in vivo (Paden et al., 
2012). Notwithstanding, the work presented in this chapter is novel in the sense that the mutations 
introduced in mLANA were based on structural data and thus specific for DNA binding (Correia et 
al., 2013), in contrast to the random mutagenesis strategy previously used to identify DNA binding-
deficient mutants (Paden et al., 2012). The structural basis for DNA recognition was inferred from 
the observed phosphate binding pattern, which demonstrated that residues H186 and K187 were 
involved in interactions with phosphate ions of DNA (Correia et al., 2013). Therefore, the 
phenotypic alterations of vmLANAH186D/K187E recombinant virus can be specifically attributed to the 
loss of mLANA-mediated DNA binding. The resolution of the crystal structure of mLANA DBD 
complexed with viral TR DNA, revealing the residues bound to DNA, would be the unequivocal 
demonstration that vmLANAH186D/K187E recombinant virus contains mutations in the residues of 
mLANA directly involved in DNA binding.  
 
Disruption of targeted residues on mLANA ventral face abolishing DNA binding also severely 
compromised virus persistence, as assessed at 21 and 50 dpi, demonstrating that mLANA binding 
to viral TR DNA is also required for maintenance of MuHV-4 latency. Moreover, these data suggest 
that the virus incapability to amplify latency in GC B cells has a great impact on long-term 
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maintenance of latency. These findings support the proposed model in which MuHV-4 expansion of 
latent infection in GC B cells as a strategy to access persistence in long-lived memory B cells is 
vital for host colonization, reminiscent of the strategy employed by EBV (Flano et al., 2002; 
Thorley-Lawson, 2001). 
 
The ability of LANA proteins to bind TR DNA is important for both viral DNA replication and 
episome persistence (Ballestas and Kaye, 2011; Habison et al., 2012; Uppal et al., 2014). Although 
a role of mLANA in the replication of the MuHV-4 genome is not formally demonstrated, it is 
reasonable to think that, given its functional homology to KSHV kLANA, mLANA is involved in viral 
DNA replication. Hence, the phenotypic alterations observed for vmLANAH186D/K187E recombinant 
virus can be ascribed both to a loss of mLANA-mediated episome persistence and to a lack of 
mLANA-mediated DNA replication. However, kLANA-dependent origin of replication at the TRs 
was shown to play only a limited role in KSHV genome replication (Verma et al., 2011), supporting 
the hypothesis that the deficiency of mLANA episome maintenance function exerts a major 
contribution to make latency unviable compared to the impairment of genome replication function. 
 
Although the kinetics of lytic replication was essentially preserved for vmLANAH186D/K187E 
recombinant virus compared to vWT virus, vmLANAH186D/K187E exhibited a 10-fold reduction in lytic 
replication levels in the lungs of infected mice, similar to the phenotype reported before for mLANA-
null virus in C57BL/6 mice (Moorman et al., 2003). This result suggests that mLANA binding to viral 
TR DNA may have a minor role in lytic replication in vivo. For instance, if virus reactivation from 
some latently infected cell types contributes to lytic replication in vivo, as previously proposed by 
Moorman et al., mLANA binding to DNA may be important for the establishment of that early 
latency.  
 
In conclusion, the resolution of the crystal structure of mLANA DBD enabled the rational 
design of mutations in the DNA binding interface that resulted in loss of DNA binding and 
consequently severely compromised virus-associated GC B cell proliferation and persistence of 
viable virus in the host. Hence, this work highlights the importance of combining structural data with 
an animal model of infection to investigate gammaherpesvirus pathogenesis. 
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mLANA dorsal positive patch is required for efficient expansion 
of gammaherpesvirus latency in GC B cells 
 
3.1. Introduction 
 
The crystal structure of mLANA DBD revealed an extensive positive patch on its dorsal side 
(Figure 3.1, panel A), opposite to the DNA binding interface. This dorsal positive patch, unique to 
LANA proteins, includes lysine (K) residues 224, 225, 228, 229, 231, 251 and 253, and arginine (R) 
residues 156 and 232 of mLANA. Notably, four key lysine residues are conserved in both mLANA 
(K228, K229, K251 and K253) and kLANA (K1113, K1114, K1138 and K1140). mLANA residues 
K228 and K229 are located at the periphery of the positive patch, whereas K251 and K253 are in 
the central region of the positive patch (Figure 3.1, panel B) (Correia et al., 2013; Domsic et al., 
2013; Hellert et al., 2013).  
 
Interestingly, mLANA dorsal positive patch harbours the identified 226QAKKLK231 motif that is 
involved in binding to BET proteins, particularly Brd2 and Brd4 (Correia et al., 2013; Hellert et al., 
2013; Ottinger et al., 2009). Previous studies demonstrated that mLANA interacts with BET 
proteins to associate with cellular chromatin and activate BET-responsive promoters of G1/S 
cyclins, thus promoting cell cycle progression (Ottinger et al., 2009). 
 
To investigate if the dorsal positive patch exerts a functional role in vivo, MuHV-4 recombinant 
viruses containing mLANA mutations that targeted either the central or the peripheral regions of the 
dorsal positive patch were engineered. Recombinant viruses were intranasally administered to 
C57BL/6 mice and the effect of the engineered mLANA mutations on establishment and 
maintenance of latent infection was assessed by three complementary assays. Latent load in 
spleen was determined by quantification of ex vivo reactivation-competent viruses in total 
splenocytes by infectious centre assay. Limiting dilution coupled to real-time PCR to detect viral 
DNA-positive cells (Marques et al., 2003) was applied to quantify the frequency of infection of total 
splenocytes and of GC B cells. In situ hybridization of splenic sections with viral tRNAs/miRNAs 
(Bowden et al., 1997; Simas et al., 1999) was performed to identify infected cells within the spleen. 
 
Data presented in this chapter is included in the publication in Appendix 1 (Correia et al., 
2013).  
 
Chapter 3 
 
 
50 
 
Figure 3.1. The dorsal positive patch of mLANA DBD. (A) Electrostatic surface potential representation 
showing the dorsal side of mLANA dimer DBD. Residues R156, K224, K225, K228, K229, K231 and R232, 
which run along the spine of the dorsal face, contribute to the positive electrostatic potential. The QAKKLK 
motif is highlighted. The surface potentials displayed scale from -0.5 V (red, negatively charged) to +0.5 V 
(blue, positively charged) (Correia et al., 2013). (B) Ribbon representation of mLANA dimer in the same 
orientation as in (A). Residues K224, K228 and K229, at the periphery of the dorsal positive patch, and 
residues K251 and K253, in the central region, are highlighted. Helix α3 is identified. This figure was gently 
provided by Dr Rajesh Ponnusamy from Dr C.E. McVey’s laboratory (ITQB, Universidade Nova de Lisboa, 
Portugal). 
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3.2. Results 
 
3.2.1. Generation of a MuHV-4 recombinant virus harbouring mutations on 
mLANA dorsal positive patch 
 
To clarify the role of mLANA dorsal positive patch in MuHV-4 latent infection, four recombinant 
viruses were engineered. vmLANAK224A/K228A/K229A and vmLANAK224E/K228E/K229E recombinants 
harboured lysine (K) residues 224, 228 and 229, at the periphery of mLANA positive patch, 
substituted by alanine (A) or glutamate (E), respectively, whereas vmLANAK251A/K253A and 
vmLANAK251E/K253E recombinants contained similar substitutions in residues K251 and K253, which 
are located in the central region of the positive patch (Figure 3.1, panel B). K228, K229, K251 and 
K253 are conserved between LANA proteins, suggesting that they might be important for LANA 
function. K224 is not a conserved residue, but it was also mutated since it is exposed on the 
surface of helix α3, similarly to K228 and K229 (Figure 3.1, panel B) (Correia et al., 2013; Domsic 
et al., 2013; Hellert et al., 2013).  
 
MuHV-4 recombinants were generated by mutagenesis of the viral genome cloned as a BAC 
(Adler et al., 2000), as described in detail in Materials and Methods, section 8.2.5. Verification of 
the introduced mutations was carried out by sequencing across ORF73 gene in the BAC vector. 
The genomic structure of generated virus was verified by examination of restriction enzyme 
digestion profiles of E. coli-derived BAC DNA. Infectious viruses were reconstituted by transfection 
of BAC DNA into BHK-21 fibroblasts and BAC sequences were removed by propagating the 
viruses in NIH-3T3 fibroblasts expressing Cre recombinase (Stevenson et al., 2002). The stability 
of the introduced mutations was checked in viruses recovered from latently infected spleens, by 
sequencing ORF73 gene in viral HMW DNA extracted from frozen-thawed splenocyte suspensions 
of infected mice. This analysis confirmed the retention of the engineered point mutations following 
in vivo infection. 
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3.2.2. Recombinant viruses containing mutations on mLANA dorsal positive 
patch display normal lytic replication kinetics in vitro and in vivo 
 
In vitro lytic replication kinetics of recombinant viruses containing mutations on mLANA dorsal 
positive patch was compared to that of the vWT virus by a multi-step growth curve in permissive 
BHK-21 fibroblasts. Cells were infected at a low MOI and virus titres were determined at 0, 24, 48, 
72, 96 and 120 hours post-infection. vmLANAK224E/K228E/K229E, vmLANAK251A/K253A and 
vmLANAK251E/K253E viruses exhibited an in vitro growth kinetics equivalent to the vWT virus (Figure 
3.2, panel A), with increasing levels of replication until 96 hours post-infection, when a growth 
plateau was established. vmLANAK224A/K228A/K229A replicated to higher levels than vWT for the first 
72 hours post-infection, followed by a growth plateau until 96 hours post-infection, when lytic 
replication started to decline (Figure 3.2, panel A). Despite these differences, the lytic replication 
kinetics in vitro was essentially preserved for vmLANAK224A/K228A/K229A virus. 
 
Next, in vivo acute phase replication kinetics of recombinant viruses was determined and 
compared to that of vWT virus in lung tissue of infected C57BL/6 mice. Following intranasal 
inoculation of C57BL/6 mice, lungs were removed at 3, 7 and 14 dpi, and the titre of infectious 
viruses was determined in frozen-thawed lung homogenates by plaque assay. Recombinant 
viruses showed identical lytic replication kinetics in the lungs of infected mice (Figure 3.2, panel B), 
with peak titres at 7 dpi and clearance at 14 dpi.  
 
Taken together, these results demonstrate that the mutations introduced on mLANA dorsal 
positive patch did not affect viral lytic replication kinetics in vitro and in vivo, consistent with mLANA 
having a predominant role in latency (Fowler et al., 2003; Marques et al., 2003). 
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Figure 3.2. Recombinant viruses containing mutations on mLANA dorsal positive patch display 
normal lytic replication kinetics in vitro and in vivo. (A) Multi-step growth curves were constructed by 
infection of BHK-21 cells with the indicated viruses at low MOI (0.01 PFU/cell). At the indicated times post-
infection, samples were harvested and virus titres were determined by plaque assay of frozen-thawed 
samples. (B) C57BL/6 mice were intranasally infected with 104 PFU of the indicated viruses. At 3, 7 and 14 
days post-infection, lungs were removed and infectious viruses were titrated by plaque assay of frozen-thawed 
lung homogenates. Each point shows the titre of an individual mouse. Horizontal lines indicate arithmetic 
means. The dashed line represents the limit of detection of the assay.  
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3.2.3. The positive patch periphery of mLANA dorsal face is required for 
efficient expansion of MuHV-4 latency 
 
To investigate the role of mLANA dorsal positive patch in MuHV-4 latent infection, C57BL/6 
mice were intranasally infected with the recombinant viruses described in section 3.2.1. vWT virus 
was included in the experiments for comparative purposes. Latent load in spleen was then 
determined by quantification of ex vivo reactivation-competent viruses in total splenocytes by 
infectious centre assay at 14, 21 and 50 dpi.  
 
The results obtained are shown in Figure 3.3. vmLANAK224A/K228A/K229A and 
vmLANAK224E/K228E/K229E viruses, bearing mutations at the positive patch periphery of the dorsal 
surface of mLANA, exhibited a substantial deficit in latency at 14 dpi (Figure 3.3, panel A). In 
contrast, vmLANAK251A/K253A and vmLANAK251E/K253E viruses, containing mutations in the central 
region of the dorsal positive patch, showed a mild attenuation of latency levels at 14 dpi (Figure 
3.3, panel A). Similarly to vWT virus, the latent load of all recombinant viruses declined at 21 dpi 
(Figure 3.3, panel A) and was barely detected at 50 dpi (Figure 3.3, panel A).  
 
Infectious centre assays were then complemented with limiting dilution coupled to real-time 
PCR to detect viral DNA-positive cells (Marques et al., 2003), as a second measure of the 
frequency of infection of total splenocytes. To this end, total splenocytes of C57BL/6 mice 
intranasally infected with vWT or recombinant viruses were analysed at 14, 21 and 50 dpi by real-
time PCR, using the fluorescent TaqMan methodology with primers and probe specific for MuHV-4 
M9 gene (Marques et al., 2003) (Materials and Methods, section 8.2.10). 
 
The results obtained are consistent with results from infectious centre assays. At 14 dpi, the 
peak of latency amplification, the frequency of vmLANAK224A/K228A/K229A and vmLANAK224E/K228E/K229E 
DNA-positive total splenocytes was approximately 10-fold lower than vWT infection (Figure 3.3, 
panel B and Table 3.1). In contrast, the frequency of vmLANAK251A/K253A and vmLANAK251E/K253E 
infection in total splenocytes was similar to that of vWT virus (Figure 3.3, panel B and Table 3.1). 
Frequencies of infection for all recombinant viruses declined at 21 dpi (Figure 3.3, panel B and 
Table 3.1), reaching low levels of long-term persistence at 50 dpi (Figure 3.3, panel B and Table 
3.1). 
 
Altogether, these data demonstrate that residues at the charged patch periphery of mLANA 
dorsal face are required for efficient expansion of MuHV-4 latent infection, whereas substitution of 
residues in the central region have little effect.  
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Figure 3.3. The positive patch periphery of mLANA dorsal face is required for efficient expansion of 
MuHV-4 latency. (A) Quantification of latent infection in spleen by ex vivo reactivation assay. C57BL/6 mice 
were intranasally infected with 104 PFU of the indicated viruses. At days 14, 21 and 50 post-infection, latent 
viruses in spleens were titrated by infectious centre assay (closed circles). Titres of preformed infectious 
viruses were determined in frozen-thawed splenocyte suspensions (open circles). Each circle represents the 
titre of an individual mouse. Horizontal bars show arithmetic means. The dashed line represents the limit of 
detection of the assay. (B) Quantification of viral DNA-positive cells in total splenocytes. C57BL/6 mice were 
intranasally infected with 104 PFU of the indicated viruses. At days 14, 21 and 50 post-infection, reciprocal 
frequencies of viral infection in total splenocytes were determined by limiting dilution and real-time PCR. Data 
were obtained from pools of five spleens per group. Bars represent the frequency of viral DNA-positive cells 
with 95% confidence intervals. 
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Table 3.1. Frequency of MuHV-4 latent infection in total splenocytesa. 
Virus Dpi Reciprocal frequencyb of viral DNA+ cells (95% CI) 
vWT 
14 310 (198-707) 
21 2243 (1405-5545) 
50 4976 (3220-10952) 
vmLANAK224A/K228A/K229A 
14 2242 (1311-7712) 
21 3322 (2148-7334) 
50 24175 (15796-51478) 
vmLANAK224E/K228E/K229E 
14 3953 (2502-9373) 
21 7985 (5134-17955) 
50 28081 (18461-58638) 
vmLANAK251A/K253A 
14 499 (317-1170) 
21 5979 (3653-16461) 
50 16282 (10332-38380) 
vmLANAK251E/K253E 
14 448 (287-1019) 
21 2296 (1442-5630) 
50 12444 (8010-27880) 
aData were obtained from pools of 5 spleens. 
bFrequencies were calculated by limiting dilution coupled to real-time PCR, with 95% confidence intervals (CI). 
 
 
 
3.2.4. The positive patch periphery of mLANA dorsal face is required for 
efficient MuHV-4 colonization of GC B cells 
 
To assess whether the deficit in the establishment of latency exhibited by recombinant viruses 
bearing mutations at the positive patch periphery of mLANA dorsal face reflected an impairment of 
latency amplification in GC B cells, the frequency of viral DNA-positive cells in this subpopulation 
was determined by limiting dilution combined with real-time PCR (Marques et al., 2003). 
 
To this end, GC B cells from C57BL/6 mice intranasally infected with vWT or recombinant 
viruses were FACS-purified at 14 dpi, by enriching for CD19+CD95hiGL7hi cells. The purity of the 
sorted GC B cell population was higher than 95%. Purified GC B cells were then analysed by real-
time PCR for the presence of viral genomes, using a set of primers and probe specific for MuHV-4 
M9 gene (Marques et al., 2003) (Materials and Methods, section 8.2.10). 
 
The results obtained are shown in Figure 3.4 and Table 3.2. The frequency of infection in GC 
B cells at 14 dpi was one order of magnitude lower for vmLANAK224A/K228A/K229A and two orders of 
magnitude lower for vmLANAK224E/K228E/K229E, comparing to vWT infection. The frequency of 
vmLANAK251A/K253A and vmLANAK251E/K253E infection in GC B cells was similar to that of vWT virus. 
mLANA dorsal positive patch has a role in efficient latency expansion 
 
 
57 
These data show that the latency deficit of vmLANAK224A/K228A/K229A and vmLANAK224E/K228E/K229E 
recombinants correlates with an impairment in latency expansion in GC B cells. Therefore, K224, 
K228 and K229 residues, located at the periphery of the dorsal positive patch of mLANA, are 
required for MuHV-4 to efficiently colonize GC B cells and expand latent infection, whereas the 
central region of mLANA dorsal positive patch has little impact on latency amplification in GC B 
cells.  
 
 
 
Figure 3.4. The positive patch periphery of mLANA dorsal face is required for efficient MuHV-4 
colonization of GC B cells. Quantification of viral DNA-positive cells in GC B cells. C57BL/6 mice were 
intranasally infected with 104 PFU of the indicated viruses. At day 14 post-infection, reciprocal frequencies of 
viral infection in FACS-purified GC B cells (CD19+CD95hiGL7hi) were determined by limiting dilution and real-
time PCR. Data were obtained from pools of five spleens per group. Bars represent the frequency of viral 
DNA-positive cells with 95% confidence intervals. 
 
 
 
Table 3.2. Frequency of MuHV-4 latent infection in GC B cellsa. 
Virus Dpi Reciprocal frequencyb of viral DNA+ cells (95% CI) 
vWT 
14 
6 (4-14) 
vmLANAK224A/K228A/K229A 30 (20-59) 
vmLANAK224E/K228E/K229E 284 (171-841) 
vmLANAK251A/K253A 16 (10-39) 
vmLANAK251E/K253E 6 (4-13) 
aData were obtained from pools of 5 spleens. The purity of sorted cells was determined by FACS analysis and 
was always greater 95%. 
bFrequencies were calculated by limiting dilution coupled to real-time PCR, with 95% confidence intervals (CI). 
 
14 dpi
W
T
K
22
4A
/K
22
8A
/K
22
9A
K
22
4E
/K
22
8E
/K
22
9E
K
25
1A
/K
25
3A
K
25
1E
/K
25
3E
10 - 4
10 - 3
10 - 2
10 - 1
100
vmLANA:
F
re
q
u
e
n
c
ie
s
 o
f 
v
ir
a
l 
D
N
A
+
G
C
 B
 c
e
ll
s
Chapter 3 
 
 
58 
3.2.5. The positive patch periphery of mLANA dorsal face is required for 
efficient MuHV-4 latency amplification in splenic follicles 
 
To confirm the role of the mutations introduced on mLANA dorsal positive patch in the 
formation of infected GCs, the ability of recombinant viruses to colonize splenic follicles and to 
induce latency expansion in GCs was assessed by in situ hybridization, using a probe specific for 
MuHV-4 tRNAs and miRNAs (Bowden et al., 1997; Pfeffer et al., 2005; Simas et al., 1999).  
 
Spleen sections from C57BL/6 mice intranasally infected with vWT or recombinant viruses 
were prepared at 14 dpi and processed for in situ hybridization (Materials and Methods, section 
8.2.11). Mice infected with vmLANAK224A/K228A/K229A and vmLANAK224E/K228E/K229E viruses showed a 
reduction in the number of infected cells within positive follicles in comparison to vWT (Figure 3.5, 
panels b and c, respectively). In contrast, the pattern of splenic follicles colonization exhibited by 
vmLANAK251A/K253A and vmLANAK251E/K253E was similar to that of vWT virus, with large clusters of 
infected cells within GCs (Figure 3.5, panels d and e, respectively).  
 
Consistent with the previous data, these results demonstrate that mutations at the periphery of 
the positive patch of mLANA dorsal face impair GC colonization and consequent expansion of the 
latently infected cell pool within splenic follicles, whereas mutations in the central region of mLANA 
dorsal positive patch have little effect on splenic follicle colonization. 
 
 
Figure 3.5. The positive patch periphery of mLANA dorsal face is required for efficient MuHV-4 latency 
amplification in splenic follicles. C57BL/6 mice were intranasally infected with 104 PFU of the indicated 
viruses. At 14 days post-infection, spleens were dissected and processed for in situ hybridization with a viral 
tRNA/miRNA-specific riboprobe. Panels show representative spleen sections from each group of animals. 
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Dark staining indicates cells positive for virally encoded tRNAs/miRNAs. All sections are magnified x200 and 
counterstained with haematoxylin. 
 
 
 
3.2.6. Phenotypic changes in dorsal recombinant viruses are intrinsic to 
ORF73 locus and not the consequence of mutations elsewhere in MuHV-
4 genome  
 
To ensure that the phenotypic alterations observed for vmLANAK224A/K228A/K229A and 
vmLANAK224E/K228E/K229E recombinant viruses reflected the mutations introduced in mLANA and were 
not the consequence of mutations introduced elsewhere in MuHV-4 genome during mutagenesis, 
the ORF73 locus was restored to the wild-type status. To this end, revertant viruses 
(vmLANAK224A/K228A/K229A-R and vmLANAK224E/K228E/K229E-R) were generated from the respective 
mutant viral genomes cloned as a BAC (Materials and Methods, section 8.2.5). A revertant of 
vmLANAK251A/K253A virus (vmLANAK251A/K253A-R) was also constructed, as a control of mutations 
introduced in the central region of the dorsal positive patch of mLANA. 
 
C57BL/6 mice were intranasally infected with vWT or revertant viruses and latent load in 
spleen was determined by quantification of ex vivo reactivation-competent viruses in total 
splenocytes by infectious centre assay at 14 dpi. All revertant viruses were able to establish normal 
latency levels in spleen (Figure 3.6).  
 
Therefore, these results confirm that the phenotypic changes observed for recombinant 
viruses result from the mutations introduced in mLANA, and not from mutations introduced 
elsewhere in the viral genome. 
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Figure 3.6. Phenotypic changes in dorsal recombinant viruses are intrinsic to ORF73 locus and not the 
consequence of mutations elsewhere in MuHV-4 genome. Quantification of latent infection in spleen by ex 
vivo reactivation assay. C57BL/6 mice were intranasally infected with 104 PFU of the indicated viruses. At day 
14 post-infection, latent viruses in spleens were titrated by infectious centre assay (closed circles). Titres of 
preformed infectious viruses were determined in frozen-thawed splenocyte suspensions (open circles). Each 
circle represents the titre of an individual mouse. Horizontal bars show arithmetic means. The dashed line 
represents the limit of detection of the assay. 
 
 
 
3.3. Discussion 
 
The work presented in this chapter highlights the importance of mLANA dorsal positively 
charged patch for the expansion of MuHV-4 latency in GC B cells. MuHV-4 recombinant viruses 
containing mutations at the periphery of mLANA dorsal patch displayed a substantial deficit in 
latency establishment, whereas recombinants with mutations in the central region of the dorsal 
patch exhibited only a mild attenuation of latency levels in spleen. However, the mechanisms by 
which mLANA dorsal patch exerts its function remain to be clarified. 
 
The finding that mutations in the peripheral region of mLANA dorsal positive patch resulted in 
a substantially latency deficit is supported by other work (Hellert et al., 2013). In fact, Hellert and 
colleagues found that a MuHV-4 recombinant virus harbouring mLANA mutations 
K228A/K229A/L230A/K231A exhibited a pronounced reduction of latency levels in the spleen of 
infected mice. mLANA dorsal positive patch harbours the identified 226QAKKLK231 motif, which was 
previously shown to bind to BET proteins, specifically Brd2 and Brd4 (Ottinger et al., 2009). BET 
proteins are important regulators of cellular transcription, interacting via their bromodomains with 
acetylated histones and recruiting transcriptional regulatory complexes to acetylated chromatin (Shi 
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and Vakoc, 2014; Wang and Filippakopoulos, 2015). Brd2 and Brd4, in particular, have been 
implicated in cell cycle control, and their deregulation has been associated with cancer (Prinjha et 
al., 2012). Previous studies demonstrated that mLANA interacts with BET proteins to associate 
with cellular chromatin and activate BET-responsive promoters of G1/S cyclins, thus promoting cell 
cycle progression (Ottinger et al., 2009). Notably, substitution of positively charged for negative 
residues in mLANAK224E/K228E/K229E reduced Brd4 binding, although substitution with neutral residues 
in mLANAK224A/K228A/K229A did not, as demonstrated elsewhere (Correia et al., 2013). Similarly, 
mLANAK251E/K253E, but not mLANAK251A/K251A, was reduced for Brd4 binding, suggesting possible 
electrostatic inhibition when positively charged residues were substituted for ones with a negative 
charge. Therefore, the deficit in latency of vmLANAK224A/K228A/K229A and vmLANAK224E/K228E/K229E 
recombinant viruses observed in the present study does not correlate with binding to Brd4 protein, 
since mLANAK224A/K228A/K229A bound Brd4 normally. Moreover, mLANAK251E/K253E showed 
substantially reduced Brd4 binding but vmLANAK251E/K253E recombinant only exhibited mild latency 
attenuation. Altogether, these data indicate that the charged patch periphery of mLANA dorsal face 
contributes to the expansion of latency in GC B cells through a mechanism independent of Brd4. 
Nonetheless, it remains a possibility that mLANA dorsal patch periphery acts through interaction 
with Brd2, since binding of the mLANA dorsal mutants to this host protein has not been tested. 
Alternatively, the dorsal positive patch of mLANA may interact with other host protein(s) necessary 
for efficient latency expansion in GC B cells, as a replication factor or a chromosome-binding 
protein, thereby facilitating episome replication and persistence in proliferating cells. 
 
The dorsal positive patch is a common feature of both MuHV-4 mLANA and KSHV kLANA 
(Correia et al., 2013; Domsic et al., 2013; Hellert et al., 2013). Although the role of kLANA dorsal 
positive patch in the context of KSHV infection in vivo has not been formally demonstrated, kLANA 
dorsal positive patch, particularly the peripheral region, was recently shown to facilitate viral DNA 
replication and episome persistence in latently infected cells in culture (Domsic et al., 2013; Li et 
al., 2015). Experiments with kLANA dorsal mutants revealed that reductions in episome 
maintenance were independent of BET protein binding, but closely correlated with DNA replication 
deficiencies, suggesting that the replication defects account for the reduced episome persistence. 
The reduced DNA replication was not due to inability of kLANA to efficiently bind TR DNA. Given 
these findings and since mLANA mediates MuHV-4 episome persistence using mechanisms similar 
to kLANA (Habison et al., 2012), it is likely that the disruption of mLANA dorsal positive patch, 
specially the peripheral region, impacts on viral DNA replication and episome persistence. This 
could explain the reductions in latency observed for the MuHV-4 recombinant viruses described in 
this chapter. Interestingly, all mLANA dorsal mutants used here bound to TR DNA, similarly to 
kLANA dorsal mutants (Correia et al., 2013).  
 
The dorsal positive patch of kLANA was recently shown to mediate interaction with DNA of 
arbitrary sequence, allowing the assembly into supermolecular spirals around DNA by self-
association of kLANA (Hellert et al., 2015). These spiral structures may also contain a plethora of 
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cellular proteins interacting with kLANA. To date, no spiral-like structures have been described for 
mLANA. However, mLANA has been shown to oligomerize (Correia et al., 2013; Hellert et al., 
2013; Ponnusamy et al., 2015) and the possibility that its dorsal positive patch is involved in the 
formation of supermolecular structures, with possible roles in viral DNA replication, may not be 
excluded. 
 
In summary, mLANA dorsal positive patch could be divided into two regions with different 
functional effects, a central region and a peripheral region. Although the former had little effect on 
MuHV-4 latency establishment, the latter was required for efficient latency expansion in GC B cells. 
Future work should elucidate whether the dorsal positive patch exerts its effects through 
interactions with a particular host cell partner(s) other than Brd4 or through another mechanism, 
such as interacting with DNA in a sequence-independent manner to induce the formation of 
specific complexes required for episome replication and maintenance. 
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mLANA E3 ubiquitin-ligase activity impacts on 
gammaherpesvirus latency amplification 
 
4.1. Introduction 
 
E3 ubiquitin-ligases control a broad range of cellular pathways, through ubiquitination of target 
proteins (Lydeard et al., 2013). Previous studies in our laboratory demonstrated that mLANA 
assembles an E3 ubiquitin-ligase complex (EC5SmLANA) by recruiting cellular ElonginB/C and 
Cullin5, through an unconventional SOCS-box motif (amino acid residues 199-206) present in 
mLANA C-terminal domain (Rodrigues et al., 2009). mLANA also acts as the substrate recognition 
component of the EC5SmLANA complex, interacting with cellular substrates through motifs 
independent of the SOCS-box, as yet unidentified (Rodrigues et al., 2009; Rodrigues et al., 2013). 
Two cellular targets of mLANA E3 ubiquitin-ligase activity are known: NF-κB and Myc. mLANA 
mediates poly-ubiquitination-dependent proteasomal degradation of the NF-κB family member p65, 
thus inhibiting NF-κB transcriptional activity (Rodrigues et al., 2009). In contrast, mLANA stabilizes 
Myc through heterotypic poly-ubiquitination, thereby increasing Myc transcriptional activity 
(Rodrigues et al., 2013).  
 
The crystal structure of mLANA C-terminal domain revealed that the SOCS-box lies within a 
loop (β2-β3 loop, residues 199-215), which protrudes perpendicular to the DNA binding interface 
(Figure 4.1) (Correia et al., 2013). mLANA-SOCS mutant, containing mutations of four SOCS-box 
residues (199VSCLPLVP206, underlined residues mutated to alanine), fails to bind to ElonginC, 
therefore abrogating mLANA E3 ubiquitin-ligase activity (Rodrigues et al., 2009). A recombinant 
MuHV-4 virus bearing these mutations (vSOCS) exhibits a severe latency deficit, being unable to 
expand in GC B cells and persist in mice (Rodrigues et al., 2009). However, recent studies have 
shown that mLANA-SOCS mutant is unable to bind viral TR DNA and to mediate episome 
persistence (Tan et al., unpublished data), demonstrating that mutations introduced in mLANA-
SOCS mutant compromised not only mLANA E3 ubiquitin-ligase activity, but also its function as 
DNA binding and episome maintenance protein. Since binding of mLANA to TR DNA is critical for 
viral latency expansion in GC B cells and virus persistence in mice, as demonstrated in the present 
study (chapter 2), the severe latency deficit of vSOCS recombinant virus cannot be exclusively 
attributed to the suppression of mLANA E3 ubiquitin-ligase activity. Therefore, the contribution of 
mLANA E3 ubiquitin-ligase activity for latent infection remains unclear. 
 
To clarify the biological relevance of mLANA E3 ubiquitin-ligase activity for gammaherpesvirus 
pathogenesis, a structure-based (Correia et al., 2013) mutagenesis approach was employed to 
generate MuHV-4 recombinant viruses containing mutations in mLANA SOCS-box. These 
mutations were designed so that E3 ubiquitin-ligase activity was impaired without compromising 
Chapter 4 
 
 
66 
episome maintenance function of mLANA. Recombinant viruses were intranasally administered to 
BALB/c mice and their phenotype was analysed during the establishment and maintenance of 
latency by ex vivo reactivation assay to determine latent load in spleen and limiting dilution coupled 
to real-time PCR to quantify the frequency of viral DNA-positive cells in total splenocytes (section 
4.2.5).   
 
Data presented in this chapter is included in the manuscript in Appendix 2, which is being 
prepared for submission.  
 
 
 
 
Figure 4.1. β2-β3 SOCS-box loop of mLANA. The mLANA dimer interface on the ventral side is 
represented. The β2-β3 SOCS-box loop (indicated by arrows) protrudes perpendicular to the DNA binding 
interface. V199, L202, P203 and P206 residues in the SOCS-box are coloured in red. α2 is the predicted 
recognition helix. This figure was kindly provided by Dr Rajesh Ponnusamy from Dr C.E. McVey’s laboratory 
(ITQB, Universidade Nova de Lisboa, Portugal). 
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4.2. Results 
 
4.2.1. mLANAV199A, mLANAV199A/L202A and mLANAP203A/P206A mutants exhibit 
impaired ability to inhibit NF-κB and to activate Myc transcriptional 
activities 
 
mLANA-SOCS mutant contained valine (V) 199, leucine (L) 202, proline (P) 203 and proline 
(P) 206 residues substituted by alanine (A) (V199A, L202A, P203A and P206A) (Rodrigues et al., 
2009). To minimize the interference with DNA binding interface, six mLANA constructs containing 
different combinations of these mutations were generated: mLANAV199A, mLANAL202A, 
mLANAV199A/L202A, mLANAP203A, mLANAP206A and mLANAP203A/P206A (Figure 4.1). First, E3 ubiquitin-
ligase activity of mLANA mutants towards NF-κB and Myc was evaluated, through reporter gene 
assays. Human embryonic kidney (HEK) 293T cells were transiently transfected with a NF-κB or 
Myc reporter plasmid containing tandem copies of kappa B (κB) or E-box consensus sequences 
(respectively) regulating the expression of luciferase (Brostjan et al., 1997), and a plasmid 
encoding mLANA (WT or mutants). Tumour necrosis factor (TNF)-α was used as a stimulus 
leading to NF-κB activation. Luciferase activity was correlated with the amount of luciferase 
produced, which in turn depended on the amount of NF-κB or MYC molecules bound to the 
consensus sequences regulating luciferase expression. Therefore, NF-κB and MYC transcriptional 
activities could be quantified by measuring luciferase activity in each experimental condition.  
 
NF-κB reporter assays showed that mLANA-WT inhibited TNF-driven NF-κB activation, while 
mLANA-SOCS mutations reverted this phenotype (Figure 4.2, panel A), reproducing the results of 
earlier studies (Rodrigues et al., 2009). mLANAV199A, mLANAV199A/L202A and mLANAP203A/P206A 
mutants exhibited impaired ability to inhibit TNF-driven NF-κB activation (Figure 4.2, panel A). In 
contrast, mLANAL202A, mLANAP203A and mLANAP206A mutants behaved similarly to mLANA-WT, 
inhibiting NF-κB transcriptional activity (Figure 4.2, panel A). Myc reporter assays demonstrated 
that mLANA-WT promoted Myc transcriptional activity, whereas mLANA-SOCS mutant was unable 
to modulate Myc (Figure 4.2, panel B), as previously described (Rodrigues et al., 2013). 
mLANAV199A, mLANAV199A/L202A and mLANAP203A/P206A mutants exhibited impaired ability to increase 
Myc transcriptional activity, while mLANAL202A, mLANAP203A and mLANAP206A mutants behaved 
similarly to mLANA-WT (Figure 4.2, panel B). Importantly, the levels of expression of mLANA 
mutants were similar (Figure 4.2, panel B, bottom panel). Taken together, these data demonstrate 
that mutations at residues V199, V199/L202 or P203/P206 compromise mLANA E3 ubiquitin-ligase 
activity.  
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Figure 4.2. mLANAV199A, mLANAV199A/L202A and mLANAP203A/P206A exhibit impaired ability to inhibit NF-κB 
and to activate Myc transcriptional activities. HEK 293T cells were transiently transfected with a NF-κB (A) 
or Myc (B) luciferase reporter vector and a plasmid encoding mLANA (WT or mutants), as indicated at the 
bottom. In (A), transfected cells were either stimulated with 50 ng/ml of TNF (filled bars) or left unstimulated 
(open bars). NF-κB (A) and Myc (B) transcriptional activities associated with each sample were assayed using 
a luminometer. Results are shown as the fold induction relative to luciferase activity measured in unstimulated 
cells (A) or in cells that did not express mLANA (B). Error bars represent SEM from triplicates from two 
independent transfection experiments. In addition, representative aliquots of the total cellular lysates were 
used to detect appropriate expression of mLANA (bottom panel). 
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4.2.2. mLANAV199A, mLANAV199A/L202A and mLANAP203A/P206A mutants exhibit 
diminished capability to promote p65 and Myc poly-ubiquitination 
 
mLANA targets nuclear p65 for poly-ubiquitination and subsequent proteasomal degradation, 
leading to a downmodulation of NF-κB transcriptional activity (Rodrigues et al., 2009). In contrast, 
mLANA stabilizes Myc through heterotypic poly-ubiquitination, thereby promoting Myc 
transcriptional activity (Rodrigues et al., 2013). Therefore, poly-ubiquitination assays were 
performed in order to investigate whether modulation of NF-κB and Myc mediated by mLANA 
mutants was dependent on the mechanism of substrate poly-ubiquitination. To accomplish this, 
HEK 293T cells were transiently transfected with expression plasmids encoding p65 or Myc, 
mLANA (WT or mutants) and His-tagged ubiquitin. His-tagged ubiquitin is incorporated into poly-
ubiquitin chains, hence poly-ubiquitinated proteins are His-tagged. Ni-NTA beads have high affinity 
for His-tagged proteins, allowing their purification from an expression system. Thus, ubiquitinated 
proteins were pulled-down using Ni-NTA beads and the levels of ubiquitinated p65 and Myc 
present in each condition were analysed by Western-blot. 
 
Poly-ubiquitination assays revealed that, similarly to mLANA-SOCS mutant, mLANAV199A, 
mLANAV199A/L202A and mLANAP203A/P206A had diminished capability to promote both p65 (Figure 4.3, 
panel A) and Myc (Figure 4.3, panel B) poly-ubiquitination. In contrast, mLANAL202A, mLANAP203A 
and mLANAP206A mutants enhanced p65 (Figure 4.3, panel A) and Myc (Figure 4.3, panel B) poly-
ubiquitination as efficiently as mLANA-WT. These data demonstrate that the defective modulation 
of NF-κB and Myc transcriptional activities observed for mLANAV199A, mLANAV199A/L202A and 
mLANAP203A/P206A mutants can be attributed to inefficient substrate poly-ubiquitination mediated by 
these mutants.  
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Figure 4.3. mLANAV199A, mLANAV199A/L202A and mLANAP203A/P206A exhibit diminished capability to 
promote p65 and Myc poly-ubiquitination. HEK 293T cells were transiently transfected with plasmids 
encoding mLANA (WT or mutants), p65 (A) or Myc (B) and histidine-tagged ubiquitin, as indicated on top. 
After 48 h, total cellular lysates were subjected to a Ni-NTA pull-down, allowing the purification of ubiquitinated 
proteins. The levels of ubiquitinated p65 (A) or Myc (B) in each condition were assayed using an anti-p65 or 
anti-Myc antibody (first panel), respectively. Representative aliquots of the total cellular lysates were used to 
detect the appropriate expression of p65 (A) or Myc (B) (second panel) and mLANA (third panel). Graphs at 
the bottom show densitometry analysis of ubiquitinated p65 (A) and ubiquitinated Myc (B) levels present in 
each experimental condition, expressed as fold induction relative to cells not expressing mLANA. -, without; +, 
with; PD, pull-down; TCL, total cellular lysates; Ub, ubiquitinated. 
 
 
 
4.2.3. mLANAV199A, mLANAV199A/L202A and mLANAP203A/P206A mutants weakly 
associate with ElonginC and Cullin5  
 
To investigate whether poly-ubiquitination activity of mLANA mutants relied on the 
reconstitution of an E3 ubiquitin-ligase complex, their ability to associate with ElonginC and Cullin5 
was tested by co-immunoprecipitation experiments. HEK 293T cells were transiently transfected 
with expression plasmids encoding ElonginC or Cullin5 and mLANA (WT or mutants). Cell lysates 
were incubated with antibodies to ElonginC or Cullin5 and immunecomplexes were recovered by 
incubation with beads coupled to Protein G, which binds to the Fc region of class G 
immunoglobulin (IgG) from several mammalian species (Akerstrom et al., 1985). The presence of 
mLANA in immunecomplexes was then analysed by Western-blot, using the appropriate 
antibodies. 
 
As reported previously (Rodrigues et al., 2009), mLANA-WT associated with ElonginC and 
Cullin5 (Figure 4.4, panels A and B, respectively), and mutations introduced at mLANA-SOCS 
resulted in loss of binding to those proteins (Figure 4.4). mLANAV199A, mLANAV199A/L202A and 
mLANAP203A/P206A mutants were unable to recruit ElonginC (Figure 4.4, panel A) and weakly 
associated with Cullin5 (Figure 4.4, panel B), whereas mLANAL202A, mLANAP203A and mLANAP206A 
efficiently recruited both ElonginC (Figure 4.4, panel A) and Cullin5 (Figure 4.4, panel B). These 
results demonstrate that mLANAV199A, mLANAV199A/L202A and mLANAP203A/P206A mutants have 
impaired ability to assemble an E3 ubiquitin-ligase complex, thereby compromising their poly-
ubiquitination activity towards p65 and Myc.  
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Figure 4.4. mLANAV199A, mLANAV199A/L202A and mLANAP203A/P206A weakly associate with ElonginC and 
Cullin5. HEK 293T cells were transiently transfected with plasmids encoding mLANA (WT or mutants) and 
ElonginC (A) or Cullin5 (B), as indicated on top. After 48 h, cells were lysed and total cellular lysates were 
subjected to immunoprecipitation using an anti-ElonginC (A) or anti-Cullin5 (B) antibody. Immunoprecipitates 
were analysed by Western-blot (first and second panels). Representative aliquots of the total cellular lysates 
were used to detect the appropriate expression of mLANA (third panel). -, without; +, with; α, anti; IP, 
immunoprecipitation; TCL, total cellular lysates; EloC, ElonginC; Cul5, Cullin5. 
 
 
Taken together, the data obtained indicate that mutations at residue V199, residues 
V199/L202 and residues P203/P206 of mLANA disrupt recruitment of ElonginC and, to a lower 
extent, Cullin5, thus impairing the formation of EC5SmLANA E3 ubiquitin-ligase complex and, 
consequently, mLANA function as a mediator of p65 and Myc poly-ubiquitination. Hence, mutations 
at these residues impair mLANA E3 ubiquitin-ligase activity, which impacts on its ability to 
modulate NF-κB and Myc transcriptional activities.  
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4.2.4. Generation of MuHV-4 recombinant viruses harbouring mutations in 
mLANA SOCS-box 
 
To assess whether the mutations introduced in SOCS-box impacted on episome maintenance 
function of mLANA, our collaborator Dr Min Tan from Prof. K.M. Kaye’s laboratory (Harvard 
Medical School, USA) further characterized these mutants regarding their ability to bind TR DNA 
and maintain viral episome (Tan et al., unpublished data). His experiments demonstrated that 
mLANAV199A, mLANAL202A, mLANAP203A, mLANAP206A, and mLANAP203A/P206A mutants were able to 
maintain episomes, despite only mLANAL202A and mLANAP206A exhibited strong binding to TR DNA. 
mLANAV199A/L202A mutant showed a severe DNA binding deficiency and failed to maintain episomes.  
 
To assess the impact of mLANA E3 ubiquitin-ligase impairment in the physiological context of 
latency in vivo, two MuHV-4 recombinant viruses containing E3 ubiquitin-ligase deficient mLANA 
with mutation V199A (vmLANAV199A) or mutations P203A/P206A (vmLANAP203A/P206A) were 
generated. Recombinant viruses bearing mLANA mutations P203A (vmLANAP203A), which exerted 
WT E3 ubiquitin-ligase activity, or V199A/L202A (vmLANAV199A/L202A), which was E3 ubiquitin-ligase 
deficient and did not maintain episome persistence, were generated as controls.  
 
MuHV-4 recombinants were generated by mutagenesis of the viral genome cloned as a BAC 
(Adler et al., 2000), as described in detail in Materials and Methods, section 8.2.5. Verification of 
the introduced mutations was carried out by restriction enzyme digestion and sequencing across 
ORF73 gene in the BAC vector. The genomic structure of generated viruses was verified by 
examination of restriction enzyme digestion profiles of E. coli-derived BAC DNA. Infectious viruses 
were reconstituted by transfection of BAC DNA into BHK-21 fibroblasts and BAC sequences were 
removed by propagating the viruses in NIH-3T3 fibroblasts expressing Cre recombinase 
(Stevenson et al., 2002). The stability of the introduced mutations was checked in viruses 
recovered from latently infected spleens, by sequencing ORF73 gene in viral HMW DNA extracted 
from frozen-thawed splenocyte suspensions of infected mice. This analysis confirmed the retention 
of the engineered point mutations following in vivo infection. 
 
Previous work in our laboratory found that vSOCS recombinant virus displayed normal lytic 
replication kinetics in vitro and in vivo (Rodrigues et al., 2009), demonstrating that the mutations 
introduced in mLANA SOCS-box did not affect virus lytic replication. Since the recombinant viruses 
engineered in this section harboured different combinations of vSOCS mutations, it is reasonable 
to assume that they also exhibit normal lytic replication. 
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4.2.5. Impairment of mLANA E3 ubiquitin-ligase activity impacts on MuHV-4 
latency amplification 
 
To clarify the biological relevance of mLANA E3 ubiquitin-ligase activity for gammaherpesvirus 
latency, MuHV-4 recombinant viruses described in section 4.2.4 were used to intranasally infect 
BALB/c mice. vWT virus was included in the experiments for comparative purposes. The effect of 
the engineered mLANA mutations on latent infection was then assessed by two complementary 
experiments. Latent load in spleen was examined by quantification of ex vivo reactivation-
competent viruses by infectious centre assay. Limiting dilution combined with real-time PCR to 
detect viral DNA-positive cells (Marques et al., 2003) was applied to determine the frequency of 
infection of total splenocytes.  
 
All viruses were evaluated at 14 and 21 dpi for their ability to establish and expand a latent 
load in spleen. The results obtained are shown in Figure 4.5. vWT virus presented the expected 
peak of infection at 14 dpi (Figure 4.5, panel A), with latent infection subsiding at 21 dpi (Figure 4.5, 
panel C), as previously described (Cardin et al., 1996; Flano et al., 2003; Marques et al., 2003; 
Simas and Efstathiou, 1998; Sunil-Chandra et al., 1992b). In contrast, vmLANAV199A and 
vmLANAP203A/P206A viruses exhibited an attenuation of latency at 14 dpi (Figure 4.5, panel A). 
Consistent with this result, the frequency of vmLANAV199A and vmLANAP203A/P206A infection in total 
splenocytes at 14 dpi was about 10-fold lower than vWT infection (Figure 4.5, panel B, and Table 
4.1). At 21 dpi, levels of latent infection were similar for vmLANAV199A, vmLANAP203A/P206A and vWT 
(Figure 4.5, panel C). No preformed infectious viruses were detected at any time point by 
suspension assay of frozen-thawed spleen homogenates, showing that splenic infection was only 
latent (Figure 4.5, panels A and C, open circles). Altogether, these data demonstrate that the 
impairment of mLANA E3 ubiquitin-ligase activity impacts on MuHV-4 latency amplification.  
 
The splenic latency levels established by vmLANAP203A virus at 14 dpi were identical to vWT 
(Figure 4.5, panel A), declining at 21 dpi (Figure 4.5, panel C). This is in good agreement with the 
previous observation that E3 ubiquitin-ligase and episome maintenance functions of mLANAP203A 
mutant were intact. 
 
Unexpectedly, vmLANAV199A/L202A virus only exhibited an attenuation of latency at 14 dpi 
(Figure 4.5, panel A), which is not in agreement with the observation that mLANAV199A/L202A does 
not mediate episome maintenance (Tan et al., unpublished data). As demonstrated in chapter 2, a 
virus containing mLANA unable to bind to viral TR DNA, and hence unable to mediate episome 
persistence, is severely compromised in establishment of latent infection in mice. Therefore, it was 
expected that vmLANAV199A/L202A virus would be incapable of viable latency in mice. These findings 
gave rise to a new set of experiments, described in chapter 5. For this reason, these results will not 
be analysed in the discussion below, but rather in the next chapter of this thesis. 
 
mLANA E3 ubiquitin-ligase activity impacts on latency amplification 
 
 
75 
 
Figure 4.5. Impairment of mLANA E3 ubiquitin-ligase activity impacts on MuHV-4 latency amplification. 
(A and C) Quantification of latent infection in spleen by ex vivo reactivation assay. BALB/c mice were 
intranasally infected with 104 PFU of the indicated viruses. At days 14 (A) and 21 (C) post-infection, latent 
viruses in spleens were titrated by infectious centre assay (closed circles). Titres of preformed infectious 
viruses were determined in frozen-thawed splenocyte suspensions (open circles). Each circle represents the 
titre of an individual mouse. Horizontal bars show arithmetic means. The dashed line represents the limit of 
detection of the assay. (B) Quantification of viral DNA-positive cells in total splenocytes. BALB/c mice were 
intranasally infected with 104 PFU of the indicated viruses. At 14 dpi, reciprocal frequencies of viral infection in 
total splenocytes were determined by limiting dilution and real-time PCR. Data were obtained from pools of 
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three to four spleens per group. Bars represent the frequency of viral DNA-positive cells with 95% confidence 
intervals.  
 
 
 
Table 4.1. Frequency of MuHV-4 latent infection in total splenocytesa. 
Virus Dpi Reciprocal frequencyb of viral DNA+ cells (95% CI) 
vWT 
14 
151 (95-367) 
vmLANAP203A 98 (63-219) 
vmLANAV199A 1877 (998-15734) 
vmLANAP203A/P206A 1544 (855-7916) 
vmLANAV199A/L202A 663 (411-1710) 
aData were obtained from pools of 3-4 spleens. 
bFrequencies were calculated by limiting dilution coupled to real-time PCR, with 95% confidence intervals (CI). 
 
 
 
 
4.3. Discussion 
 
E3 ubiquitin-ligases control a broad range of cellular pathways, through ubiquitination of target 
proteins (Lydeard et al., 2013). This study established a link between the E3 ubiquitin-ligase activity 
of mLANA viral protein and murid gammaherpesvirus pathogenesis in vivo. MuHV-4 recombinant 
viruses with mutations in mLANA SOCS-box compromising E3 ubiquitin-ligase activity, without 
abrogating episome maintenance function, exhibited an attenuation of latency. Therefore, mLANA 
E3 ubiquitin-ligase activity contributes to gammaherpesvirus latency expansion.  
 
Myc is central to GC biology, being essential for the formation and maintenance of GCs 
(Basso and Dalla-Favera, 2015; Calado et al., 2012; De Silva and Klein, 2015; Dominguez-Sola et 
al., 2012). mLANA modulates Myc through heterotypic poly-ubiquitination, increasing protein 
stability and prolonging its half-life (Rodrigues et al., 2013). Therefore, mLANA increases Myc 
transcriptional activity and expression of Myc target genes, promoting cell divisions during the 
expansion of MuHV-4 infected B cells in GCs. In the current study, mLANA E3 ubiquitin-ligase 
activity was impaired, thus inhibiting mLANA-mediated Myc modulation. Hence, the impairment of 
mLANA E3 ubiquitin-ligase activity may have decreased the proliferative potential of latently 
infected B cells within GCs, attenuating viral latency amplification. Furthermore, centroblasts – the 
proliferating GC B cells – do not display NF-kB activation, suggesting that NF-kB signalling needs 
to be switched off during GC proliferation in order to prevent premature differentiation into plasma 
and memory B cells (Basso et al., 2004; Heise et al., 2014; Shaffer et al., 2001). Previous research 
conducted in our laboratory indicated that mLANA mimics the GC physiological inhibition of NF-kB 
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to promote the development of virus-driven GC reactions to expand the host pool of latently 
infected cells (Rodrigues et al., 2009). Hence, the partial loss of mLANA-mediated NF-kB inhibition 
observed in the present study may have impaired the proliferation of latently infected GC B cells, 
thus contributing to a deficit in viral latency expansion. In addition, mLANA may target other cellular 
proteins for poly-ubiquitination, so that impairing E3 ubiquitin-ligase activity may hamper mLANA-
mediated modulation of other proteins relevant to MuHV-4 latency expansion. Quantification of 
infection in GC B cells for recombinant viruses containing mLANA deficient for E3 ubiquitin-ligase 
activity would be required to establish a definitive link between mLANA E3 ubiquitin-ligase activity 
and latency expansion in GCs. 
 
The results of the in vivo experiments performed in this study showed that the impairment of 
mLANA E3 ubiquitin-ligase activity did not eliminate latency amplification. This result likely reflects 
the fact that the mutations introduced in mLANA SOCS-box did not completely abolish the E3 
ubiquitin-ligase activity of mLANA. Therefore, the remaining activity may have sufficed to enable 
the virus to modulate NF-kB and Myc, although less efficiently, and thus to expand latency in GC B 
cells. To demonstrate an unequivocal effect of mLANA E3 ubiquitin-ligase activity on viral latency, 
a complete ablation of this function would be required. However, despite several efforts in our 
laboratory to identify residues in mLANA SOCS-box which are essential to E3 ubiquitin-ligase 
activity, it has not been possible to find a set of mutations that completely disrupt E3 ubiquitin-
ligase activity without compromising episome maintenance function. In fact, the mLANA-SOCS 
mutant (V199A/L202A/P203A/P206A) reported earlier (Rodrigues et al., 2009) exhibited an 
ablation of E3 ubiquitin-ligase activity, but could not bind TR DNA nor maintain viral episome, as 
demonstrated in the current study. The crystal structure of mLANA C-terminal domain revealed that 
the SOCS-box lies within a loop (β2-β3 loop, residues 199-215), which protrudes perpendicular to 
the DNA binding interface (Correia et al., 2013). Given the spatial proximity of these two functional 
regions, it is possible that the introduction of certain mutations in SOCS-box impacts on the 
predicted DNA recognition helix α2, disrupting DNA binding interface and, consequently, mLANA-
mediated episome persistence. Current structural studies on mLANA-ElonginB/C-Cullin5 complex 
are being performed in our laboratory, since determining the structure of mLANA in complex with 
its ligands may reveal key interacting residues in mLANA SOCS-box. In any case, the finding that 
deficient mLANA E3 ubiquitin-ligase activity reduced viral latency suggests that complete inhibition 
of this activity could result in an even more severe effect on the ability of the virus to establish 
latent infection, perhaps abolishing it. 
 
KSHV kLANA is also able to assemble an EC5S ubiquitin-ligase complex (EC5SkLANA) through 
a SOCS-box motif (Cai et al., 2006). EC5SkLANA complex promotes poly-ubiquitination of p53, VHL 
and p65, targeting these substrates for degradation (Cai et al., 2006; Li et al., 2011). In addition, 
kLANA stabilizes Myc through two mechanisms which do not involve its E3 ubiquitin-ligase activity 
(Liu et al., 2007). kLANA blocks GSK-3-mediated phosphorylation of Myc at T58 residue and thus 
Myc degradation, while independently stimulating ERK1-mediated phosphorylation of Myc at S62 
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residue, an event that stabilizes Myc (Liu et al., 2007; Sears et al., 2000). Therefore, similarly to 
mLANA, kLANA inhibits NF-kB and promotes Myc stabilization, highlighting the importance of the 
modulation of these cellular transcription factors for gammaherpesvirus latency.  
 
The property of a viral protein assembling an EC5S E3 ubiquitin-ligase complex through a 
SOCS-box motif is not unique to LANA proteins. However, the biological significance of such a 
mechanism for viral pathogenesis in vivo remains largely unknown. A recent study showed that 
HIV-1 Vif-mediated degradation of APOBEC3 proteins, the targets of Vif E3 ubiquitin-ligase activity, 
is important for viral propagation in vivo (Sato et al., 2014). The authors infected a humanized 
mouse model with HIV-1 mutants, which contained mutations in Vif motifs involved in interaction 
with APOBEC3 proteins. Although those mutations did not specifically inhibit Vif E3 ubiquitin-ligase 
activity, since they were introduced in Vif substrate binding motifs rather than in its SOCS-box, this 
study points out the importance of Vif E3 ubiquitin-ligase activity in vivo, at least on APOBEC3 
proteins. However, the work presented in this thesis is novel in the sense that it assesses the 
impact of the assembly of an E3 ubiquitin-ligase complex by a gammaherpesvirus protein during 
latency in vivo. 
 
Given the importance of the ubiquitin system, it is not surprising that gammaherpesviruses 
have developed a strategy to hijack host proteins involved in the ubiquitination pathway. This work 
provides evidence for the in vivo importance of the E3 ubiquitin-ligase complex, through which 
mLANA modulates at least two cellular proteins whose regulation is critical for GC reaction, NF-kB 
and Myc, thus promoting virus expansion during latency. Although mLANA E3 ubiquitin-ligase 
activity was not completely ablated, the partial impairment of this function was sufficient to reduce 
viral latency levels. Thus, pharmacological inhibition of LANA E3 ubiquitin-ligase activity through 
targeting of SOCS-box motifs is a putative strategy to control gammaherpesvirus infection. 
 
  
 
 
 
 
 
CHAPTER 5 
DNA binding-deficient mLANA mediates episome persistence 
in the context of multiple TR elements 
 
 
  
  
 
Impact of mLANA DNA binding deficiencies in episome persistence  
 
 
81 
DNA binding-deficient mLANA mediates episome persistence in 
the context of multiple TR elements  
 
5.1. Introduction 
 
Chapter 2 of this study demonstrated that mLANA binding to viral TR DNA is critical for the 
establishment and maintenance of MuHV-4 latency in vivo. However, vmLANAV199A/L202A 
recombinant virus, engineered in chapter 4, was able to expand latency in mice (Figure 4.5, panel 
A) despite mutations in mLANA which severely compromised DNA binding and abolished episome 
persistence. Hence, it was reasonable to consider the hypothesis that mLANAV199A/L202A likely 
mediated MuHV-4 episome maintenance although no viral episomes were detected in the 
presence of this mLANA mutant, as assessed by our collaborator Dr M. Tan from Prof. K.M. Kaye’s 
laboratory (Harvard Medical School, USA) (Tan et al., unpublished data). 
 
In episome maintenance assays, performed by Dr M. Tan, a plasmid containing 
mLANAV199A/L202A coding sequence and four TR elements was transfected into mouse embryonic 
fibroblast (MEF) cells (Tan et al., unpublished data). mLANA acts on TR elements to mediate 
episome persistence, thereby allowing the maintenance of the transfected plasmid, whose 
presence is then detected in Gardella gels (Gardella et al., 1984; Habison et al., 2012). The 
number of TR elements in MuHV-4 genome is unknown. If MuHV-4 genome contains 
approximately 40 TR elements, similarly to KSHV (Lagunoff and Ganem, 1997), it is possible that 
this number may be necessary for mLANA episome maintenance function and that 
mLANAV199A/L202A may exert episome maintenance function in the setting of a higher number of TR 
elements. In fact, it was previously shown that mLANA episome maintenance efficiency was 
increased with eight compared to two or four TR elements (Habison et al., 2012).  
 
To investigate whether mLANAV199A/L202A could mediate MuHV-4 episome persistence in a 
whole-virus context, an in vitro system was set up during this study, using a MuHV-4 ORF50-
deficient virus previously described (Milho et al., 2009). MuHV-4 ORF50-deficient virus (MuHV-4 
M3-Luc/ORF50-eGFP) contains a deletion of ORF50 exon 2 (Figure 5.1), preventing the 
expression of ORF50, the major lytic transactivator protein of MuHV-4 (Pavlova et al., 2003; Wu et 
al., 2000). As a consequence, when ORF50-deficient virus infects a permissive cell, it is unable to 
go through lytic replication and hence remains latent in the infected cell, persisting as an episome. 
This enables the establishment of cell lines latently infected with MuHV-4 and analysis of their 
content in viral episomes. 
 
Data presented in this chapter is included in the manuscript in Appendix 2, which is being 
prepared for submission. 
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Figure 5.1. Schematic diagram of MuHV-4 ORF50-deficient virus (MuHV-4 M3-Luc/ORF50-eGFP). eGFP 
was inserted in place of the removed ORF50 gene, and a M3 promoter-luciferase-polyA cassette was inserted 
between ORFs 57 and 58 (Milho et al., 2009). Relevant restrictions sites are shown. eGFP, enhanced green 
fluorescent protein; Luc, luciferase.  
 
 
 
5.2. Results 
 
5.2.1. Generation of MuHV-4 ORF50-deficient recombinant viruses harbouring 
mutations in mLANA SOCS-box 
 
To test the episome maintenance function of mLANAV199A/L202A mutant in a whole-virus context, 
an ORF50-deficient recombinant virus containing mLANA V199A/L202A mutation in the 
background of MuHV-4 ORF50-deficient genome (vORF50-mLANAV199A/L202A) was generated. 
mLANA-SOCS mutant was also tested using this approach, since it was previously characterized 
as being unable to bind viral TR DNA and to mediate episome persistence (Tan et al., unpublished 
data), similarly to mLANAV199A/L202A mutant. Thus, an ORF50-deficient recombinant virus bearing 
mLANA V199A/L202A/P203A/P206A mutations (vORF50-mLANA-SOCS) was constructed. 
ORF50-deficient virus containing mLANA-WT (vORF50-mLANA-WT) was used as a positive 
control for episome maintenance. 
 
MuHV-4 ORF50-deficient recombinants were generated by mutagenesis of MuHV-4 M3-
Luc/ORF50-eGFP genome cloned as a BAC (Milho et al., 2009), as described in detail in Materials 
and Methods, section 8.2.5. MuHV-4 M3-Luc/ORF50-eGFP contains a deletion of ORF50 exon 2 
(Figure 5.1), preventing the expression of ORF50. The coding sequence of eGFP is cloned in place 
of the removed fragment and a cassette consisting of the M3 promoter driving luciferase 
transcription is inserted between ORF57/58 (Figure 5.1).  
 
Verification of the introduced mLANA mutations in the background of MuHV-4 ORF50-
deficient genome was carried out by restriction enzyme digestion and sequencing across ORF73 
gene in the BAC vector. The genomic structure of generated viruses was verified by examination of 
restriction enzyme digestion profiles of E. coli-derived BAC DNA. Infectious viruses were 
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reconstituted by transfection of BAC DNA into 3T3-ORF50 complementing cell lines (Milho et al., 
2009) and treating cells with doxycycline. 3T3-ORF50 complementing cell lines express ORF50 
under a doxycycline-inducible promoter. Thus, by treating infected cells with doxycycline, ORF50-
deficient virus reactivates from latency and viral replication occurs, allowing the production of virus 
working stocks (Milho et al., 2009).  
 
 
5.2.2. Generation of cell lines latently infected with MuHV-4 ORF50-deficient 
recombinant viruses 
 
To generate latently infected cell lines, MEF-1 cells were infected with MuHV-4 ORF50-
deficient recombinant viruses at a MOI of 3 PFU per cell, to ensure that nearly all cells were 
infected. Cells were seeded at low density, to generate individual clones, and placed under drug 
selection with mycophenolic acid (MPA) and xanthine (Figure 5.2). 
 
 
Figure 5.2. Experimental strategy to establish cell lines latently infected with MuHV-4 ORF50-deficient 
recombinant viruses. MEF-1 cells were infected with ORF50-deficient recombinant viruses at a MOI of 3 
PFU per cell. Two days after infection, cells were trypsinised, counted and seeded at low cell density. Fresh 
medium containing MPA and xanthine was added. Resistant clones were picked, expanded under continued 
drug selection and analysed in Gardella gels for the presence of viral genomes. MPA, mycophenolic acid. 
 
 
MPA inhibits de novo synthesis of cellular purines, thereby inhibiting nucleic acid synthesis 
and preventing cell growth (Franklin and Cook, 1969; Mulligan and Berg, 1981). However, cells 
expressing E. coli enzyme guanosine phosphoribosyl transferase (GPT) can grow under these 
conditions, since this enzyme is able to synthesize purine precursors from xanthine (Mulligan and 
Berg, 1981). BAC-derived MuHV-4 ORF50-deficient viruses retain the BAC cassette (Milho et al., 
2009), which contains gpt gene from E. coli (Adler et al., 2000), encoding GPT enzyme (Figure 
5.3). Therefore, gpt acted as a selective marker, allowing selection of cells latently infected with 
ORF50-deficient viruses in the presence of MPA and xanthine. Since mLANA is essential for viral 
episome maintenance (Habison et al., 2012), only MEF cells latently infected with an ORF50-
deficient virus containing mLANA able to mediate episome persistence are expected to efficiently 
persist under drug selection.  
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Figure 5.3. Schematic diagram of the left end of BAC-cloned MuHV-4 genome. Viral terminal repeats and 
the gpt gene, BAC sequences and gfp gene, flanked by loxP sites, are shown, as described by Adler et al., 
2000. TR, terminal repeats; gpt, guanosine phosphoribosyl transferase; BAC, bacterial artificial chromosome; 
gfp, green fluorescent protein. 
 
 
The same number of MEF cells was infected with each virus. Infection with vORF50-mLANA-
SOCS resulted in only five MPA-resistant clones, whereas the number of MPA-resistant clones for 
vORF50-mLANA-WT or vORF50-mLANAV199A/L202A was too numerous to count (Table 5.1). The 
high rate of MPA outgrowth for vORF50-mLANAV199A/L202A, similar to vORF50-mLANA-WT, 
suggested that mLANAV199A/L202A mediated episome maintenance, whereas the low outgrowth of 
vORF50-mLANA-SOCS was consistent with absence of episome maintenance. Ten vORF50-
mLANA-WT or vORF50-mLANAV199A/L202A clones, and all five vORF50-mLANA-SOCS clones were 
picked for expansion under drug selection with MPA and xanthine in order to establish stable cell 
lines latently infected with MuHV-4 ORF50-deficient viruses. 
 
Six of ten vORF50-mLANA-WT and eight of ten vORF50-mLANAV199A/L202A clones could be 
expanded after 98 days (Table 5.1). In contrast, all five vORF50-mLANA-SOCS clones failed to 
expand and cells died (Table 5.1). These results are consistent with mLANA-WT and 
mLANAV199A/L202A, but not mLANA-SOCS, efficiently maintaining viral episomes.  
 
 
 
5.2.3. mLANAV199A/L202A mutant efficiently mediates episome persistence in a 
whole-virus context  
 
To confirm the presence of episomal DNA, MPA-resistant cells were assessed by Gardella gel 
analysis (Gardella et al., 1984). These experiments were performed by Dr M. Tan from Prof. K.M. 
Kaye’s laboratory (Harvard Medical School, USA) and data presented in this section were 
produced by him, using cell lines latently infected with MuHV-4 ORF50-deficient viruses obtained 
by me. 
 
Five million cells of each cell line were loaded into Gardella gels and lysed in situ as 
electrophoresis occurred. DNA was then transferred to a nylon membrane and detected with a TR 
probe to detect viral DNA. Gardella gel analysis showed that all six vORF50-mLANA-WT and all 
eight vORF50-mLANAV199A/L202A cell lines contained episomes (Figure 5.4 and Table 5.1). 
Therefore, mLANAV199A/L202A mediates MuHV-4 episome persistence. 
 
TR lo
x
P
gpt BAC gfp
lo
x
P
Impact of mLANA DNA binding deficiencies in episome persistence  
 
 
85 
The finding that mLANAV199A/L202A mediates episome persistence is consistent with the 
previous observation that vmLANAV199A/L202A recombinant virus was able to establish viable latency 
in mice (Figure 4.5, panel A). Notably, mLANAV199A/L202A mediated episome persistence as 
efficiently as did mLANA-WT. Therefore, the attenuation of latency expansion exhibited by 
vmLANAV199A/L202A can be attributed to the impairment of mLANA E3 ubiquitin-ligase activity 
(chapter 4). 
 
 
Figure 5.4. mLANAV199A/L202A efficiently mediates MuHV-4 episome persistence. After 98 days of MPA 
selection, approximately 5x106 cells were loaded per lane for Gardella gel analysis. DNA was then transferred 
to a nylon membrane and detected with a TR probe to detect viral DNA. Gardella gel contained uninfected 
MEF cells (lanes 1-2), vORF50-mLANA-WT (lanes 3-8) or vORF50-mLANAV199A/L202A (lanes 9-16) infected 
MEF cells. O, gel origin, E, episomal DNA, L, linear MuHV-4 DNA resulting from low level lytic replication. 
These data were obtained by Dr Min Tan from Prof. K.M. Kaye Lab (Harvard Medical School, USA). 
 
 
Table 5.1. Number of resistant clones obtained from infection of MEF cells with ORF50-deficient 
viruses. 
Virus 
Number of resistant 
clones 
Number of resistant 
clones after 98 days of 
drug selection 
Number of resistant 
clones containing 
episomes 
vORF50-mLANA-WT TNTC 6/10 6/6 
vORF50-mLANA-SOCS 5 0/5 NA 
vORF50-mLANAV199A/L202A TNTC 8/10 8/8 
TNTC, Too Numerous To Count; NA, Not Applicable. 
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5.3. Discussion 
 
This work demonstrates that mLANA is capable of episome maintenance despite mutations 
that result in considerably reduced TR DNA binding, depending on the number of TR elements 
present in episomes. Moreover, given the finding that mLANAV199A/L202A mutant actually mediates 
episome persistence, the attenuation of latency expansion exhibited by vmLANAV199A/L202A 
recombinant virus reported in chapter 4 can be attributed to the impairment of mLANA E3 ubiquitin-
ligase activity. 
 
It is particularly noteworthy that despite a severe TR DNA binding deficiency and the failure to 
mediate episome maintenance with four TR elements, mLANAV199A/L202A efficiently mediated 
episome persistence in the setting of a full complement of TRs in MuHV-4. It is likely that 
cooperative binding in the context of multiple TR elements compensates for mLANA DNA binding 
deficiencies. However, such compensation by an increased TR number is not without limit, as 
MuHV-4 with mLANA-SOCS or other mLANA mutants that are completely abolished for DNA 
binding cannot establish viable latent infection (Correia et al., 2013; Paden et al., 2012; Rodrigues 
et al., 2009). It was previously observed that episome persistence efficiency increased with eight 
TR elements as compared to two or four TR elements (Habison et al., 2012). Remarkably, mLANA 
or kLANA plasmids containing up to eight TR elements increased in size when maintained as 
episomes in transfected cells, compared to the input plasmids (Ballestas and Kaye, 2001; De Leon 
Vazquez and Kaye, 2011; Habison et al., 2012). This increase in episome size was found to be due 
to TR duplication and recombination of input plasmids into multimers. KSHV genome contains 
approximately 40 TR elements (Lagunoff and Ganem, 1997) and MuHV-4 may contain a similar 
number. Therefore, it is likely that there is strong selection for recombination events that lead to a 
TR number similar to that in the virus. A recent study reported that at least 16 TR elements are 
necessary for optimal KSHV episome maintenance (Shrestha and Sugden, 2014). 
 
As mentioned before, the dorsal positive patch of kLANA DBD was shown to interact with DNA 
of arbitrary sequence and assemble into supermolecular spirals around DNA by self-association of 
kLANA (Hellert et al., 2015). Since mLANA has a similar positively charged patch (Correia et al., 
2013; Hellert et al., 2013), it is possible that higher order mLANA structures may form and exert 
compensatory roles to overcome DNA binding deficiency. 
 
Overall, these data reveal that deficiencies in mLANA binding to TR DNA are tolerated to 
some extent without disruption of episome maintenance function, possibly through cooperative 
binding of mLANA to multiple TR elements in the MuHV-4 genome. Further investigation is 
necessary to clarify this compensatory mechanism. 
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Full-length mLANA is expressed in insect cells using baculovirus 
MultiBac system 
 
6.1. Introduction  
 
The resolution of the crystal structure of C-terminal mLANA enabled the rational design of 
mutations targeting specific functions of the viral protein, as demonstrated in chapters 2, 3 and 4 of 
this thesis. Therefore, determining the crystal structure of full-length mLANA would likely provide an 
opportunity to investigate thoroughly mLANA functions in vivo, and hence identify other motifs in 
this protein that could be used as putative pharmacological targets to control viral infection. 
However, the crystal structure of full-length mLANA remains undetermined, mainly due to the 
failure in obtaining appropriate protein expression levels. 
 
Prokaryotic hosts, in particular E. coli, have been the systems of choice for recombinant 
protein expression, due to their simplicity, versatility and low cost (Vincentelli and Romier, 2013). 
However, the expression levels of full-length mLANA achieved using E. coli were very poor (Pires 
de Miranda et al., unpublished data). Therefore, it was necessary to find an alternative system 
which allowed good expression levels of full-length mLANA. 
 
Eukaryotic hosts, including yeast, insect cells and mammalian cells, have been successfully 
used for production of recombinant proteins (Bieniossek et al., 2012). In particular, the use of insect 
cell cultures infected with a recombinant baculovirus, carrying the gene of interest, has become an 
important tool in recombinant protein expression. 
 
Dr Imre Berger’s laboratory (EMBL, Grenoble, France) has developed MultiBac system 
(Berger et al., 2004; Bieniossek et al., 2008; Trowitzsch et al., 2010; Vijayachandran et al., 2011), 
in which an engineered Autographa californica nuclear polyhedrosis virus (AcNPV) baculoviral 
genome, containing the heterologous gene, is used to infect cells of the caterpillar Spodoptera 
frugiperda. Dr I. Berger’s team at EMBL Grenoble is very experienced in protein expression and 
runs the Eukaryotic Expression Facility, where visitors receive specific training in MultiBac system. 
 
To investigate whether full-length mLANA could be expressed in insect cells using 
baculovirus, two recombinant baculoviruses containing the ORF73 gene were generated using the 
MultiBac system. The feasibility study of mLANA expression in insect cells was performed by me at 
the Eukaryotic Expression Facility at EMBL Grenoble, under the supervision of Dr I. Berger, 
Frederic Garzoni and Alice Aubert. Chronologically, these experiments were performed before the 
ones presented in the previous chapters, and were also included in the consortium of HMS-PT 
Program. 
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6.2. Results 
 
6.2.1. Construction of transfer plasmids for integration of ORF73 gene into 
baculovirus genome 
 
To achieve higher levels of mLANA expression in Spodoptera frugiperda 21 (Sf21) insect 
cells, the ORF73 gene sequence was optimized for codon usage in insect cells. Codon 
optimization was performed by GenScript company, using OptimumGene algorithm. 63% of ORF73 
codons were modified (data not shown). Two codon optimized ORF73 constructs were engineered 
(Figure 6.1): GST-His-mLANA and His-mLANA, encoding mLANA with a N-terminus GST-8xHis-
tag or 8xHis-tag, respectively, followed by a PreScission protease cleavage site. These tags were 
introduced to allow subsequent purification of mLANA from insect cells. 
 
 
 
Figure 6.1. Schematic diagram of mLANA constructs for expression in insect cells. GST-His-mLANA (A) 
and His-mLANA (B) constructs encode mLANA with a N-terminus GST-8xHis-tag or 8xHis-tag, followed by a 
PreScission protease cleavage site (PCS). mLANA coding sequence was codon optimized for expression in 
insect cells. 
 
 
GST-His-mLANA and His-mLANA coding sequences were then subcloned into pPBac transfer 
plasmid (Vijayachandran et al., 2011) (details in Materials and Methods, section 8.2.3.3). pPBac 
contains the expression cassette, where the heterologous genes are inserted, flanked by Tn7L and 
Tn7R DNA sequences, thus allowing Tn7-mediated integration of the genes of interest into the 
baculovirus genome (section 6.2.2). 
 
 
  
8xHis mLANAPCS
8xHis mLANAPCSGST
A
B
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6.2.2. Generation of recombinant baculoviruses expressing full-length mLANA  
 
Recombinant baculoviruses were derived from yellow fluorescent protein (YFP)-expressing 
AcNPV baculovirus genome cloned as a BAC (EMBacY) (Bieniossek et al., 2008; Trowitzsch et al., 
2010). EMBacY contains a Tn7 attachment site embedded in a lacZα gene for integrating foreign 
genes into the baculovirus genome, via transfer plasmids. Therefore, successful integration of the 
expression cassette disrupts lacZα gene, allowing selection of positive clones by blue/white 
screening. In addition, EMBacY contains a YFP coding gene elsewhere in the genome that allows 
a tracking of infection. 
 
Transfer plasmids harbouring GST-His-mLANA or His-mLANA coding sequences were 
transformed into an E. coli strain containing EMBacY plasmid (Bieniossek et al., 2008; Trowitzsch 
et al., 2010). Positive clones, with mLANA coding sequences integrated into the baculovirus 
genome, were then selected. Recombinant baculoviruses were reconstituted by transfection of the 
recombinant EMBacY plasmid into Sf21 insect cells. Each transfection was performed in duplicate. 
Further details are described in Materials and Methods, sections 8.2.6.3 and 8.2.6.4. 
 
For production of the initial baculovirus stocks (V0), supernatants of Sf21 cell cultures 
transfected with the recombinant EMBacY plasmids were harvested, after incubation for 48 h 
(Figure 6.2).  
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Figure 6.2. Protocol for gene expression test in insect cells using MultiBac system. Transfer plasmids 
harbouring the heterologous gene(s) are integrated into EMBacY baculoviral DNA via Tn7 transposition. 
Positive clones are identified by blue/white screening. Recombinant baculoviral DNA is isolated from cultures 
of single colonies and used to transfect Sf21 cells in 6-well plate format. Two clones obtained with the same 
construct are processed in parallel. After 48 h, media containing initial virus (V0) is harvested from the wells 
and used to infect a new insect cell culture (25 ml volume) in an Erlenmeyer shaker flask. Infected cell cultures 
are counted every 24 h and split as needed until cell proliferation arrest occurs. After proliferation arrest, 1x106 
cells are sampled every 24 h for measuring YFP fluorescence. Media containing amplified virus (V1) is 
removed 48 h after proliferation arrest, and fresh medium is replenished instead. Cells are harvested when the 
YFP signal has reached a plateau (typically after 3-4 days). Protein production is then analysed by sodium 
dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) (adapted from Trowitzsch et al., 2010). 
 
Clone Selection
Transfection and Production of V0
Sf21 cells
Harvest of V0 and Production of V1
48 h
V1
Expression Analysis
Count cells every 24 h until proliferation arrest
Measure YFP fluorescence every 24 h until plateau
SDS-PAGE
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6.2.3. Small-scale expression of full-length mLANA 
 
To assess expression of mLANA constructs in insect cells, a small-scale protein expression 
test was performed. V0 stocks were added to fresh Sf21 cells and infected cell cultures were grown. 
YFP fluorescence was then measured every day after cell proliferation arrest occurred, until YFP 
fluorescence reached a plateau. At that point, cells were harvested and mLANA expression was 
analysed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), followed by 
Coomassie Blue staining and Western-blot (Figure 6.2).  
 
The YFP coding gene, inserted into loxP site of EMBacY plasmid, is under control of 
polyhedrin promoter, as heterologous genes (Bieniossek et al., 2008; Trowitzsch et al., 2010). Dr I. 
Berger’s group observed that when YFP expression reaches a plateau, the expression of 
heterologous proteins under the same promoter also reach their peak production. Therefore, 
heterologous protein production levels can be monitored by following YFP expression. As observed 
in Figure 6.3, YFP levels increased for all the constructs for the first 96 h after proliferation arrest. 
Since at this time point the YFP levels for one of the constructs, His-mLANA #2, (Figure 6.3, panel 
D) nearly reached a plateau, cells were harvested for analysis of mLANA expression.  
 
 
Figure 6.3. Yellow fluorescent protein (YFP) expression from recombinant EMBacY baculoviral DNA. 
Samples from infected cell cultures were briefly sonicated and, following centrifugation, the supernatant was 
24 48 72 96
0
2000
4000
6000
8000
10000
12000
14000
16000
Hours after dpa
Y
F
P
 c
o
u
n
ts
24 48 72 96
0
2000
4000
6000
8000
10000
12000
14000
16000
Hours after dpa
Y
F
P
 c
o
u
n
ts
24 48 72 96
0
2000
4000
6000
8000
10000
12000
14000
16000
Hours after dpa
Y
F
P
 c
o
u
n
ts
GST-His-mLANA #1 GST-His-mLANA #2
ND
24 48 72 96
0
2000
4000
6000
8000
10000
12000
14000
16000
Hours after dpa
Y
F
P
 c
o
u
n
ts
His-mLANA #1
A B
C His-mLANA #2D
Chapter 6 
 
 
94 
used for YFP fluorescence measurement, using a fluorescence spectrophotometer. YFP fluorescence was 
measured every day after cell proliferation arrest occurred, until YFP levels reached a plateau. At that point, 
cells were harvested and mLANA expression was analysed. Two clones for each construct were processed in 
parallel (#1 and #2). dpa, day of proliferation arrest; ND, not determined.  
 
 
The harvested cells were then analysed by SDS-PAGE, followed by Coomassie Blue staining 
and Western-blot, to assess mLANA expression. GST-His-mLANA (≈75 kDa) was detected both in 
Coomassie staining (Figure 6.4, top panel, lanes 1-4, asterisks) and in Western-blot (Figure 6.4, 
bottom panel, lanes 1-4). The band below 75 kDa detected for this samples in the Western-blot 
(Figure 6.4, bottom panel, lanes 1-4) likely correspond to degradation of GST-His-mLANA 
constructs. In contrast, His-mLANA (≈50 kDa) was only detected by Western-blot (Figure 6.4, 
bottom panel, lanes 5-8), but it is possible that it is masked in the Coomassie by other proteins of 
the same size. 
 
 
Figure 6.4. Full-length mLANA is expressed in insect cells using baculovirus MultiBac system. 
Samples from infected cell cultures were harvested at 96 h after cell proliferation arrest and sonicated. An 
aliquot of sonicated sample was removed for whole cell extract (WCE) analysis. The remaining sample was 
centrifuged and an aliquot of supernatant was removed for soluble lysate (SL) analysis. WCE and SL samples 
were boiled in Laemmli’s sample buffer, resolved by SDS-PAGE and either stained with Coomassie Blue (top 
panel), or transferred to nitrocellulose and immunoblotted with anti-mLANA antibody to detect expression of 
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mLANA constructs (bottom panel). A sample of non-infected Sf21 cells was processed in parallel as control 
(cell control, CC). Approximately 2.5 x 104 cells were loaded in each well. Asterisks mark the band 
corresponding to GST-His-mLANA construct. 
 
 
To amplify baculovirus stocks expressing GST-His-mLANA and His-mLANA, cell cultures 
infected with V0 were centrifuged 48 h after proliferation arrest, and supernatants were harvested, 
constituting the V1 stock (Figure 6.2). V1 corresponds to a stock of amplified virus, which can be 
used to infect larger volumes of Sf21 cultures to produce mLANA in large scale.  
 
Overall, these results show that full-length mLANA can be expressed in insect cells using 
baculovirus MultiBac system.  
 
 
 
 
6.3. Discussion 
 
The feasibility study of mLANA expression in insect cells using baculovirus demonstrated that 
the full-length protein can be successfully expressed with this system. Remarkably, the achieved 
levels of expression were good, particularly for GST-His-mLANA construct, as this protein was 
readily detected in the Coomassie staining. However, it is a possibility that His-mLANA construct is 
masked in the Coomassie by other proteins of the same size (≈50 kDa). 
 
The crystal structure of full-length mLANA remains unknown. Although the determination of 
the crystal structure requires the surmounting of several critical steps, the accomplishment of good 
levels of protein expression is a major contribute to obtain good quality structural data (Aloy and 
Russell, 2006). Therefore, the use of MultiBac system for expression in insect cells as an approach 
to express mLANA may be an important tool for structural studies on full-length mLANA. 
Subsequent experiments performed by Dr Marta Miranda in our laboratory succeeded in purifying 
mLANA from the frozen pellets obtained in section 6.2.3, and large-scale expression in insect cells 
has been started, using the V1 amplified baculovirus stock. The first structural studies on full-length 
mLANA using small-angle X-ray scattering (SAXS) are being performed by Dr C.E. McVey’s team 
(Instituto de Tecnologia Química e Biológica (ITQB), Universidade Nova de Lisboa, Portugal). 
Importantly, SAXS analysis allows the determination of low-resolution structure of proteins in 
solution, with no need for crystals. For instance, the binding modes of mLANA and kLANA C-
terminal DBDs to viral TR DNA were recently inferred from SAXS low-resolution structural analysis 
of mLANA/kLANA-DNA complexes in solution (Ponnusamy et al., 2015). 
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Notably, the resolution of the crystal structure of mLANA DBD enabled the rational design of 
mutations targeting specific functions of the viral protein (Correia et al., 2013; Hellert et al., 2013). 
Hence, structural data on full-length mLANA will likely provide an invaluable contribution to mLANA 
pathogenesis studies, and the finding that mLANA can be successfully expressed in insect cells 
using the MultiBac system of EMBL Grenoble is a major achievement. Future work on the three-
dimensional structure of full-length mLANA complexed with its cellular partners so far identified 
may also be relevant. Moreover, the expression of full-length mLANA using this expression system 
may also be useful for other studies that require pure full-length protein, for instance binding 
studies. 
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Final Considerations 
 
Gammaherpesviruses drive proliferation of latently infected B cells in GCs to expand latency 
and to achieve long-term persistence in memory B cells. During latency, the viral genome is 
maintained as an extrachromosomal circular episome within the host cell nucleus. To persist in 
proliferating cells, viral episomes must replicate in step with normal cell division and segregate to 
newly formed nuclei after mitosis. This process is mediated by gammaherpesvirus episome 
maintenance proteins, which include EBV EBNA1, KSHV kLANA and MuHV-4 mLANA (Ballestas 
et al., 1999; Ballestas and Kaye, 2001, 2011; Habison et al., 2012; Yates et al., 1985). The crystal 
structures of the DNA binding domains (DBDs) of these proteins were solved and revealed a 
common overall fold, containing a dimeric central eight-stranded anti-parallel β-barrel, with four β-
strands contributing from each monomer and flanked on either side by three α-helices (Bochkarev 
et al., 1996; Bochkarev et al., 1995; Correia et al., 2013; Domsic et al., 2013; Hellert et al., 2015; 
Hellert et al., 2013; Ponnusamy et al., 2015). The DBD allows episome maintenance proteins to 
bind to viral DNA. LANA proteins, in particular, cooperatively bind to multiple sites within the TR 
sequences of the viral genome through their DBD and tether viral episomes to host cell mitotic 
chromosomes, thereby promoting efficient segregation of episomes into daughter nuclei. Other 
LANA structural features associated with specific functions were also revealed by the crystal 
structure of DBD. The study of the mechanisms underlying LANA functions is crucial, since this 
protein is essential for the establishment and maintenance of latent infection in vivo. However, the 
individual contribution of each function assigned to LANA during the natural infection remains 
largely uncharacterized. 
 
A major limitation to the study of the human gammaherpesviruses is the absence of a robust 
small animal model in which to investigate viral pathogenesis, due to the very narrow host tropism 
exhibited by EBV and KSHV (Barton et al., 2011; Simas and Efstathiou, 1998). The identification of 
MuHV-4 (Blaskovic et al., 1980) offered the possibility of developing a mouse model of 
gammaherpesvirus pathogenesis. Remarkably, MuHV-4 mLANA shares structural and functional 
homology to KSHV kLANA (Correia et al., 2013; Fowler et al., 2003; Habison et al., 2012; Hellert et 
al., 2013; Rodrigues et al., 2009; Rodrigues et al., 2013), particularly in the DBD, thereby 
emphasising the use of mLANA as a model to study kLANA pathogenesis in the mouse and to 
potentially test pharmacological inhibitors of LANA functions through targeting of key structural 
features of the DBD.  
 
The work presented in this thesis was inserted into the project «Pathogenesis of Kaposi’s 
sarcoma herpesvirus LANA» of the HMS-PT Program from FCT, gathering the expertise of three 
research teams in KSHV LANA (Prof. K.M. Kaye group), structural biology (Prof. M.A. Carrondo 
and Dr C.E. McVey group) and in the murine model of MuHV-4 infection (Prof. J.P. Simas group). 
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The aim of this thesis was to address the importance of particular LANA functions in the context of 
gammaherpesvirus latent infection in vivo, integrating LANA structural data and the animal model 
of infection with MuHV-4. mLANA was used as a model to investigate LANA pathogenesis in mice. 
To this end, MuHV-4 recombinant viruses harbouring structure-based mutations targeting specific 
mLANA interfaces were engineered, and the ability of these recombinants to establish and 
maintain latent infection was analysed upon intranasal infection of mice. The results presented in 
this study support a critical role of LANA in gammaherpesvirus latency, particularly due to its 
function as a DNA binding protein. Other LANA functions, as E3 ubiquitin-ligase activity or dorsal 
positive patch-associated functions, were also shown to contribute to latency expansion. 
 
The crystal structure of mLANA DBD allowed the identification of a DNA binding interface 
containing a cluster of positively charged residues. In particular, residues H186 and K187, in the 
predicted DNA recognition helix α2, were found to be involved in interactions with phosphate ions 
of DNA and mutations at these residues disrupted mLANA binding to TR DNA (Correia et al., 
2013). To validate in vivo the DNA binding structural data, a MuHV-4 recombinant virus containing 
mLANA mutations H186D/K187E (vmLANAH186D/K187E) was engineered in the scope of this thesis 
(chapter 2). mLANA binding to the TR elements in viral genome was found to be essential for 
latency expansion in GC B cells and persistence in the host, thereby validating the importance of 
mLANA binding to viral DNA during latent infection in vivo. This is consistent with mLANA acting on 
TR elements to mediate episome persistence (Habison et al., 2012). Interestingly, deficiencies in 
mLANA binding to TR DNA were tolerated to some extent without abrogation of episome 
maintenance function (chapter 5), possibly due to cooperative binding of mLANA to multiple TR 
elements in the MuHV-4 genome. Further investigation is necessary to clarify this compensatory 
mechanism. 
 
The crystal structure of mLANA DBD also revealed an extensive positive patch on its dorsal 
side, opposite to the DNA binding interface. This dorsal positive patch harbours the 226QAKKLK231 
motif, which is involved in binding to BET proteins, particularly Brd2 and Brd4 (Correia et al., 2013; 
Hellert et al., 2013; Ottinger et al., 2009). To investigate if the dorsal positive patch exerted a 
functional role in vivo, MuHV-4 recombinant viruses containing mLANA mutations that targeted 
either the central (K251, K253) or the peripheral (K224, K228, K229) regions of the patch were 
engineered (chapter 3). The work presented in this thesis demonstrated that the dorsal positive 
patch of mLANA, particularly the peripheral region, is required for efficient latency expansion in GC 
B cells, exerting its functions through an unknown mechanism. Interestingly, the deficit in latency 
for some recombinant viruses did not correlate with binding to Brd4 protein. It is possible that the 
dorsal positive patch associates with a host cell partner(s) other than Brd4 or, alternatively, 
interacts with viral DNA in a sequence-independent manner to induce the formation of specific 
complexes required for episome replication and maintenance. This is an important question that 
should be addressed in future experiments. Notably, KSHV kLANA exhibits a similar dorsal positive 
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patch, which was recently shown to facilitate viral DNA replication and episome persistence in 
latently infected cells in culture (Domsic et al., 2013; Li et al., 2015). 
 
LANA proteins are also known as modulators of cellular transcription, particularly due to their 
E3 ubiquitin-ligase activity (Cai et al., 2006; Li et al., 2011; Rodrigues et al., 2009; Rodrigues et al., 
2013). The crystal structure of mLANA DBD showed that the SOCS-box, through which mLANA 
recruits cellular ElonginB/C and Cullin5 in order to assemble the E3 ubiquitin-ligase complex, lies 
within a loop protruding perpendicular to the DNA binding interface (Correia et al., 2013). To clarify 
the biological relevance of mLANA E3 ubiquitin-ligase activity for gammaherpesvirus pathogenesis, 
MuHV-4 recombinant viruses containing mutations in mLANA SOCS-box which impaired E3 
ubiquitin-ligase activity without compromising episome maintenance function were generated 
(chapter 4). The results obtained in this study revealed that the impairment of mLANA E3 ubiquitin-
ligase activity results in an attenuation of latency levels in spleen, demonstrating that this function 
of mLANA contributes to latency expansion. Quantification of infection in GC B cells would be 
necessary to establish a definitive link between mLANA E3 ubiquitin-ligase activity and latency 
expansion in GCs. mLANA has two known cellular targets for poly-ubiquitination, NF-κB and Myc 
(Rodrigues et al., 2009; Rodrigues et al., 2013). Given that mLANA acts as the substrate 
recognition component of the E3 ubiquitin-ligase complex, interacting with the NF-κB family 
member p65 and with Myc through motifs independent from the SOCS-box, as yet unidentified, it 
could be a possibility that the dorsal positive patch of mLANA would be the binding site to these 
substrates. However, previous experiments performed in our laboratory mapped interactions with 
p65 and Myc to N-terminal mLANA (residues 1-140) (Rodrigues et al., unpublished data), thereby 
rejecting the hypothesis that the C-terminal dorsal positive patch could be involved in these 
interactions. Remarkably, KSHV kLANA is also able to assemble an E3 ubiquitin-ligase complex 
through a SOCS-box motif, promoting the poly-ubiquitination of p53, VHL and p65, and targeting 
these substrates for degradation, thereby potentially providing a favourable environment for cell 
growth (Cai et al., 2006; Li et al., 2011). Hence, although kLANA substrates are different from the 
ones of mLANA, it is likely that targeting the E3 ubiquitin-ligase function of kLANA will have an 
impact on KSHV latency in the host. 
 
Overall, this thesis reinforces the overview of LANA as a multifunctional protein and addresses 
the contribution of several LANA functions to gammaherpesvirus latent infection in vivo, using 
MuHV-4 mLANA as a model. One of the hallmarks of herpesvirus latency is the highly restricted 
pattern of viral protein expression, in order to reduce the chance of being detected by the host 
immune system (Wu et al., 2010). Therefore, by concentrating several critical functions in the same 
viral protein, the virus limits the amount of antigen produced while efficiently maintaining latency. 
Interestingly, mLANA was shown to reduce the presentation of an MHC class I-restricted epitope 
linked to it in cis, suggesting that mLANA exerts a mechanism to limit its presentation to CTLs, 
similarly to EBV EBNA1 (Bennett et al., 2005). 
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Furthermore, this work provides evidence that it is quite advantageous to perform 
pathogenesis studies guided by protein structural data, as several structural features are 
associated with specific functions of the protein, thereby enabling the rational design of mutations 
targeting a particular function. In this sense, determining the crystal structure of full-length mLANA, 
which is currently unknown, would likely provide an opportunity to investigate thoroughly mLANA 
functions in vivo. This project revealed that full-length mLANA can be successfully expressed in 
insect cells using baculovirus (chapter 6). This is a first step towards the resolution of mLANA full-
length structure, which may allow novel structure-guided pathogenesis studies with mLANA. 
 
Herein, the impact of disruption of several mLANA structural interfaces was evaluated. Three 
possible targets to control gammaherpesvirus infection were identified: the DNA binding interface, 
the dorsal positive patch and the SOCS-box. The DNA binding interface is likely the best 
candidate, as a virus bearing mutations abrogating TR DNA binding was severely compromised in 
establishment of latency in mice. Notably, KSHV kLANA exhibits a DNA binding interface similar to 
mLANA (Domsic et al., 2013; Hellert et al., 2015; Hellert et al., 2013; Ponnusamy et al., 2015), and 
mutation of residues P1065, Y1066 and G1067, in the DNA recognition helix α2, abolishes binding 
of kLANA to the LBS sites in the KSHV TRs (Han et al., 2010; Kelley-Clarke et al., 2007b). 
Therefore, these residues are likely candidates to disrupt episome persistence and, consequently, 
KSHV latency in the natural context of infection. Future work using small molecule inhibitors 
targeting these structural features is necessary to clarify whether the pharmacological disruption of 
such structures is an effective strategy to control gammaherpesvirus latent infection and associated 
pathologies. 
 
Other latent DNA viruses maintain genomes as extrachromosomal circular episomes within 
the nuclei of infected cells. Virus-encoded cis- and trans-acting genome maintenance functions 
seem to be dispensable when latency is established in non-dividing cell populations, as is the case 
of neurotropic herpes simplex virus (HSV) (Nicoll et al., 2012). In contrast, episome maintenance 
proteins assume a prominent role when latency is established within proliferating cells, and this is 
not exclusive to lymphotropic gammaherpesviruses. For instance, papillomavirus encodes a DNA 
binding protein, the E2 protein, which was shown to mediate virus episome persistence through a 
mechanism resembling the tethering mechanism of gammaherpesvirus EBNA1 and LANA. The 
papillomavirus E2 protein contains a DBD which allows it to bind to specific sites in the viral 
genome, while other regions of E2 interact with chromosomal proteins, thereby tethering viral 
episome to mitotic chromosomes in the proliferating basal cells (Bastien and McBride, 2000; Ilves 
et al., 1999; Lehman and Botchan, 1998; McBride, 2013; Piirsoo et al., 1996; Skiadopoulos and 
McBride, 1998). Notably, the crystal structure of E2 DBD exhibits great structural homology to the 
EBNA1 and LANA DBDs, despite the absence of sequence homology to these gammaherpesvirus 
proteins (Bochkarev et al., 1995; Correia et al., 2013; Dell et al., 2003; Domsic et al., 2013; Hegde 
et al., 1992; Hellert et al., 2013). Therefore, virus-encoded DBD-containing episome maintenance 
proteins that bind to specific DNA sequences in the viral genome and tether it to mitotic 
Final Considerations  
 
 
103 
chromosomes likely represent an overall strategy employed by episomal DNA viruses to ensure 
that the virus is not lost during cell division. This emphasizes the perspective of episome 
maintenance proteins as putative targets to disrupt viral latency. 
 
Gammaherpesvirus latent infection is characterized by stable low levels of latently infected 
memory B cells, as a consequence of the dynamic equilibrium between virus-driven B cell 
proliferation and host immune control. However, when the virus-host equilibrium is disrupted, 
latently infected B cells can proliferate unchecked, leading to the development of 
lymphoproliferative diseases (Cesarman, 2014; Kutok and Wang, 2006; Thorley-Lawson and 
Gross, 2004). EBV is aetiologically linked to three B cell malignancies, Burkitt’s lymphoma, 
Hodgkin’s lymphoma and post-transplant lymphoproliferative disorder, to a subset of T and natural 
killer (NK) cell lymphomas, and to an epithelial tumour, nasopharyngeal carcinoma (Cesarman, 
2014; Kutok and Wang, 2006). KSHV is similarly associated with B cell lymphoproliferative 
diseases, such as primary effusion lymphoma (PEL) and multicentric Castleman’s disease (MCD), 
and to a tumour of endothelial origin, Kaposi’s sarcoma (KS) (Cesarman et al., 1995; Chang et al., 
1994; Soulier et al., 1995). These malignancies are characterized by uncontrolled proliferation of 
latently infected cells expressing EBNA1 or kLANA. Although other functions of these proteins have 
been hypothesised to contribute to oncogenesis, it is their episome maintenance function that has 
been linked to the successful persistence strategy of gammaherpesvirus, avoiding viral episomes 
to be lost during cell division in proliferating tumour cells (Ballestas and Kaye, 2011; Barton et al., 
2011; Cesarman, 2014; Gramolelli and Schulz, 2015; Kang and Kieff, 2015; Schulz and Cesarman, 
2015). This places episome maintenance proteins at the centre of gammaherpesvirus 
pathogenesis. The work presented in this thesis demonstrated that disruption of LANA DNA 
binding interface severely impairs viral persistence in proliferating B cells in vivo (chapter 2), 
reinforcing the use of episome maintenance proteins DBD as a pharmacological target to disrupt 
latency and thus control gammaherpesvirus-associated pathologies. In fact, recent studies have 
shown that EBNA1 DBD can be targeted by small molecules identified by high-throughput cell-
based screens, resulting in inhibition of EBNA1 binding to its cognate DNA, progressive loss of 
EBV episome, and limited growth of EBV-infected lymphoblastoid cell lines or Burkitt’s lymphoma 
cells (Lee et al., 2014). The use of mLANA in the context of the MuHV-4 mouse model of infection 
may add insightful contribution to these screenings.  
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Materials and Methods 
 
8.1. Materials  
 
 
8.1.1. General reagents  
Analytical or molecular biology grade chemicals were obtained from Bio-Rad, Calbiochem, 
Invitrogen, Merck, NZYTech, Roche and Sigma-Aldrich. Molecular biology reagents and enzymes 
were obtained from Agilent, Fermentas, Invitrogen, New England Biolabs, NZYTech, Promega and 
Roche. Synthetic oligonucleotides were synthesized by Thermo Scientific. Protein methods 
reagents were obtained from Bio-Rad, Fujifilm, GE Healthcare, Promega, Qiagen, Roche, Sigma-
Aldrich and Thermo Scientific. Tissue culture reagents and supplements were obtained from Gibco. 
 
 
8.1.2. Antibodies 
8.1.2.1. Primary antibodies 
Anti-mLANA mouse monoclonal antibody (Rodrigues et al., 2013) was raised against the C-
terminal domain (residues 140-314) of purified GST-mLANA protein. The antibodies against 
this region of mLANA were generated at the Monoclonal Antibodies Core Facility, European 
Molecular Biology Laboratory (EMBL). This antibody was used in Western-blot experiments.  
Anti-mLANA rabbit polyclonal serum (Rodrigues et al., 2009) was generated by immunization of 
New Zealand white rabbits (Abcam) with purified GST-mLANA protein. This antibody was 
used in immunoprecipitation experiments. 
The other primary antibodies used in this study are commercially available and are described in 
Table 8.1: 
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Table 8.1. Primary antibodies (commercially available) used in this study. 
Name (Clone) Assay Type Species Supplier 
c-Myc 
(9E10) 
WB 
Monoclonal 
IgG1 
Mouse Clontech 
HA 
(16B12) 
WB 
Monoclonal 
IgG1 
Mouse Covance 
FLAG 
(M2) 
WB 
Monoclonal 
IgG1 
Mouse Sigma-Aldrich 
p65 
(F-6) 
WB 
Monoclonal 
IgG1 
Mouse 
Santa Cruz 
Biotechnology 
c-Myc 
(N-262) 
WB Polyclonal Rabbit 
Santa Cruz 
Biotechnology 
EloC 
(R-20) 
WB Polyclonal Goat 
Santa Cruz 
Biotechnology 
Cul5 
(H-300) 
WB Polyclonal Rabbit 
Santa Cruz 
Biotechnology 
Actin 
(A2066) 
WB Polyclonal Rabbit Sigma-Aldrich 
CD16/32 
(2.4G2) 
FC 
Monoclonal 
IgG2b, κ 
Rat 
BD Pharmingen 
(BD Biosciences) 
CD19-APC-H7 
(1D3) 
FC 
Monoclonal 
IgG2a, κ 
Rat 
BD Pharmingen 
(BD Biosciences) 
CD95-PE 
(Jo2) 
FC 
Monoclonal 
IgG2, λ2 
Hamster 
BD Pharmingen 
(BD Biosciences) 
GL7-eFluor660 
(GL7) 
FC 
Monoclonal 
IgM 
Rat eBioscience 
Dig-AP ISH Polyclonal Sheep Roche 
WB, Western-blot; FC, Flow Cytometry; ISH, In Situ Hybridization. 
 
8.1.2.2. Secondary antibodies 
Horseradish peroxidase (HRP)-conjugated secondary antibodies against mouse or goat class G 
immunoglobulins (IgGs) were purchased from Jackson Immunoresearch. HRP-conjugated 
secondary antibody against rabbit IgGs was purchased from GE Healthcare. These secondary 
antibodies were used in Western-blot experiments. 
 
 
8.1.3. Cell lines 
Baby hamster kidney (BHK)-21 fibroblast cells were used for growing and titrating viral stocks, in 
vitro growth curves, ex vivo reactivation, plaque assays and analysis of mLANA expression. 
NIH-3T3-CRE mouse fibroblast cells were kindly provided by Dr Philip Stevenson (Sir Albert 
Sakzewski Virus Research Centre, School of Chemistry and Molecular Biosciences, 
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University of Queensland and Royal Children's Hospital, Australia) and were used during the 
construction of murid herpesvirus-4 (MuHV-4) recombinant viruses, for removing the loxP-
flanked bacterial artificial chromosome (BAC) cassette. This cell line was established by 
transduction of NIH-3T3 cells with a retrovirus derived from Phoenix-ecotropic cells 
transfected with pMSCV-CRE-NEO (cre of bacteriophage P1 cloned into the EcoRI-XhoI 
sites of pMSCV-NEO) and selection with 1mg/mL of G418 (Stevenson et al., 2002).  
3T3-ORF50 mouse fibroblast cells were a kind gift by Dr Stacey Efstathiou (Division of Virology, 
Department of Pathology, University of Cambridge, UK) and Dr P. Stevenson, and were 
used to grow and titrate MuHV-4 ORF50-deficient recombinant viruses. This cell line was 
established by serially transducing NIH-3T3 cells with three retroviruses: one expressing 
ORF50 from a promoter with doxycycline-responsive (TRE) promoter, one expressing 
constitutively a transcriptional suppressor with doxycycline-inactivated TRE-binding, and one 
expressing constitutively a transcriptional activator with doxycycline-activated TRE-binding, 
thus allowing doxycycline-inducible ORF50 expression. ORF50 coding sequence was 
amplified by polymerase chain reaction (PCR) from infected cell cDNA and cloned into 
pREV-TRE. TRE-binding transcriptional suppressor was excised from pTET-tTS with 
EcoRI/ClaI, ClaI site was blunted with T4 DNA polymerase and the fragment was ligated into 
EcoRI-blunted XhoI sites of pMSCV-IRES-PURO. TRE-binding transcriptional activator was 
from pREV-TET-ON. Each plasmid was transfected into human embryonic kidney (HEK) 
293T cells together with pEQPAM3 packaging plasmid. Retroviruses were collected after 48 
and 72 h, and added to cells with 6 µg/mL of polybrene. Triply transduced cells were 
selected with puromycin, hygromycin and G418 (Milho et al., 2009). 
Mouse embryonic fibroblast (MEF-1) cells were used for episome maintenance assays with MuHV-
4 ORF50-deficient recombinant viruses.  
Human embryonic kidney (HEK) 293T epithelial cells were used for reporter gene assays, poly-
ubiquitination assays and immunoprecipitation assays. 
Spodoptera frugiperda 21 (Sf21) insect cells were a kind gift from Dr Imre Berger (EMBL, 
Grenoble, France) and were used for propagation of recombinant baculovirus stocks and 
production of full-length mLANA. 
 
 
8.1.4. Bacterial strains 
Escherichia coli strain DH5α (Invitrogen), genotype F- Φ80lacZΔM15 Δ(lacZYA-argF) U169 recA1 
endA1 hsdR17(rk-, mk+) phoA supE44 thi-1 gyrA96 relA1 λ-, was used to grow high-copy 
plasmids. 
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E. coli strain XL10-Gold Ultracompetent (Agilent Technologies), genotype TetrΔ(mcrA)183 
Δ(mcrCB-hsdSMR-mrr)173 endA1 supE44 thi-1 recA1 gyrA96 relA1 lac Hte [F´ proAB 
lacIqZΔM15 Tn10(Tetr) Amy Camr], was used to grow plasmids generated by PCR 
mutagenesis and shuttle vector derived plasmids. 
E. coli strain DH10B (Invitrogen), genotype F- mcrA Δ(mrr-hsdRMS-mcrBC) Φ80lacZΔM15 
ΔlacX74 recA1 endA1 araD139 Δ (ara, leu)7697 galU galK λ- rpsL (Strr) nupG, containing 
the MuHV-4 BAC pHA3 (Adler et al., 2000), was provided by Dr Heiko Adler (Helmholtz 
Zentrum Munich, German Research Center for Environmental Health, Germany) and Dr 
Ulrich Koszinowski (Max von Pettenkofer-Institut, Ludwig-Maximilians-Universität, Munich, 
Germany) and was used for mutagenesis of MuHV-4 BAC pHA3. 
E. coli strain DH10B containing the MuHV-4 M3-Luc/ORF50-eGFP BAC (Milho et al., 2009) 
was a kind gift from Dr S. Efstathiou and Dr P. Stevenson, and was used for mutagenesis of 
MuHV-4 M3-Luc/ORF50-eGFP BAC. 
E. coli DH10EMBacY, containing the yellow fluorescent protein (YFP)-expressing 
Autographa californica nuclear polyhedrosis virus (AcNPV) baculoviral genome cloned as a 
BAC (EMBacY) (Bieniossek et al., 2008; Trowitzsch et al., 2010), was gently provided by Dr 
I. Berger and was used for generation of recombinant baculoviruses. In addition, E. coli 
DH10EMBacY contains a helper plasmid (tetracycline-resistance marker) that expresses the 
Tn7 transposon complex upon induction with isopropyl-β-D-thiogalactopyranoside (IPTG). 
 
 
8.1.5. Plasmids  
8.1.5.1. Plasmids for transient expression in mammalian cells 
pCMV-Myc, a commercial plasmid (Clontech), was used for transient expression of proteins in 
fusion with Myc epitope or as a transfection control. 
pCMV-HA, a commercial plasmid (Clontech), was used for transient expression of proteins in 
fusion with HA epitope or as a transfection control. 
pCMV-Myc-mLANA was used for transient expression of mLANA wild-type (WT) viral protein. This 
plasmid was constructed by Dr Lénia Rodrigues (Instituto de Medicina Molecular, Faculdade 
de Medicina da Universidade de Lisboa, Portugal) (Rodrigues et al., 2009). 
pCMV-Myc-mLANA-SOCS was used for transient expression of a mutant version of mLANA viral 
protein (mLANA-SOCS), containing valine (V) residue 199, leucine (L) residue 202, proline 
(P) residue 203 and proline (P) residue 206 substituted by alanine (A). This plasmid was 
constructed by Dr L. Rodrigues (Rodrigues et al., 2009). 
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pCMV-Myc-mLANAH186D/K187E was used for transient expression of a mutant version of mLANA viral 
protein (mLANAH186D/K187E), containing histidine (H) residue 186 and lysine (K) residue 187 
substituted by aspartate (D) and glutamate (E), respectively. This plasmid was constructed in 
this study by site-directed mutagenesis, using QuikChange II XL Site-Directed Mutagenesis 
Kit (Agilent Technologies) according to the manufacturer’s instructions. The oligonucleotides 
used in PCR are described in Table 8.2. 
pCMV-Myc-mLANAK224A/K228A/K229A was used for transient expression of a mutant version of mLANA 
viral protein (mLANAK224A/K228A/K229A), containing lysine (K) residues 224, 228 and 229 
substituted by alanine (A). This plasmid was constructed in this study by site-directed 
mutagenesis, using QuikChange II XL Site-Directed Mutagenesis Kit (Agilent Technologies) 
according to the manufacturer’s instructions. The oligonucleotides used in PCR are 
described in Table 8.2. 
pCMV-Myc-mLANAK224E/K228E/K229E was used for transient expression  of a mutant version of 
mLANA viral protein (mLANAK224E/K228E/K229E), containing lysine (K) residues 224, 228 and 
229 substituted by glutamate (E). This plasmid was constructed in this study by site-directed 
mutagenesis, using QuikChange II XL Site-Directed Mutagenesis Kit (Agilent Technologies) 
according to the manufacturer’s instructions. The oligonucleotides used in PCR are 
described in Table 8.2. 
pCMV-Myc-mLANAK251A/K253A was used for transient expression of a mutant version of mLANA viral 
protein (mLANAK251A/K253A), containing lysine (K) residues 251 and 253 substituted by alanine 
(A). This plasmid was constructed in this study by site-directed mutagenesis, using 
QuikChange II XL Site-Directed Mutagenesis Kit (Agilent Technologies) according to the 
manufacturer’s instructions. The oligonucleotides used in PCR are described in Table 8.2. 
pCMV-Myc-mLANAK251E/K253E was used for transient expression of a mutant version of mLANA viral 
protein (mLANAK251E/K253E), containing lysine (K) residues 251 and 253 substituted by 
glutamate (E). This plasmid was constructed in this study by site-directed mutagenesis, 
using QuikChange II XL Site-Directed Mutagenesis Kit (Agilent Technologies) according to 
the manufacturer’s instructions. The oligonucleotides used in PCR are described in Table 
8.2. 
pCMV-Myc-mLANAV199A was used for transient expression of a mutant version of mLANA viral 
protein (mLANAV199A), containing valine (V) residue 199 substituted by alanine (A). This 
plasmid was constructed in this study by site-directed mutagenesis, using QuikChange II XL 
Site-Directed Mutagenesis Kit (Agilent Technologies) according to the manufacturer’s 
instructions. The oligonucleotides used in PCR are described in Table 8.2. 
pCMV-Myc-mLANAL202A was used for transient expression of a mutant version of mLANA viral 
protein (mLANAL202A), containing leucine (L) residue 202 substituted by alanine (A). This 
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plasmid was constructed by Dr L. Rodrigues, by site-directed mutagenesis, using 
QuikChange II XL Site-Directed Mutagenesis Kit (Agilent Technologies) according to the 
manufacturer’s instructions. The oligonucleotides used in PCR are described in Table 8.2. 
pCMV-Myc-mLANAV199A/L202A was used for transient expression of a mutant version of mLANA viral 
protein (mLANAV199A/L202A), containing valine (V) residue 199 and leucine (L) residue 202 
substituted by alanine (A). This plasmid was constructed in this study by site-directed 
mutagenesis, using QuikChange II XL Site-Directed Mutagenesis Kit (Agilent Technologies) 
according to the manufacturer’s instructions. The oligonucleotides used in PCR are 
described in Table 8.2. 
pCMV-Myc-mLANAP203A was used for transient expression of a mutant version of mLANA viral 
protein (mLANAP203A), containing proline (P) residue 203 substituted by alanine (A). This 
plasmid was constructed by Dr L. Rodrigues, by site-directed mutagenesis, using 
QuikChange II XL Site-Directed Mutagenesis Kit (Agilent Technologies) according to the 
manufacturer’s instructions. The oligonucleotides used in PCR are described in Table 8.2. 
pCMV-Myc-mLANAP206A was used for transient expression of a mutant version of mLANA viral 
protein (mLANAP206A), containing proline (P) residue 206 substituted by alanine (A). This 
plasmid was constructed by Dr L. Rodrigues, by site-directed mutagenesis, using 
QuikChange II XL Site-Directed Mutagenesis Kit (Agilent Technologies) according to the 
manufacturer’s instructions. The oligonucleotides used in PCR are described in Table 8.2. 
pCMV-Myc-mLANAP203A/P206A was used for transient expression of a mutant version of mLANA viral 
protein (mLANAP203A/P206A), containing proline (P) residue 203 and proline (P) residue 206 
substituted by alanine (A). This plasmid was constructed in this study by site-directed 
mutagenesis, using QuikChange II XL Site-Directed Mutagenesis Kit (Agilent Technologies) 
according to the manufacturer’s instructions. The oligonucleotides used in PCR are 
described in Table 8.2. 
pCMV-Myc-p65 was used for transient expression of p65 protein. This plasmid was described 
earlier (Anrather et al., 1999). 
pCMV-HA-Myc was used for transient expression of Myc protein. This plasmid was constructed by 
Dr L. Rodrigues (Rodrigues et al., 2013). 
pEBB-FLAG-EloC was used for transient expression of FLAG-tagged ElonginC protein. This 
plasmid was kindly offered by Dr Ezra Burstein (Department of Internal Medicine and 
Department of Molecular Biology, University of Texas Southwestern Medical Center, USA). 
VR1012-Cul5-Myc was used for transient expression of Myc-tagged Cullin5 protein. This plasmid 
was kindly offered by Dr Xiao-Fang Yu (Department of Molecular Microbiology and 
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Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, USA) and it was 
described earlier (Yu et al., 2003). 
His6-ubiq was used for transient expression of 6xhistidine-tagged ubiquitin. This plasmid was kindly 
offered by Dr Dirk Bohmann (Department of Biomedical Genetics, University of Rochester 
Medical Center, USA). 
pC45 (κB -Luc), containing three copies of kappa B (κB) consensus sequence regulating the 
expression of firefly luciferase (Luc), was used as a nuclear factor-kappa B (NF-κB) reporter 
plasmid. This plasmid was described earlier (Brostjan et al., 1997). 
pMyc-TA-Luc, containing six tandem copies of the E-box consensus sequence driving the 
expression of firefly luciferase, was used as a Myc reporter plasmid. This plasmid was 
purchased from Clontech. 
Renilla plasmid was used for transient expression of Renilla luciferase. This plasmid was kindly 
offered by Dr Xosé R. Bustelo (Centro de Investigación del Cáncer and Instituto de Biología 
Molecular y Celular del Cáncer, University of Salamanca, Spain). 
 
8.1.5.2. Plasmids for construction of MuHV-4 recombinant viruses  
pACYC184-BamG (pBamG) is a pACYC184 (New England Biolabs) based plasmid in which the 
BamHI-G MuHV-4 genomic fragment (coordinates 101,654 to 106,903) (Efstathiou et al., 
1990), containing ORF73 coding and flanking regions, was cloned into the BamHI site, and a 
BspHI restriction site on the pACY184 backbone was removed by overlapping PCR. This 
plasmid was kindly provided by Dr P. Stevenson. 
pST76K-SR (shuttle vector) (Adler et al., 2000) was a kind gift from Dr H. Adler and Dr U. 
Koszinowski.  
BamHI-G shuttle plasmid, constructed by Dr Sofia Marques (Instituto de Medicina Molecular, 
Faculdade de Medicina da Universidade de Lisboa, Portugal), is the BamHI-G genomic 
fragment of MuHV-4 (coordinates 101,654 to 106,903) cloned in the pST76K-SR plasmid. 
This plasmid was used to insert the desired mutations in the BAC plasmid, by homologous 
recombination in E. coli. 
pHA3 is the MuHV-4 genome cloned as a BAC (Adler et al., 2000) and was kindly provided by Dr 
H. Adler and Dr U. Koszinowski. 
M3-Luc/ORF50-eGFP BAC is the MuHV-4 M3-Luc/ORF50-eGFP genome cloned as a BAC (Milho 
et al., 2009) (Figure 5.1) and was a kind gift from Dr S. Efstathiou and Dr P. Stevenson. The 
luciferase coding sequence plus polyadenylation (polyA) signal were removed from pGL4.10 
(Promega) by digestion with BglII/SalI and cloned into the BamHI/SalI sites of pSP73 
(Promega), downstream of a 500 bp MuHV-4 M3 promoter (May et al., 2005). M3-luciferase-
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polyA was then excised with BglII/SalI, blunted with Klenow fragment DNA polymerase and 
cloned into the blunted MfeI site (genomic coordinate 77,176) of a BglII MuHV-4 genomic 
clone (coordinates 75,338 to 78,717) in pSP73. The expression cassette plus genomic flanks 
were subcloned into the BamHI site of the pST76K-SR shuttle vector and recombined into a 
MuHV-4 BAC (Adler et al., 2000). An ORF50-deficient derivative was made by cloning a 
HincII genomic fragment (coordinates 63,844 to 70,433) into the HincII site of pUC9 (New 
England Biolabs), with the BamHI site of pUC9 at the 70,433 end of the insert. This was cut 
with BsmI (67,792) and ClaI (69,177) to remove most of ORF50 exon 2 (67,661 to 69,376), 
blunted and dephosphorylated with Antarctic alkaline phosphatase (New England Biolabs). 
The enhanced green fluorescent protein (eGFP) coding sequence from pEGFP-N3 
(Clontech) was ligated in place of the removed fragment. eGFP plus its genomic flanks were 
then excised using a genomic KpnI site (66,120) and the BamHI site in pUC9, cloned into the 
BamHI/KpnI sites of pST76K-SR, and recombined into the MuHV-4 M3-Luc BAC.  
 
8.1.5.3. Plasmids for in situ hybridization 
pEH1.4 is a pBluescript based plasmid containing the 1.4 kb HindIII-EcoRI subfragment of the 
HindIII-E MuHV-4 genomic fragment (nt 107 to 1518) cloned in an antigenomic orientation. It 
contains viral tRNA 1 to 4 and viral miRNA miR-M1-1 to 6, 10 and 11 transcripts. This 
plasmid was used to generate the digoxigenin (DIG)-labelled probe used to detect viral tRNA 
1 to 4 and viral miRNA miR-M1-1 to 6, 10 and 11 transcripts by ISH. Plasmid was linearized 
with HindIII and DIG-labelled antisense probes were synthesized by in vitro transcription with 
T7 RNA polymerase via the T7 phage promoter. This plasmid was constructed by Dr Rory 
Bowden (Bowden et al., 1997).  
 
8.1.5.4. Plasmids for baculovirus studies 
pUC57-GST-His-mLANA is a plasmid encoding mLANA with a N-terminus GST-8xHis-tag. The tag 
is preceded by a TEV cleavage site and followed by a PreScission protease cleavage site. 
ORF73 gene encoding mLANA was codon optimized at GenScript for expression in insect 
cells (section 8.2.6.1). 
pUC57-His-mLANA is a plasmid encoding mLANA with a N-terminus 8xHis-tag. The tag is 
preceded by a TEV cleavage site and followed by a PreScission protease cleavage site. 
ORF73 gene encoding mLANA was codon optimized at GenScript for expression in insect 
cells (section 8.2.6.1). 
pPBac is a transfer plasmid used for integration of the genes of interest into EMBacY plasmid 
(Vijayachandran et al., 2011) and was a kind gift from Dr I. Berger. pPBac contains a 
resistance marker (gentamicin-resistance) and an expression cassette flanked by a 
polyhedrin promoter and a terminator derived from the SV40 polyA signal sequence. The 
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cassette harbours an ORF encoding TEV protease, followed by a short linker DNA sequence 
with a BstEII restriction site and a RsrII restriction site, which are used to clone the genes of 
interest into pPBac. The resistance marker and the expression cassette are flanked by Tn7L 
and Tn7R DNA sequences, which are recognised by Tn7 transposase, allowing integration 
of heterologous genes into the Tn7 attachment site of EMBacY plasmid. 
pPBac-GST-His-mLANA is the GST-His-tagged mLANA coding sequence cloned into pPBac. This 
plasmid was constructed in this study and it was used to integrate GST-His-tagged mLANA 
DNA sequence into EMBacY plasmid (section 8.2.6.3). 
pPBac-His-mLANA is the His-tagged mLANA coding sequence cloned into pPBac. This plasmid 
was constructed in this study and it was used to integrate His-tagged mLANA DNA 
sequence into EMBacY plasmid (section 8.2.6.3). 
EMBacY is the YFP-expressing AcNPV baculovirus genome cloned as a BAC (Bieniossek et al., 
2008; Trowitzsch et al., 2010) and was kindly provided by Dr I. Berger. EMBacY contains a 
resistance marker (kanamycin-resistance), a F-factor for single-copy replication and a lacZα 
blue/white selection cassette harbouring a Tn7 attachment site. In addition, EMBacY 
contains a YFP coding gene under the control of the polyhedrin promoter into a loxP site, 
allowing monitorization of virus performance during infection. 
 
 
8.1.6. Viruses 
8.1.6.1. MuHV-4 viruses 
MuHV-4 used in this study belongs to the strain murine herpesvirus-68 (MHV-68) that was 
originally isolated by Prof. Dusan Blaskovic (Blaskovic et al., 1980). Clone G2.4 was isolated from 
virus grown in BHK-21 cells by Dr S. Efstathiou (Efstathiou et al., 1990). 
Wild-type virus (vWT) used in animal experiments was derived from a genomic BAC and was a 
kind gift from Dr H. Adler and Dr U. Koszinowski. This virus is essentially MHV-68 clone 
G2.4 but contains a single loxP site (Adler et al., 2001; Adler et al., 2000).  
vmLANAH186D/K187E recombinant virus was engineered in this study by mutagenesis of the virus 
genome in E. coli using the MuHV-4 BAC pHA3 (Adler et al., 2000) as described in detail in 
section 8.2.5. It contains histidine (H) residue 186 and lysine (K) residue 187 of mLANA 
substituted by aspartate (D) and glutamate (E), respectively.  
vmLANAK224A/K228A/K229A recombinant virus was engineered in this study by mutagenesis of the virus 
genome in E. coli using the MuHV-4 BAC pHA3 (Adler et al., 2000) as described in detail in 
section 8.2.5. It contains lysine (K) residues 224, 228 and 229 of mLANA substituted by 
alanine (A).  
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vmLANAK224E/K228E/K229E recombinant virus was engineered in this study by mutagenesis of the virus 
genome in E. coli using the MuHV-4 BAC pHA3 (Adler et al., 2000) as described in detail in 
section 8.2.5. It contains lysine (K) residues 224, 228 and 229 of mLANA substituted by 
glutamate (E).  
vmLANAK251A/K253A recombinant virus was engineered in this study by mutagenesis of the virus 
genome in E. coli using the MuHV-4 BAC pHA3 (Adler et al., 2000) as described in detail in 
section 8.2.5. It contains lysine (K) residues 251 and 253 of mLANA substituted by alanine 
(A).  
vmLANAK251E/K253E recombinant virus was engineered in this study by mutagenesis of the virus 
genome in E. coli using the MuHV-4 BAC pHA3 (Adler et al., 2000) as described in detail in 
section 8.2.5. It contains lysine (K) residues 251 and 253 of mLANA substituted by glutamate 
(E).  
vmLANAP203A recombinant virus was engineered in this study by mutagenesis of the virus genome 
in E. coli using the MuHV-4 BAC pHA3 (Adler et al., 2000) as described in detail in section 
8.2.5. It contains proline (P) residue 203 of mLANA substituted by alanine (A).  
vmLANAP203A/P206A recombinant virus was engineered in this study by mutagenesis of the virus 
genome in E. coli using the MuHV-4 BAC pHA3 (Adler et al., 2000) as described in detail in 
section 8.2.5. It contains proline (P) residues 203 and 206 of mLANA substituted by alanine 
(A).  
vmLANAV199A recombinant virus was engineered in this study by mutagenesis of the virus genome 
in E. coli using the MuHV-4 BAC pHA3 (Adler et al., 2000) as described in detail in section 
8.2.5. It contains valine (V) residue 199 of mLANA substituted by alanine (A).  
vmLANAV199A/L202A recombinant virus was engineered in this study by mutagenesis of the virus 
genome in E. coli using the MuHV-4 BAC pHA3 (Adler et al., 2000) as described in detail in 
section 8.2.5. It contains valine (V) residue 199 and leucine (L) residue 202 of mLANA 
substituted by alanine (A). 
vmLANAH186D/K187E-R revertant virus was engineered in this study by mutagenesis of the virus 
genome in E. coli using the mutant MuHV-4-mLANAH186D/K187E BAC pHA3 as described in 
detail in section 8.2.5. It contains the mLANAH186D/K187E locus restored to the wild-type status. 
vmLANAK224A/K228A/K229A-R revertant virus was engineered in this study by mutagenesis of the virus 
genome in E. coli using the mutant MuHV-4-mLANAK224A/K228A/K229A BAC pHA3 as described 
in detail in section 8.2.5. It contains the mLANAK224A/K228A/K229A locus restored to the wild-type 
status.  
vmLANAK224E/K228E/K229E-R revertant virus was engineered in this study by mutagenesis of the virus 
genome in E. coli using the mutant MuHV-4-mLANAK224E/K228E/K229E BAC pHA3 as described 
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in detail in section 8.2.5. It contains the mLANAK224E/K228E/K229E locus restored to the wild-type 
status.  
vmLANAK251A/K253A-R revertant virus was engineered in this study by mutagenesis of the virus 
genome in E. coli using the mutant MuHV-4-mLANAK251A/K253A BAC pHA3 as described in 
detail in section 8.2.5. It contains the mLANAK251A/K253A locus restored to the wild-type status.   
vORF50- mLANA-WT recombinant virus was derived from a genomic MuHV-4 M3-Luc/ORF50-
eGFP BAC (Milho et al., 2009), as described in detail in section 8.1.5.4, and was a kind gift 
from Dr S. Efstathiou and Dr P. Stevenson. This virus retains the loxP-flanked BAC cassette 
(Adler et al., 2000), since it was not passed through NIH-3T3-CRE cells.  
vORF50- mLANA-SOCS recombinant virus was engineered in this study by mutagenesis of the 
virus genome in E. coli using the mutant MuHV-4 M3-Luc/ORF50-eGFP BAC pHA3 (Milho et 
al., 2009) as described in detail in section 8.2.5. It contains valine (V) residue 199, leucine 
(L) residue 202, proline (P) residue 203 and proline (P) residue 206 of mLANA substituted by 
alanine (A). This virus retains the loxP-flanked BAC cassette (Adler et al., 2000), since it was 
not passed through NIH-3T3-CRE cells. 
vORF50- mLANAV199A/L202A recombinant virus was engineered in this study by mutagenesis of the 
virus genome in E. coli using the mutant MuHV-4 M3-Luc/ORF50-eGFP BAC pHA3 (Milho et 
al., 2009) as described in detail in section 8.2.5. It contains valine (V) residue 199 and 
leucine (L) residue 202 of mLANA substituted by alanine (A). This virus retains the loxP-
flanked BAC cassette (Adler et al., 2000), since it was not passed through NIH-3T3-CRE 
cells. 
 
8.1.6.2. Baculoviruses 
Baculoviruses used in this study were derived from YFP-expressing AcNPV baculovirus genome 
cloned as a BAC (EMBacY) (Bieniossek et al., 2008; Trowitzsch et al., 2010) (section 8.1.5.4).  
vEMBacY-GST-His-mLANA recombinant virus was engineered in this study using MultiBac system, 
developed by Dr I. Berger at EMBL Grenoble (Berger et al., 2004; Bieniossek et al., 2008; 
Trowitzsch et al., 2010; Vijayachandran et al., 2011), as described in detail in section 8.2.6. 
This baculovirus contains the GST-His-tagged mLANA coding sequence integrated into its 
genome. 
vEMBacY-His-mLANA recombinant virus was engineered in this study using MultiBac system, 
developed by Dr I. Berger at EMBL Grenoble (Berger et al., 2004; Bieniossek et al., 2008; 
Trowitzsch et al., 2010; Vijayachandran et al., 2011), as described in detail in section 8.2.6. 
This baculovirus contains the His-tagged mLANA coding sequence integrated into its 
genome. 
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8.1.7. Mice 
BALB/c and C57BL/6 mice used in this study were from Charles Rivers Laboratories International. 
Animals were housed and subjected to experimental procedures in specific pathogen-free 
conditions, at Instituto de Medicina Molecular animal facility, Lisbon, Portugal. 
 
 
 
8.2. Methods 
 
 
8.2.1. Isolation and analysis of DNA 
8.2.1.1. High molecular weight (HMW) cellular/viral DNA extractions  
High molecular weight (HMW) DNA was extracted from frozen-thawed splenocyte 
suspensions of infected mice. To this end, frozen-thawed splenocyte suspensions were centrifuged 
at 500 x g for 5 min. The pellet was resuspended in 750 μl of Tris-ethylenediaminetetraacetic acid 
(TE) lysis buffer (10 mM Tris-HCl pH 8.0, 50 mM ethylenediaminetetraacetic acid (EDTA), 0.5% 
sodium dodecyl sulfate (SDS) and 20 μg/ml Proteinase K) and incubated overnight (ON) at 37ºC. 
DNA samples containing proteins and salts were purified by deproteinization using 
phenol/chloroform extraction and concentrated by ethanol precipitation. An equal volume of TE-
buffered phenol:chroloform:isoamyl alcohol (25:24:1) was added to the DNA solution, mixed well by 
vigorous shaking or vortexing, incubated for 5 min at room temperature (RT) and centrifuged at 
10,500 x g for 5 min at RT. The upper aqueous phase containing DNA was transferred to a clean 
tube and re-extracted twice with an equal volume of chloroform. DNA was precipitated using 0.1 
volumes of 3 M KOAc or NaOAc (pH 5.5) and 2.5 volumes of 100% ethanol. Samples were gently 
mixed well, left for 10 min at RT and HMW DNA was extracted by spooling onto a glass Pasteur 
pipette. DNA was washed with cold 70% ethanol, left for 10-20 min at RT to air-dry and then 
resuspended in MilliQ water or TE. 
 
8.2.1.2. Plasmid DNA isolation  
Plasmid DNA was isolated from plasmid-containing E. coli strains (section 8.1.4) grown in 
Luria Bertani (LB) broth (tryptone 1%, yeast extract 0.5%, NaCl 1%) containing the appropriate 
antibiotic(s), using an alkaline lysis method modified accordingly to the scale of the preparation and 
plasmid size. Antibiotics were used at the following concentrations: 100 μg/ml ampicillin, 17 μg/ml 
chloramphenicol, 30 μg/ml kanamycin (or 50 μg/ml for EMBacY-containing bacteria), 24 μg/ml 
tetracycline and 10 μg/ml gentamicin.  
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Small scale plasmid preparation 
For small scale plasmid preparations (plasmid minipreps), 3-10 mL of LB broth cultures 
containing the appropriate antibiotic(s) were inoculated from single bacterial colonies and 
incubated with vigorous shaking 12-18 h at 37 or 30ºC. Cultures were pelleted by centrifugation for 
5 min at 3,000 x g. Plasmid DNA was obtained using the Wizard Plus SV Minipreps DNA 
Purification System (Promega), by column purification of DNA prepared by alkaline lysis, according 
to manufacturer’s instructions. DNA was eluted in 50-100 μl of MilliQ water and stored at -20ºC. 
Large scale plasmid preparation 
For large scale plasmid preparations (plasmid maxipreps), cultures of plasmid-containing 
bacteria were prepared by inoculation of 200 mL of LB broth cultures containing the appropriate 
antibiotic(s) from single colonies and incubation with shaking 12-18 h at 37 or 30ºC. Bacterial 
cultures were pelleted by centrifugation at 6,000 x g for 15 min at 4ºC and DNA was purified using 
the LFU / Plasmid Purification MAXI Kit (JETSTAR), following manufacturer’s instructions. DNA 
was resuspended in 200-600 μl of MilliQ water and stored at -20ºC. 
Small scale BAC plasmid preparation 
For small scale BAC plasmid preparations (BAC plasmid minipreps), 10 ml of LB broth 
containing chloramphenicol were inoculated from single bacterial colonies and incubated with 
vigorous shaking 12-18 h at 37ºC. Bacteria were pelleted by centrifugation at 2,500 x g for 10 min 
at 4ºC. Pellet was thoroughly resuspended in 200 μl of buffer S1 (50 mM Tris-HCl pH 8.0, 10 mM 
EDTA; from NucleoBond BAC 100 Kit, Macherey-Nagel) plus 100 μg/ml RNase A. 300 μl of buffer 
S2 (200 mM NaOH, 1% SDS; from NucleoBond BAC 100 Kit, Macherey-Nagel) were promptly 
added and the suspension was mixed by gentle inversion and left at RT for 5 min. 300 μl of chilled 
buffer S3 (2.8 M KAc pH 5.1; from NucleoBond BAC 100 Kit, Macherey-Nagel) were added, tube 
was gently inverted to mix solution, incubated on ice for 15 min and centrifuged for 10 min at 
18,000 x g and 4ºC. Supernatant was transferred to a new tube and 1 ml of phenol/chloroform (1:1) 
was added and mixed by inversion. Mixture was left 5 min at RT and then centrifuged 10 min at 
18,000 x g and 4ºC. Aqueous phase was recovered and precipitated with 0.7 volumes of 
isopropanol and left at RT for 5 min. BAC plasmid DNA was pelleted by centrifugation for 20 min at 
18,000 x g and 4ºC. Supernatant was discharged and the pellet was washed with 100 µl of 70% 
ethanol, centrifuged another 10 min, drained and air dried. DNA was resuspended in 60 μl of TE 
(10 mM Tris, 1 mM EDTA, pH 8.0) supplemented with RNase A (10 μg/ml) and stored at 4ºC. 
Large scale BAC plasmid preparation 
For large scale BAC plasmid preparations (BAC plasmid maxipreps), cultures of BAC plasmid-
containing bacteria were prepared by inoculation of 400 ml of LB broth supplemented with 
chloramphenicol from single colonies and incubation with shaking 12-18 h at 37ºC. Bacteria were 
pelleted by centrifugation at 6,000 x g for 15 min at 4ºC. BAC plasmid DNA was isolated using 
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NucleoBond BAC 100 plasmid purification kit (Macherey-Nagel), according to manufacturer’s 
instructions. BAC DNA was resuspended in 100-200 μl of MilliQ water and stored at 4ºC. 
Small scale EMBacY plasmid preparation 
For small scale EMBacY plasmid preparations (EMBacY plasmid minipreps), 2 ml of LB broth 
containing kanamycin, tetracycline and gentamicin were inoculated from single bacterial colonies 
and incubated with vigorous shaking ON at 37ºC. Bacteria were pelleted by centrifugation at 2,500 
x g for 10 min at 4ºC. Pellet was thoroughly resuspended in 300 μl of buffer P1 (50 mM Tris-HCl pH 
8.0, 10 mM EDTA; from Qiagen Large-Construct Kit) plus 100 μg/ml RNase A. 300 μl of buffer P2 
(200 mM NaOH, 1% SDS; from Qiagen Large-Construct Kit) were added and the suspension was 
mixed by gentle inversion and left at RT for 5 min. 300 μl of chilled buffer P3 (3 M KAc pH 5.5; from 
Qiagen Large-Construct Kit) were added, tube was gently inverted to mix solution, incubated on ice 
for 10 min and centrifuged for 10 min at 18,000 x g and 4ºC. Supernatant was transferred to a new 
tube and centrifuged again for 3 min at 18,000 x g and 4ºC. Supernatant was transferred to a new 
tube and DNA was precipitated with 700 µl of isopropanol and pelleted by centrifugation for 10 min 
at 18,000 x g and 4ºC. Supernatant was discharged and the pellet was washed with 200 µl of 70% 
ethanol and centrifuged another 5 min. Supernatant was discharged and the pellet was washed 
again with 50 µl of 70% ethanol. Ethanol was removed in a sterile hood and the pellet was air dried 
for 10 min. DNA was gently resuspended in 30 μl of filter sterilized water. 
 
8.2.1.3. Quantification of DNA  
DNA was quantified by ultraviolet (UV) spectrophotometry using a Nanodrop (ND-1000) 
spectrophotometer. 
 
8.2.1.4. Restriction endonuclease digestion  
Restriction endonuclease digestion of plasmids or PCR products was used either to prepare 
linear or insert purified DNA, or to screen DNA for a desired digestion profile or for the presence of 
inserts cloned in expression vectors. Restriction enzyme assays were performed using the 
appropriate restriction endonucleases and correspondent reaction buffers, according to 
manufacturer’s instructions. The volume of the reaction as well as the amount of DNA and 
enzymes used depended on purpose of the assay. Typically, digestion of plasmids or PCR 
products for subsequent ligation and cloning was performed for 1-4 h, with 1-5 μg of DNA and 0.1-
10 U of restriction endonuclease per μg of DNA, using the manufacturer’s recommended conditions 
in a volume of 50-60 μl. Diagnosis digestion was performed with 1 μg of DNA, 1-10 U of restriction 
endonuclease, using manufacturer´s recommended conditions, in a volume of 20-50 μL for 1-2 h. 
Multiple digestions of the same DNA were performed when possible with the same buffer; 
otherwise salt conditions were adjusted for subsequent digestion steps or DNA was re-purified in 
column. Restriction profile and completeness of the digestion were assessed by analytical agarose 
gel electrophoresis. 
Materials and Methods  
 
 
121 
8.2.1.5. Analysis and isolation of DNA by gel electrophoresis  
Linear DNA was size fractioned and visualized on agarose gels stained with GelRed (Biotium) 
or RedSafe (iNtRON Biotechnology), according to manufacturer’s instructions. Gels were prepared 
using 0.8-1.5% agarose in 1x Tris-acetate-EDTA (TAE) (40 mM Tris-acetate, 1 mM EDTA, pH 8.0). 
DNA samples were mixed with the appropriate volume of DNA loading buffer (10 mM EDTA, 5% 
glycerol, 0.025% bromophenol blue and 0.025% xylene cyanol) prior to loading into the gel. 
Samples were electrophoresed at 0.5-5.0 V/cm in 1x TAE buffer. DNA was visualized by UV 
transillumination. The size of DNA bands was estimated by comparison with linear DNA standards 
of known molecular weight (1 Kb plus DNA ladder, Invitrogen) run along with samples. 
Following analysis of DNA by agarose gel electrophoresis, the DNA fragments of interest were 
purified by excision of the resolved bands from the gel and recovered on High Pure PCR Product 
Purification Kit columns (Roche), according to manufacturer´s instructions. Typically, DNA was 
eluted in 50 μl of MilliQ water and a fraction of the purified samples (1/10 of the total volume of the 
eluate) was re-run on an agarose gel, in order to check the DNA purification. 
 
8.2.1.6. DNA sequencing  
The integrity of the plasmids constructed in this study was confirmed by sequencing the PCR-
generated inserts. During recombinant virus construction, identification of mutant BAC clones was 
performed by sequencing across ORF73 in the BAC vector. Recombinant viruses were also 
sequenced in the region subjected to mutagenesis to confirm the retention of the engineered point 
mutations following in vivo infection. 
DNA was sequenced at STAB VIDA according to the Sanger method and using an automatic 
DNA sequencer (ABI 3730XL). DNA sequences were analysed and compared to sequences 
deposited in the National Centre for Biotechnology Information (NCBI) database using the Basic 
Local Alignment Search Tool (BLAST) and Multiple Sequence Alignment with Hierarchical 
Clustering – MultAlin software. 
 
 
8.2.2. Polymerase Chain Reaction (PCR)  
PCR was used for different purposes. 
During construction of pCMV-Myc plasmids encoding mLANA mutants, mutations in ORF73 
gene were introduced by PCR using pCMV-Myc-mLANA plasmid as a template. The mutagenic 
primers used are described in Table 8.2. PCR was performed using the QuikChange II XL Site-
Directed Mutagenesis Kit (Agilent Technologies), according to manufacturer´s instructions. 
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Table 8.2. Primers used to generate pCMV-Myc-mLANA mutants. 
mLANA 
mutations 
mLANA 
template 
Oligonucleotide 
sequence (5’-3’) 
H186D/K187E WT 
CACATCCCTACACTTTGAATAAACTTGACGAGTGTATCCAAAGCAA 
ACATG 
K224A WT 
ACTATTTACTTTCATTTGTTGAAGACGCGAAACAGGCCAAAAAACT 
AAAAAGGG 
K224A/K228A/K229A K224A 
TTGTTGAAGACGCGAAACAGGCCGCAGCACTAAAAAGGGTTGTCT 
TGGCCT 
K224E WT 
CTATTTACTTTCATTTGTTGAAGACGAGAAACAGGCCAAAAAACTA 
AAAAG 
K224E/K228E/K229E K224E 
TTTGTTGAAGACGAGAAACAGGCCGAGGAGCTAAAAAGGGTTGTC 
TTGGCCTAC 
K251A/K253A WT 
AGCAGCGTAGAAGGTACTATAGTCGCGGCAGCGCCTTATTTTCCC 
TTACCAGAG 
K251E/K253E WT GCGTAGAAGGTACTATAGTCGAGGCAGAGCCTTATTTTCCCTTA 
V199A WT TGTACTCTCAACACCAGCTAGCTGTTTACCCTTGG 
L202A WT TGTACTCTCAACACCAGTTAGCTGTGCACCCTTGGTACCA 
V199A/L202A V199A TGTACTCTCAACACCAGCTAGCTGTGCACCCTTGGTACCA 
P203A WT CACCAGTTAGCTGTTTAGCCTTGGTACCAGGC 
P206A WT AGTTAGCTGTTTACCCTTGGTAGCAGGCACAACAC 
P203A/P206A WT CAACACCAGTTAGCTGTTTAGCCTTGGTAGCAGGCACAACA 
Mutations introduced in template mLANA DNA sequence are underlined. WT, wild-type. 
 
 
ORF73 region was amplified by PCR from BAC plasmid or HMW DNA for subsequent 
verification of the introduced mutations in recombinant viruses by restriction endonuclease 
digestion (section 8.2.1.4) or DNA sequencing (section 8.2.1.6). The primers designed were 
specific for ORF73 gene and generated a fragment of 966 bp (Table 8.3). PCR was performed 
using GoTaq Flexi DNA Polymerase (Promega). PCR mixes were prepared in a total volume of 50 
μl (made up in sterile MilliQ water) and consisted of 300 nM of each primer, 1x GoTaq Flexi buffer 
(Promega), 2 mM of MgCl2, 200 μM of each deoxynucleotide (dNTP), 1.25 U of GoTaq Flexi DNA 
polymerase (Promega) and <100 ng of template DNA. DNA was amplified on a MyCycler thermal 
cycler (Bio-Rad), under the following conditions: an initial melting step of 95ºC for 5 min followed by 
30 cycles of amplification, composed of denaturation at 95ºC for 45 sec, annealing at 59ºC for 45 
sec (depending on the optimal annealing temperature for each specific set of primers) and 
extension at 72ºC for 1 min; a final extension step was performed at 72ºC for 5 min. PCR products 
were purified with High Pure PCR Product Purification Kit (Roche) (section 8.2.1.5), according to 
manufacturer´s instructions.  
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Table 8.3. Primers used to amplify ORF73 gene. 
Oligonucleotide Sequence (5’-3’) Amplicon (bp) 
Upper primer AAAGGATCCTATGCCCACATCCCCAC 966 
Lower primer AAAGCGGCCGCTTATGTCTGAGACCCTTGTC 966 
 
 
8.2.3. Cloning procedures  
8.2.3.1. Cloning of inserts into pBamG vector  
pCMV-Myc constructs encoding mLANAK224A/K228A/K229A, mLANAK224E/K228E/K229E, 
mLANAK251A/K253A, mLANAK251E/K253E, mLANAP203A, mLANAV199A, mLANAP203A/P206A and 
mLANAV199A/L202A were digested with HindIII and PciI restriction endonucleases (section 8.2.1.4) to 
isolate the fragments harbouring the desired mutations. pCMV-Myc construct encoding 
mLANAH186D/K187E was digested with BstEII and PciI restriction endonucleases. Digested inserts 
were isolated by gel electrophoresis and purified from agarose gel using the High Pure PCR 
Product Purification Kit (Roche) (section 8.2.1.5), according to manufacturer’s instructions. pBamG 
plasmid (pACYC184-BamG), containing the BamHI-G MuHV-4 genomic fragment (coordinates 
101,654 to 106,903) (section 8.1.5.2), was digested with HindIII and PciI, or BstEII and PciI 
restriction endonucleases, creating compatible cohesive ends with the insert. Digested vector was 
isolated by gel electrophoresis and purified from agarose gel using the High Pure PCR Product 
Purification Kit (Roche). Prepared insert and vector were ligated as described in section 8.2.3.4 
and ligations were transformed into E. coli DH5α competent cells (section 8.2.3.5). DNA was 
isolated from colonies by plasmid miniprep (section 8.2.1.2) and plasmid structure was screened by 
restriction analysis with the appropriate endonucleases (section 8.2.1.4).  
 
8.2.3.2. Subcloning of inserts into the shuttle vector 
Inserts in pBamG constructs described in section 8.2.3.1 were subcloned into a BamHI-G 
MuHV-4 genomic fragment (coordinates 101,654 to 106,903) cloned into pST76K-SR plasmid 
(BamHI-G shuttle plasmid). Both plasmids were digested with BamHI restriction enzyme, creating 
compatible cohesive ends. Digested vector was dephosphorylated with 2 U of alkaline 
phosphatase (Roche) per μg of DNA, for 30 min at 37ºC. Digested insert and vector were then 
isolated by gel electrophoresis and purified from agarose gel using the High Pure PCR Product 
Purification Kit (Roche) (section 8.2.1.5). Insert and vector were ligated as described in section 
8.2.3.4 and ligations were transformed into XL10-Gold Ultracompetent cells (Agilent Technologies) 
(section 8.2.3.5). DNA was isolated from colonies by plasmid miniprep (section 8.2.1.2) and 
plasmid structure was screened by restriction analysis with the appropriate endonucleases (section 
8.2.1.4). 
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8.2.3.3. Subcloning of GST-His-mLANA and His-mLANA inserts into pPBac 
plasmid 
GST-His-mLANA and His-mLANA coding sequences cloned into pUC57 (section 8.1.5.4) were 
subcloned into pPBac plasmid. Both plasmids were digested with BstEII and RsrII restriction 
enzymes, creating compatible cohesive ends. Digested insert and vector were then isolated by gel 
electrophoresis and purified from agarose gel using the High Pure PCR Product Purification Kit 
(Roche) (section 8.2.1.5). Insert and vector were ligated as described in section 8.2.3.4 and 
ligations were transformed into E. coli strain DH5α (section 8.2.3.5). DNA was isolated from 
colonies by plasmid maxiprep (section 8.2.1.2) and plasmid structure was screened by restriction 
analysis with BstEII and RsrII restriction endonucleases (section 8.2.1.4). 
 
8.2.3.4. DNA ligation 
Digested inserts and vectors were ligated using T4 DNA ligase (Roche). Approximately 100 ng 
of vector DNA was ligated with 1-3 fold excess of insert in 20 μl reactions (made up in sterile MilliQ 
water), containing 1x ligase buffer (Roche) and 1U of T4 DNA ligase. Cohesive-end ligations were 
performed ON at 14ºC. 
 
8.2.3.5. Bacterial transformation 
Preparation of chemically competent cells 
Competent E. coli strains DH5α and DH10B (containing the MuHV-4 BAC plasmid) were 
prepared by the Inoue modified method (Inoue et al., 1990). E. coli glycerol stock was streaked into 
a LB agar plate supplemented with the appropriate antibiotic(s) and grown ON at 37ºC. On the next 
day, a single colony was inoculated into 10 ml of LB broth supplemented with the appropriate 
antibiotic(s) and incubated with vigorous shaking 12-18 h at 37ºC. 10 ml of the resulting culture 
were inoculated into 400 ml of fresh LB broth supplemented with the appropriate antibiotic(s) and 
incubated at 37ºC with vigorous shaking, until the bacterial culture reached an optical density 
(OD)600nm of 0.6. Cells were cooled on ice and centrifuged at 3,500 x g for 15 min at 4ºC. Cell pellet 
was gently resuspended in 100 ml of ice-cold sterile solution A (0.03 M KCH3COO, 0.05 M MnCl2, 
0.01 M CaCl2, 0.1 M KCl and 15% glycerol in sterile MilliQ water). Cells were centrifuged again at 
3,500 x g for 8 min at 4ºC and the pellet was resuspended in 20 ml of ice-cold sterile solution B 
(0.01 M NaMOPS pH 7.0, 0.075 M CaCl2, 0.01 M KCl and 15% glycerol in sterile MilliQ water). 100 
μl and 300 μl aliquots were made. Each aliquot was quickly frozen by transferring the vials to dry 
ice immersed in ethanol. Competent cells were stored at -80ºC until further use. 
Preparation of electrocompetent cells 
E. coli DH10EMBacY glycerol stock was streaked into a LB agar plate supplemented with 
kanamycin (50 µg/ml), tetracycline (24 µg/ml), X-Gal (100 µg/ml) and IPTG (1 mM) and grown ON 
at 37ºC. On the following day, three blue colonies were inoculated into 100 ml of LB broth 
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supplemented with kanamycin and tetracycline and incubated with vigorous shaking 12-18 h at 
37ºC. This preculture was then inoculated into 1 l of fresh LB broth supplemented with kanamycin 
and tetracycline and incubated at 37ºC with vigorous shaking, until the bacterial culture reached an 
OD600nm of 0.5. Cells were cooled on ice for 15 min and centrifuged four times at 3,500 x g for 15 
min at 4ºC. Cell pellet was gently resuspended in 500, 250, 50 and 2 ml of ice-cold sterile 10% 
glycerol solution after first to fourth centrifugation, respectively. 100 μl aliquots were made, quickly 
frozen in dry ice immersed in ethanol and stored at -80ºC until further use. Competent cells were 
tested by streak out on LB agar containing kanamycin, tetracycline, X-Gal and IPTG to confirm that 
all colonies were blue.  
Transformation of chemically competent cells 
Chemically competent E. coli was transformed by the heat shock method.  
100 µl of competent E. coli DH5α and DH10B (containing MuHV-4 BAC) were incubated on 
ice for 30 min with 100 ng of plasmid DNA or 5 μl of ligation mix. Cells were heat shocked for 45 
sec at 42ºC and subsequently chilled on ice for 2 min. 500 μl of SOC medium (2% tryptone, 0.5% 
yeast extract, 10 mM NaCl, 2.5 mM MgCl2, 10 mM MgSO4, 20 mM glucose) were added to each 
vial and cells were incubated for 1 h at 37 or 30ºC, with vigorous shaking. Cells were then spread 
onto LB agar plates containing the appropriate antibiotic(s) and incubated ON at 37 or 30ºC. 
Ampicillin was used at 100 μg/ml, chloramphenicol at 17 μg/ml, kanamycin at 30 μg/ml and 
gentamicin at 10 μg/ml. 
When using XL10-Gold Ultracompetent cells (Agilent Technologies), 2 μl of β-
mercaptoethanol mix provided with the kit were added to 45 µl of cells and incubated on ice for 10 
min before adding the DNA. 5 µl of DNA was then added to cells and incubated on ice for 30 min. 
Cells were heat shocked for 30 sec at 42ºC and subsequently chilled on ice for 2 min. 500 μl of 
preheated (42ºC) SOC medium were added to each vial and cells were incubated for 1 h at 37ºC, 
with vigorous shaking. Cells were then spread onto LB agar plates containing the appropriate 
antibiotic(s) and incubated ON at 37ºC.  
Transformation of electrocompetent cells 
Electrocompetent E. coli DH10EMBacY was transformed by electroporation. First, 0.1 cm 
electroporation cuvettes (Bio-Rad) were placed at -20ºC and electrocompetent cells were put on 
ice. 100 µl of cells were incubated with 1 µg of plasmid DNA for 1 min on ice and then the mix was 
carefully transferred into a cuvette, avoiding the formation of bubbles. The cuvette was placed in an 
electroporator (Gene Pulser Xcell – Bio-Rad) and cells were electroporated at 1,800 V, 25 µF and 
200 Ω. 600 µl of SOC medium were added to cells immediately after electroporation and the mix 
was transferred into a 1.5 ml tube and incubated ON at 37ºC with vigorous shaking.  
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8.2.4. Cell culture and transfections 
8.2.4.1. Media and culture conditions 
BHK-21 cells were cultured in Glasgow's modified Eagle's medium (GMEM) supplemented 
with 10% foetal bovine serum (FBS), 2 mM L-glutamine, 100 U/ml penicillin-streptomycin and 10% 
tryptose phosphate broth (TPB). 
NIH-3T3-CRE, 3T3-ORF50, MEF-1 and HEK 293T cells were cultured in Dulbecco’s modified 
Eagle’s medium (DMEM) supplemented with 10% FBS, 2 mM L-glutamine and 100 U/ml penicillin-
streptomycin. 
Sf21 cells were cultured in HyClone SFM4Insect medium (Thermo Scientific), at a cell density 
of 0.5-2x106 cells/ml. Since Sf21 cells double approximately every 24 h, cells were split every day 
and seeded at 0.5-1x106 cells/ml. 
BHK-21, NIH-3T3-CRE, 3T3-ORF50, MEF-1 and HEK 293T cell cultures were grown in a 
humidified tissue culture incubator at 37ºC under 5% CO2. Sf21 cell cultures were grown at 27ºC 
with shaking at 90 rpm, in a non-humidified, air regulated, non-CO2 atmosphere. 
 
8.2.4.2. Transfections 
Transient transfections were performed using FuGENE 6 or X-tremeGENE HP DNA 
Transfection Reagent (Roche), according to manufacturer’s instructions. 
On the day before transfection, 106 BHK-21 cells were plated in 6 cm cell culture dishes and 
grown to 70-90% confluency. 1 μg of BAC DNA was added to 500 μl of non-supplemented GMEM 
and gently mixed. 2 μl of X-tremeGENE HP were subsequently added and the mix was incubated 
for 15 min at RT. The obtained solution was added dropwise to cells and these cultures were 
incubated in a tissue culture incubator at 37ºC with 5% CO2, until approximately 50% of cytopathic 
effect (cpe) was visible (3-5 days). 
5x105 3T3-ORF50 cells were plated in 6 cm dishes on the day before transfection and grown 
to 70-90% confluency. 1 μg of BAC DNA was added to 500 μl of non-supplemented DMEM and 
gently mixed. 2 μl of X-tremeGENE HP were subsequently added and the mix was incubated for 15 
min at RT. The obtained solution was added dropwise to cells and cultures were treated with 
doxycycline (1 µg/ml). Cells were incubated in a tissue culture incubator at 37ºC with 5% CO2, until 
approximately 50% cpe was visible (3-5 days). 
HEK 293T cells were plated on the day before transfection and grown to 70-90% confluency. 
Approximately 24 h later, the appropriate amount of expression plasmids was added to non-
supplemented DMEM and gently mixed. The transfection reagent was added in a ratio of 2:1 (2µl of 
X-tremeGENE HP DNA Transfection Reagent per µg of DNA) and the mix was incubated for 15 
min at RT. The obtained solution was added dropwise to cells and these cultures were incubated in 
a tissue culture incubator at 37ºC with 5% CO2, for 48 h. The number of plated cells, the amount of 
expression plasmids and the volume of non-supplemented DMEM were dependent on the assay 
performed and are described in detail in sections 8.2.13.1, 8.2.13.2 and 8.2.13.3. 
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0.5-1x106 Sf21 cells were plated per well in 6-well plates, in 3 ml of HyClone medium, and 
allowed to adhere 15 min at 27ºC to form monolayers. For each EMBacY plasmid to be 
transfected, 10 µl of Fugene 6 were incubated with 100 µl of HyClone medium. This mix was added 
to EMBacY plasmid diluted in 200 µl of HyClone medium and the transfection mix was incubated 
for 15 min at 27ºC. Finally, 150 µl of transfection mix were added to each well containing cells (2 
wells per plasmid). A well containing untransfected cells and a well containing medium only were 
included as negative controls. Cell cultures were incubated at 27ºC for 48 h. 
 
 
8.2.5. Construction of MuHV-4 recombinant viruses  
MuHV-4 recombinants were derived from a BAC-cloned MuHV-4 pHA3 (Adler et al., 2001; 
Adler et al., 2000). Revertant viruses were obtained from mutant MuHV-4 BAC pHA3. ORF50-
deficient recombinants were derived from MuHV-4 M3-Luc/ORF50-eGFP BAC pHA3 (Milho et al., 
2009). Site-directed mutagenesis of MuHV-4-BAC genome was performed by homologous 
recombination in E. coli, using a two-step replacement procedure (Adler et al., 2003). 
Chloramphenicol was used at 17 μg/ml and kanamycin at 30 μg/ml. Viral progeny was 
reconstituted by transfection of the recombinant BAC plasmid into eukaryotic cells.  
 
8.2.5.1. Shuttle vector cloning  
The first step in the generation of recombinant viruses is the construction of a recombination 
plasmid (shuttle plasmid) containing the desired mutation(s) flanked by sequences homologous to 
the integration site (2 to 3 kb on each side). Mutations in ORF73 gene were introduced by PCR 
(section 8.2.2) using pCMV-Myc-mLANA plasmid as a template. pCMV-Myc constructs encoding 
mLANA mutants were digested with the appropriate restriction endonucleases (section 8.2.3.1.) to 
isolate the fragments harbouring the desired mutations. These fragments were inserted into the 
BamHI-G MuHV-4 genomic fragment (coordinates 101,654 to 106,903) cloned in pBamG plasmid 
(section 8.1.5.2), digested with the same restriction endonucleases as the insert. Inserts in pBamG 
constructs were then subcloned into a BamHI-G MuHV-4 genomic fragment cloned in pST76K-SR 
plasmid (BamHI-G shuttle plasmid), using BamHI restriction sites (section 8.2.3.2).  
 
8.2.5.2. BAC mutagenesis in E. coli  
Recombinant shuttle plasmids were transformed into E. coli strain DH10B containing MuHV-4 
BAC (Adler et al., 2000) or MuHV-4 M3-Luc/ORF50-eGFP BAC (Milho et al., 2009). To generate 
revertant viruses, the wild-type BamHI-G pST76K-SR shuttle plasmid was transformed into DH10B 
cells containing each of the mutant BAC genomes. Bacteria were plated on LB plates containing 
kanamycin (shuttle plasmid resistance marker) and chloramphenicol (BAC plasmid resistance 
marker) and incubated ON at 30ºC, since shuttle vector has a temperature-sensitive replication 
mode. The shuttle plasmid encodes the RecA protein, which promotes complete integration of the 
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shuttle plasmid into the viral BAC genome by homologous recombination (Adler et al., 2003). 
Bacteria containing the cointegrate were selected by incubation ON at 43ºC on LB plates 
containing kanamycin and chloramphenicol. Clones were replated on LB plates containing 
chloramphenicol and grown for one day at 30ºC. Under these conditions, cointegrates can 
spontaneously resolve by homologous recombination (bacteria are RecA+ at 30ºC) to either wild-
type or mutant BAC plasmid. Bacteria harbouring resolved cointegrates were selected by replating 
on LB plates containing chloramphenicol and 5% sucrose (counterselection against SacB encoded 
by the shuttle plasmid) and grown at 30ºC (selection for sucrose-resistance works best at 30ºC). 
Finally, colonies were plated in parallel on kanamycin and chloramphenicol-containing LB plates 
and grown ON at 37ºC. Chloramphenicol-resistant kanamycin-sensitive clones were characterized 
by PCR and subsequent sequencing or restriction endonuclease digestion to identify the mutant 
clones (sections 8.2.1.4, 8.2.1.6 and 8.2.2). BAC plasmids from mutant clones were isolated by 
small or large scale BAC plasmid preparations (section 8.2.1.2). The structure and integrity of the 
viral genome was verified by digestion of BAC DNA with BamHI and EcoRI restriction enzymes 
(section 8.2.1.4) and analysis of the resulting restriction patterns by agarose gel electrophoresis 
(section 8.2.1.5).  
 
8.2.5.3. Virus reconstitution 
Mutant or revertant BAC DNA was transfected into BHK-21 cells using X-tremeGENE HP DNA 
Transfection Reagent (Roche) (section 8.2.4.2). ORF50-deficient recombinant viruses were 
reconstituted by transfection of BAC DNA into 3T3-ORF50 complementing cell lines (section 8.1.3) 
using X-tremeGENE HP DNA Transfection Reagent (section 8.2.4.2) and treating cells with 
doxycycline (1µg/ml). When approximately 50% cpe was visible (after 3-5 days), cells and media 
were harvested and subjected to a freeze-thawing cycle to disrupt the cells. 1 ml aliquots were 
made and stored at -80ºC until further use. The obtained viral aliquots constituted the BAC+ virus 
master stock.  
 
8.2.5.4. Removal of BAC sequences 
BAC cassette contains a gfp gene (Adler et al., 2000), thus the screening of virus containing 
BAC sequences can be performed using green fluorescent protein (GFP) as a marker. 5x105 NIH-
3T3-CRE cells were infected with 0.3-10 µl of the obtained BAC+ master stock diluted in 750 µl of 
complete DMEM (section 8.2.8.1) to remove the loxP-flanked BAC cassette. Virus was allowed to 
adsorb to cells in 6-well plates for 1 h at 37ºC and then 2 ml of complete DMEM was added. Cell 
cultures were incubated at 37ºC until viral plaques appeared (3-4 days). Viral plaques were 
analyzed by fluorescence microscopy and, if GFP-negative, cells and media were harvested by cell 
scraping and frozen-thawed. The obtained BAC+/- master stock was then used to infect fresh NIH-
3T3-CRE cells as described above. Wells containing only GFP-negative viral plaques were 
selected and cells and media were harvested by cell scraping and frozen-thawed. 800 μl aliquots 
were made and constituted the recombinant virus BAC- master stock. 
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ORF50-deficient recombinant viruses were not passed through NIH-3T3-CRE cells, therefore 
retaining the loxP-flanked BAC cassette. 
 
 
8.2.6. Construction of recombinant baculoviruses 
Recombinant baculoviruses were derived from YFP-expressing AcNPV baculovirus genome 
cloned as a BAC (EMBacY) (Bieniossek et al., 2008; Trowitzsch et al., 2010) (section 8.1.5.4). 
Recombinant baculoviruses were engineered using MultiBac system, a Tn7 transposition-based 
approach, developed by Dr I. Berger at EMBL Grenoble (Berger et al., 2004; Bieniossek et al., 
2008; Trowitzsch et al., 2010; Vijayachandran et al., 2011). Kanamycin was used at 50 μg/ml, 
tetracycline at 24 μg/ml, gentamicin at 10 μg/ml, X-Gal at 100 µg/ml and IPTG at 1 mM. 
Baculoviruses were reconstituted by transfection of the recombinant EMBacY plasmid into Sf21 
insect cells.  
 
8.2.6.1. Codon optimization of ORF73 gene 
To achieve higher levels of mLANA expression in Sf21 cells, the ORF73 gene sequence was 
optimized for codon usage in insect cells. Codon optimization was performed by GenScript 
company, using OptimumGene algorithm. 63% of ORF73 codons were modified and the optimized 
gene was delivered in pUC57 plasmid. Two codon optimized ORF73 constructs were engineered 
(Figure 6.1): pUC57-GST-His-mLANA and pUC57-His-mLANA, encoding mLANA with a N-
terminus GST-8xHis-tag or 8xHis-tag, respectively. Each tag is preceded by a TEV cleavage site 
and followed by a PreScission protease cleavage site. Both plasmids contain engineered BstEII 
and RsrII restriction sites upstream and downstream of the optimized sequence, respectively. 
 
8.2.6.2. Subcloning of GST-His-mLANA and His-mLANA inserts into pPBac 
plasmid 
GST-His-mLANA and His-mLANA coding sequences cloned into pUC57 were subcloned into 
pPBac plasmid (section 8.1.5.4), using BstEII and RsrII restriction sites, as described in detail in 
section 8.2.3.3. 
 
8.2.6.3. Generation of recombinant EMBacY plasmids 
pPBac-GST-His-mLANA or pPBac-His-mLANA plasmids were transformed into E. coli 
DH10EMBacY containing baculovirus genome cloned as a BAC (EMBacY) (Bieniossek et al., 
2008; Trowitzsch et al., 2010). Transformation was performed by electroporation, as described in 
section 8.2.3.5, and bacteria were incubated ON at 37ºC with vigorous shaking. On the following 
day, bacteria were streaked into LB agar plates supplemented with kanamycin, tetracycline, 
gentamicin, X-Gal and IPTG in 10-fold dilution series (1:1 to 1:1000), plating 135 µl of each dilution. 
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Inoculated plates were incubated ON at 37ºC and, on the next day, white and blue colonies were 
obtained. White colonies contain the region between Tn7L and Tn7R of pPBac plasmid (including 
the heterologous insert and gentamicin-resistance marker) inserted into the Tn7 attachment site, 
thereby disrupting the lacZα gene in EMBacY and resulting in loss of blue colour phenotype. For 
each transformation, eight white colonies and one control blue colony were picked, streaked into 
LB agar plates supplemented with kanamycin, tetracycline, gentamicin, X-Gal and IPTG and 
incubated ON at 37ºC to confirm the colour. Two white colonies per transformation were separately 
inoculated into 2 ml of LB broth containing kanamycin, tetracycline and gentamicin, and 
recombinant EMBacY plasmids were isolated as described in section 8.2.1.2.  
 
8.2.6.4. Baculovirus reconstitution 
Recombinant baculoviruses were reconstituted by transfection of recombinant EMBacY DNA 
into Sf21 cells, using FuGENE 6 DNA Transfection Reagent (Roche) (section 8.2.4.2). Transfected 
Sf21 cell cultures were incubated at 27ºC for 48 h and then supernatants were harvested. This 
constituted the V0 stock, which was stored at 4ºC protected from light until further use. 
 
 
8.2.7. Animal experiments 
8.2.7.1. Ethics statement 
This study was carried out in strict accordance with the recommendations of the Portuguese 
official Veterinary Directorate (Portaria 1005/92). The Portuguese Experiments on Animal Act 
strictly comply with the European Directive 2010/63/EU and follow the Federation of European 
Laboratory Animal Science Associations (FELASA) guidelines on laboratory animal welfare. Animal 
experiments were approved by the Portuguese official veterinary department for welfare licensing 
(protocol AEC_2010_017_PS_Rdt_General) and by the Instituto de Medicina Molecular Animal 
Ethics Committee. 
 
8.2.7.2. Mice infection 
Female BALB/c and C57BL/6 mice (Charles Rivers Laboratories International) were delivered 
to Instituto de Medicina Molecular animal facility at least four days before infections were carried 
out. 6 to 8-week old mice were inoculated intranasally with 104 plaque forming units (PFU) of 
MuHV-4 or MuHV-4 recombinants. All virus inoculations were performed in 20 μl of phosphate-
buffered saline (PBS) under the effect of isofluorane anaesthesia. At different time points after 
infection, mice were sacrificed by CO2 inhalation, and lungs or spleens were removed and 
processed for subsequent analysis. 
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8.2.8. MuHV-4 virus assays 
8.2.8.1. Viral infection of cell cultures 
Cells were seeded in tissue culture flasks or plates and grown to semi-confluence for low 
multiplicity of infection (MOI) or to confluence for high MOI. Cell monolayers were adsorbed with 
virus suspension in 20% of the final volume of culture medium for 1 h at 37ºC, then covered with 
the remaining 80% of medium and incubated in a tissue culture incubator at 37ºC with 5% CO2, for 
the appropriate time.  
For infection with ORF50-deficient recombinant viruses, 3T3-ORF50 cells were seeded in 
tissue culture flasks or plates and grown to semi-confluence. Cell monolayers were adsorbed with 
virus suspension in 20% of the final volume of culture medium for 2 h at 37ºC, then covered with 
the remaining 80% of medium (DMEM complete containing doxycycline at 1 µg/ml of the final 
volume of culture medium) and incubated in a tissue culture incubator at 37ºC with 5% CO2, for the 
appropriate time. 
 
8.2.8.2. Virus working stocks 
Virus working stocks were grown by infection of BHK-21 cells at low MOI (0.001 PFU/cell) in 
175 cm2 culture flasks. When approximately 50% cpe was visible (4-5 days), cells and 
supernatants were transferred to 50 ml tubes and centrifuged at 500 x g for 5 min at 4ºC. Cell-
associated virus was resuspended in 2 ml of supernatant, subjected to freeze-thawing, and kept at 
-80ºC in 200 μl aliquots. Supernatant-associated virus was centrifuged at 15,000 x g for 2 h at 4ºC 
and pellet was resuspended in 2 ml of fresh complete GMEM medium. 100 μl aliquots were made 
and stored at -80ºC. Virus titres were determined in duplicates by suspension assay (section 
8.2.8.4).  
ORF50-deficient recombinant viruses working stocks were grown by infection of 3T3-ORF50 
cells at low MOI (0.01 PFU/cell) in 175 cm2 culture flasks (4 flasks per virus), in the presence of 
doxycycline (1 µg/ml). When approximately 60% or more cpe was visible (4-5 days), the flasks 
were frozen at -80ºC, then thawed and centrifuged at 500 x g for 5 min at 4ºC to remove cell 
debris. The supernatant was then centrifuged at 16,000 x g for 1 h 30 min at 4ºC to pellet the virus, 
and the pellet was resuspended in 1.5 ml of fresh complete DMEM medium. 100 μl aliquots were 
made and stored at -80ºC. Virus titres were determined in duplicates by suspension assay (section 
8.2.8.4). 
 
8.2.8.3. In vitro multi-step growth curves 
Low MOI growth curves were performed on confluent cell monolayers in 24-well plates. One 
day prior to infection, 5x104 BHK-21 cells were plated per well in a 24 well-plate. BHK-21 cells were 
infected at a MOI of 0.01 PFU/cell, in 200 μl of complete GMEM, and virus was allowed to adsorb 
for 1 h at 37ºC. Cells were washed in PBS and 1 ml of fresh complete GMEM was added. At each 
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time point after infection (0, 24, 48, 72, 96 and 120 h), cells and supernatants were harvested, 
subjected to freeze-thawing and kept at -80ºC. Virus titres were determined in duplicates by 
suspension assay (section 8.2.8.4). 
 
8.2.8.4. Plaque assay (suspension assay) 
Virus stocks, in vitro multi-step growth curves and infectious virus in the lung and spleen of 
infected mice were titrated by plaque assay (or suspension assay). Lungs and spleens were 
dissected into 15 ml tubes containing 5 ml of complete GMEM. Frozen-thawed lungs were 
homogenized in a glass homogenizer and frozen at -80ºC. Spleens were processed as described 
below (section 8.2.8.5) and frozen at -80ºC. Thawed lung homogenates, splenocyte suspensions, 
virus working stocks and each time point of in vitro multi-step growth curves were 10-fold serially 
diluted in 1 ml of complete GMEM. All dilutions were performed in duplicate. 5x105 BHK-21 cells 
were added to the serial 10-fold dilutions of virus suspensions in 1 ml of complete GMEM and 
adsorbed for 1 h at 37ºC with shaking. 3 ml of complete GMEM were added and then the 
suspension was plated out into 6 cm cell culture dishes. After 4 days of incubation at 37ºC with 5% 
CO2 in a humidified incubator, cell monolayers were fixed with 10% formaldehyde in PBS and 
stained with 0.05% toluidine blue. Viral plaques were counted using a magnifier lenses (Olympus 
SZ51 zoom stereo microscope) and virus titres were calculated from the number of viral plaques on 
duplicate dishes.  
ORF50-deficient recombinant viruses stocks were 10-fold serially diluted in 1 ml of complete 
DMEM (in duplicate). 5x105 3T3-ORF50 cells were added to the serial 10-fold dilutions of virus 
suspensions in 1 ml of complete DMEM and adsorbed for 2 h at 37ºC with shaking. 3 ml of 
complete DMEM with doxycycline (1 µg/ml of the final volume of culture medium) were added and 
then the suspension was plated out into 6 cm cell culture dishes. After 5 days of incubation at 37ºC 
with 5% CO2 in a humidified incubator, cell monolayers were fixed with 10% formaldehyde in PBS 
and stained with 0.05% toluidine blue. Viral plaques were counted using a magnifier lenses 
(Olympus SZ51 zoom stereo microscope) and virus titres were calculated from the number of viral 
plaques on duplicate dishes.  
  
8.2.8.5. Infectious centre assay 
Spleens were dissected from mice into 5 ml of complete GMEM and kept on ice during the 
procedure. Single cell suspensions were obtained by mechanical disruption and cell debris was 
removed by filtering through a 100 μl cell strainer. Cells were pelleted by centrifugation at 300 x g 
for 5 min at 4ºC. Red blood cells were lysed by incubation with 1 ml of red blood cell lysis (RBL) 
(154 mM NH4Cl, 14 mM NaHCO3, 1 mM EDTA pH 7.3) for 5 min on ice. 10 ml of complete GMEM 
were added, cells were centrifuged at 300 x g for 5 min at 4ºC and resuspended in 5 ml of fresh 
medium. Cell suspensions were 10-fold serially diluted in 1 ml of complete GMEM (in duplicate) 
and added to 6 cm cell culture dishes containing 5x105 BHK-21 cells in 4 ml of medium. Assays 
were incubated for 5 days at 37ºC in a humidified incubator with 5% CO2. Cell monolayers were 
Materials and Methods  
 
 
133 
fixed with 10% formaldehyde in PBS and stained with 0.05% toluidine blue. Viral plaques were 
counted using a magnifier lenses (Olympus SZ51 zoom stereo microscope) and infectious centres 
were determined from duplicate dishes. 
 
 
8.2.9. Flow cytometry 
8.2.9.1. Staining of splenocytes 
Spleens were pooled from 4-5 animals into 5 ml of 2% FBS in PBS (PBS+2%FBS) and kept 
on ice until mechanical disruption to obtain single splenocyte suspensions. Cell debris was 
removed by filtering through a 100 μl cell strainer and cells were pelleted by centrifugation at 300 x 
g for 5 min at 4ºC. Red blood cells were lysed by incubation with RBL for 5 min on ice. Cell 
suspensions were washed in PBS+2%FBS and centrifuged at 300 x g for 5 min at 4ºC. Blocking 
was performed by incubation with anti-CD16/32 (clone 2.4G2) (BD Pharmingen) for 3 min at 4ºC. 
After washing in PBS+2%FBS and centrifugation, splenocytes were stained by incubation for 30 
min, at 4ºC, in the dark, with the appropriated antibodies diluted in PBS+2%FBS (Table 8.1). 
Unbound antibodies were removed by washing with PBS+2%FBS and centrifugation. Cells were 
resuspended in PBS+2%FBS, filtered through a 40 μl cell strainer and purified by flow cytometry 
(section 8.2.9.2). 
 
8.2.9.2. Purification of germinal centre (GC) B cell populations 
Single cell suspensions of 5 pooled spleens stained with anti-CD19 (clone 1D3) APC-H7 (BD 
Pharmingen), anti-CD95 (clone Jo2) PE (BD Pharmingen) and anti-GL7 T and B cell activation 
marker (clone GL7) eFluor660 (eBioscience) were enriched for the germinal centre (GC) B cell 
population CD19+CD95hiGL7hi using a BD FACSAria Flow Cytometer (BD Biosciences). Cells were 
recovered into 50% FBS in PBS and kept on ice until further use. 
 
 
8.2.10. Limiting dilution analysis of infected splenocytes 
The frequency of viral genome-positive cells was determined by limiting dilution combined with 
real-time PCR. Total single cell splenocyte suspensions or flow activated cell sorting (FACS)-
purified GC B cells (section 8.2.9.2) were 2-fold serially diluted in PBS+2%FBS and 8 replicates 
were made per dilution. Cells were lysed by incubation in lysis buffer (10 mM Tris-HCl pH 8.3, 
0.45% Tween-20, 0.45% NP-40, 3 mM MgCl2, 50 mM KCl and 0.5 mg/mL Proteinase K) at 37ºC 
ON. On the next day, Proteinase K was inactivated by incubation at 95ºC for 5 min. Samples were 
analysed by real-time PCR (section 8.2.10.2) with primer/probe sets specific for M9 viral gene. For 
each dilution, the number of negative PCR reactions, corresponding to a failure to obtain an 
amplification curve during the PCR cycles, was determined. 
Chapter 8 
 
 
134 
8.2.10.1. Statistical analysis of limiting dilution assay 
Statistical analysis of limiting dilution assay to estimate the frequency of virus DNA+ cells was 
performed according to the method developed by Dr S. Marques (Marques et al., 2003). The 
frequency of virus DNA+ cells (f) was calculated according to the single-hit Poison Model (SHPM) 
by maximum likelihood estimation (Bonnefoix et al., 2001). This model assumes that one limiting 
cell of one cell subset is necessary and sufficient for generating a positive response. To evaluate 
the fit of the SHPM to our limiting dilution experiments, a method developed by Bonnefoix et al., 
(2001) was employed. This method consists in modelling the limiting dilution data according to the 
linear log-log regression model fitting the SHPM (− 𝑙𝑜𝑔(𝑙𝑜𝑔(𝜇𝑖)) =  𝑙𝑜𝑔(𝑓) + 𝑙𝑜𝑔(𝑥𝑖)), where 𝜇𝑖 is 
the theoretical fraction of negative wells and 𝑥𝑖 is the number of cells plated in each replicate well 
and checking this model by an appropriate slope test. Being f the frequency of virus DNA+ cells, the 
maximum likelihood of f is the value of f that maximizes the following function: 
𝑙𝑜𝑔(𝐿) =  ∑ [𝑙𝑜𝑔 (
𝑛𝑖!
𝑟𝑖! (𝑛𝑖! − 𝑟𝑖!)
) + 𝑟𝑖 𝑙𝑜𝑔(𝑃𝑖) + (𝑛𝑖 − 𝑟𝑖) 𝑙𝑜𝑔(1 − 𝑃𝑖
𝑘)]
𝑘
𝑖=1
 
where 𝑙𝑜𝑔(𝐿) is the natural logarithm of the likelihood function L, 𝑃𝑖 is given by 𝑃𝑖 = 𝑒𝑥𝑝(−𝑓𝑥𝑖) 
according to the SHPM. 𝑘 is the number of groups of replicate PCR reactions, numbered 𝑖 =
1,2,3, … , 𝑘; 𝑛𝑖 is the number of replicate reactions and 𝑟𝑖 is the number of observed negative PCR 
reactions. The standard error of f was calculated as the square root of the negative reciprocal of 
the second derivate of 𝑙𝑜𝑔(𝐿): 
SE(f) = √
−1
𝑑2 𝑙𝑜𝑔(𝐿)/𝑑𝑓2
 
The 95% confidence interval (CI) of f was calculated as 95% CI(f) = f ± 1.96SE(f). 
 
8.2.10.2. Real-time PCR  
Real-time PCR was performed on a Rotor Gene 6000 (Corbett Life Science) according to 
manufacturer’s instructions, using the fluorescent Taqman methodology. Primer/probe sets specific 
for MuHV-4 M9 gene were used (Table 8.4). Reactions were performed in a final volume of 25 μl, 
containing 2.5 μl of cell lysate, 200 μM of each primer, 300 μM of probe, 1x Platinum Quantitative 
PCR SuperMix-UDG (Invitrogen), 5 mM of MgCl2 and 1x Rox reference dye. Samples were 
subjected to a melting step of 95ºC for 10 min followed by 40 cycles of 15 s at 95ºC and 1 min at 
60ºC. Real-time PCR results were analysed on the Rotor Gene 6000 software. 
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Table 8.4. Primers and probe specific for M9 gene used to detect MuHV-4 DNA. 
Oligonucleotide Sequence (5’-3’) Genomic coordinatesa 
Upper primer GCCACGGTGGCCCTCTA 94,176 – 94,192 
Lower primer CAGGCCTCCCTCCCTTTG 94,140 – 94,157 
Probe 6-FAM-CTTCTGTTGATCTTCC-MGBb 94,159 – 94,174 
aAccording to GenBank accession no NC_001826. 
bOligonucleotide with fluorophore (6FAM) and quencher (MGB) covalently attached to the 5´- and 3´-ends, 
respectively. 
 
 
8.2.11. In situ hybridization 
8.2.11.1. Generation of digoxigenin (DIG) UTP-labelled riboprobes  
Riboprobe used in this study was in vitro transcribed from pEH1.4 plasmid using the DIG RNA 
labelling kit T7/SP6 (Roche), according to manufacturer´s instructions. Briefly, 1 μg of HindIII-
linearized plasmid was transcribed in a 20 μl reaction containing 2 μl of 10x transcription buffer, 2 
μl of 10x NTP labelling mixture, 1 μl of Protector RNase inhibitor and 2 μl of T7 RNA polymerase. 
After 2 h of incubation at 37ºC, template DNA was removed by addition of 2 μl of DNase and 
incubation for 15 min at 37ºC. Reaction was stopped by adding 2 ml of 0.2 M EDTA (pH 8.0). RNA 
was precipitated by addition of 2.5 μl of 4 M LiCl and 75 μl of ice-cold 100% ethanol, and 
incubation at -80ºC for at least 30 min. RNA was centrifuged at 18,000 x g and 4ºC for 15 min, 
supernatant was discarded and pellet was washed with 50 μl of ice-cold 70% ethanol. Pellet was 
resuspended in 100 μl MilliQ water and incubated for 30 min at 37ºC. 20 μl aliquots were made and 
stored at -80ºC until required. Concentration of labelled RNA was analysed by spot test assay, 
according to instructions provided in the DIG RNA labelling kit manual (Roche). 
 
8.2.11.2. Preparation of tissue for in situ hybridization 
Spleens for in situ hybridization were dissected from groups of mice and fixed in 10% formalin, 
ON, at RT. Spleens were then embedded in paraffin in the Histology and Comparative Pathology 
Laboratory of Instituto de Medicina Molecular. Serial 5 μm sections were cut on a Minot Microtome 
Leica RM 2145 and mounted on Superfrost Plus slides (Menzel-Glaser). 
 
8.2.11.3. In situ hybridization 
In situ hybridization was performed as described by Simas et al., 1999. Sections were 
dewaxed in xylene for 20 min, rehydrated through graded ethanol solutions (100% for 5 min, 90%, 
70% and 50% for 2 min each) and finally PBS for 5 min. Sections were then fixed in 0.1% v/v 
glutaraldehyde in PBS for 30 min at 4ºC, washed twice in PBS for 5 min and then digested with 
100 μg/ml of Proteinase K in 20 mM Tris pH 7.5 and 2 mM CaCl2 in dH2O for 8-10 min at 37ºC. 
Sections were rinsed in PBS for 2 min at RT, re-fixed in 0.1% v/v glutaraldehyde for 15 min at 4ºC, 
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rinsed in PBS again for 2 min at RT, then acetylated with fresh 0.25% v/v acetic anhydride in 0.1 M 
triethanolamine pH 8.0 while being stirred for 10 min at RT. Sections were washed in 2x saline 
sodium citrate (SSC) (300 mM NaCl and 30 mM tri-sodium-citrate) for 5 min at 4ºC before being 
dehydrated through graded ethanol (50% to 100%) and left to air dry. 
For 100 μl of probe mix, 2 μl of DIG-labelled riboprobe were mixed with 50 μl of formamide, 5 
μl of sonicated salmon sperm (10 mg/ml) and 5 μl of tRNA (10 mg/ml). Mix was denatured by 
heating for 5 min at 80ºC and then quenched for 5 min on ice. 20 μl of 5x hybridization buffer, 1 μl 
of dithiothreitol (DTT) (100 mM) and 100 U of Protector RNase inhibitor were added with MilliQ 
water to a final volume of 100 μl. 50 μl of probe mix were added to each section, covered with 
parafilm and incubated ON at 55ºC in a humidified incubator. 
After hybridization, probes were washed in 2x SSC and 10 mM Tris pH 7.5 for 15 min at RT 
with stirring and then in 0.1x SSC and 10 mM Tris pH 7.5 for additional 15 min. The stringency 
wash was performed in 30% formamide, 0.1x SSC and 10 mM Tris pH 7.5, for 30 min, at 58ºC. 
Finally sections were rinsed in 0.1x SSC and 10 mM Tris pH 7.5 for 5 min at RT with stirring. 
Hybridized probe was detected with alkaline phosphatase (AP)-conjugated anti-DIG antibody 
(Roche). Sections were rinsed for 5 min, while stirring, in buffer 1 (100 mM Tris pH 7.5 and 150 mM 
NaCl in dH2O), then blocked by incubation in blocking buffer (1% Boehringer Blocking Reagent, 
Roche, in buffer 1) for 30 min at RT. Sections were then dried around the edges and incubated with 
120 μl of anti-DIG-AP antibody (1:750 in blocking buffer) for 1 h at RT in a humidified chamber. 
Unbound antibody was removed by washing twice with buffer 1 for 15 min at RT. 
Bound antibody was revealed by colorimetric detection with nitroblue tetrazolium chloride 
(NBT). Sections were rinsed in buffer 3 (100 mM Tris pH 9.5, 100 mM NaCl and 50 mM MgCl2 in 
dH2O) for 10 min at RT. Colour development was performed in the dark by incubation of sections 
with NBT and X-Phos (Roche) in buffer 3 for at least 2 h. Reaction was stopped by rising in dH2O. 
Sections were counterstained with 10% Mayer´s Haemalum, rinsed in tap H2O and mounted with 
Aquatex (Merck). 
 
 
8.2.12. Episome maintenance assays 
MEF-1 cells were infected with MuHV-4 ORF50-deficient recombinant viruses at a MOI of 3 
PFU per cell in 10-cm dishes at about 80% confluence. Two days after infection, cells were 
trypsinised, counted and seeded at 2x104 or 2x105 cells in a 10-cm dish. On the next day, fresh 
DMEM medium containing mycophenolic acid (MPA) (25 µM) and xanthine (25 µM) was added. 
Resistant clones were picked and, after expansion under continued drug selection, their content in 
viral genomes was analysed in Gardella gels. 
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8.2.13. Protein methods 
8.2.13.1. Reporter gene assays 
For NF-κB reporter gene assays, 2x105 HEK 293T cells were plated per well in 12-well cell 
culture plates, in 1 ml of complete DMEM. On the next day, cells were transiently transfected with 
150 ng of reporter plasmid (pC45) and 1 μg of plasmid encoding mLANA (WT or mutants). A 
Renilla luciferase expression plasmid (20 ng) was used to normalize luciferase activity. 
Transfections were performed in triplicate. After 48 h in culture, cells were left unstimulated or 
stimulated with tumour necrosis factor (TNF)-α (50 ng/ml) for 7 h. Cells were washed in PBS and 
lysed in 200 μl of passive lysis buffer (Promega). Firefly luciferase and Renilla luciferase activities 
were assayed using Dual-Luciferase Reporter Assay System (Promega). Light emission in each 
sample was quantified in a luminometer. Results are shown as fold induction relative to luciferase 
activity measured in unstimulated cells. SEM was calculated from triplicates from two independent 
experiments. 
For Myc reporter gene assays, 2x105 HEK 293T cells were plated per well in 12-well plates, in 
1 ml of complete DMEM. On the next day, cells were transiently transfected with 500 ng of reporter 
plasmid (pMyc-TA-Luc) and 1 μg of plasmid encoding mLANA (WT or mutants). A Renilla 
luciferase expression plasmid (20 ng) was used to normalize luciferase activity. Transfections were 
performed in triplicate. After 48 h in culture, cells were washed in PBS and lysed in 200 μl of 
passive lysis buffer (Promega). Firefly luciferase and Renilla luciferase activities were assayed 
using Dual-Luciferase Reporter Assay System (Promega). Light emission in each sample was 
quantified in a luminometer. Results are shown as fold induction relative to luciferase activity 
measured in cells not expressing mLANA. SEM was calculated from triplicates from two 
independent experiments. 
In all reporter gene assays, representative aliquots of the total cellular lysates were used to 
detect appropriate expression of mLANA by Western-blot (section 8.2.13.6). 
 
8.2.13.2. Immunoprecipitations  
3x106 HEK 293T cells were plated in 10 cm cell culture dishes, in 10 ml of complete DMEM. 
On the next day, cells were transiently transfected with expression plasmids encoding ElonginC (2 
μg) or Cullin5 (4 μg), and mLANA (WT or mutants) (2 μg). After 48 h in culture, cells were rinsed in 
ice-cold PBS and disrupted in 500 µl of ice-cold lysis buffer containing 10 mM Tris–HCl (pH 7.5), 
150 mM NaCl, 1% Triton X-100, 1 mM NaF, 100 mM Na3VO4 and a cocktail of protease inhibitors 
(cOmplete, Roche). Lysates were harvested by cell scraping, incubated on ice for 10 min and 
clarified by centrifugation at 18,000 x g for 15 min at 4ºC. Supernatants were harvested into new 
tubes and 50 µl were removed for analysis of protein expression in total cellular lysates. The 
remaining volume of supernatant (approximately 450 µl) was incubated with 1 µg of antibodies to 
ElonginC or Cullin5 for 2 h at 4ºC, with rotation. Immunecomplexes were recovered by incubation 
with Protein G-Conjugated Sepharose Beads (GE Healthcare) (50 µl of beads:lysis buffer slurry) for 
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1 h at 4ºC, with rotation. Next, samples were centrifuged at 18,000 x g for 3 min at 4ºC and 
supernatants were discarded. Beads were washed with 1 ml of ice-cold lysis buffer and harvested 
by centrifugation at 18,000 x g for 1 min at 4ºC. After three washes, beads were collected by 
centrifugation at 18,000 x g for 3 min at 4ºC. Proteins were eluted in reducing Laemmli’s sample 
buffer (section 8.2.13.4) by incubation at 100ºC for 10 min, resolved by sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) (section 8.2.13.4), transferred to nitrocellulose 
(section 8.2.13.5), and immunoblotted with the appropriate antibodies (section 8.2.13.6).  
 
8.2.13.3. Poly-ubiquitination assays 
Levels of ubiquitinated p65 or Myc were determined by pull-down using Ni-nitrilotriacetic acid 
(NTA) agarose beads (Qiagen). 3x106 HEK 293T cells were plated in 10 cm dishes, in 10 ml of 
complete DMEM. On the following day, cells were transiently transfected with expression plasmids 
encoding p65 (2 μg) or Myc (2 μg), mLANA (WT or mutants) (2 μg), and His6-ubiquitin (4 μg). After 
48 h in culture, cells were rinsed in ice-cold PBS and lysed in 750 µl of ice-cold urea lysis buffer 
containing 8 M urea, 50 mM Tris-HCl (pH 7.5), 300 mM NaCl, 1% Triton X-100, 10 mM imidazole, 1 
mM Na3VO4 and a cocktail of protease inhibitors (cOmplete, Roche). Lysates were harvested by 
cell scraping, incubated on ice for 10 min and clarified by centrifugation at 18,000 x g for 30 min at 
4ºC. Cell debris was discarded and 50 µl of supernatant was removed for analysis of protein 
expression in total cellular lysates. The remaining volume of supernatant was incubated with 50 µl 
of Ni-NTA beads:lysis buffer slurry for 2 h at 4ºC, with rotation. After incubation, samples were 
centrifuged at 18,000 x g for 3 min at 4ºC and supernatants were discarded. Beads were washed 
with 1 ml of ice-cold urea lysis buffer and harvested by centrifugation at 18,000 x g for 1 min at 4ºC. 
After three washes, beads were collected by centrifugation at 18,000 x g for 3 min at 4ºC. Proteins 
were eluted in reducing Laemmli’s sample buffer (section 8.2.13.4) by incubation at 100ºC for 10 
min, resolved by SDS-PAGE (section 8.2.13.4), transferred to nitrocellulose (section 8.2.13.5), and 
immunoblotted with the appropriate antibodies (section 8.2.13.6). 
 
8.2.13.4. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis 
(SDS-PAGE)  
Protein samples prepared in Laemmli’s sample buffer (50 mM Tris-HCl pH 6.8, 10% glycerol, 
2% SDS, 5% β-mercaptoethanol, 0.1% bromophenol blue) and heated at 100ºC for 5-10 min were 
separated through sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE in 0.75-
1.5 mm mini-slab gels of Bio-Rad Miniprotean II Electrophoresis System. Resolving gel was 
prepared with 8-12% polyacrylamide (acrylamide:bis-acrylamide 37.5:1, Bio-Rad), 375 mM Tris-
HCl pH 8.8, 0.1% SDS, 0.1% ammonium persulfate (APS) and 0.04% tetramethylethylenediamine 
(TEMED). Stacking gel was prepared with 5% polyacrylamide, 125 mM Tris-HCl pH 6.8, 0.1% 
SDS, 0.1% APS and 0.1% TEMED. Electrophoresis was performed in running buffer (25 mM Tris-
base, 192 mM glycine and 0.1% SDS), at 120 V until maximal resolution of protein bands. 
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8.2.13.5. Transfer of proteins into nitrocellulose membranes 
After separation by SDS-PAGE as described above, proteins were transferred to a 
nitrocellulose membrane (Protran, GE Healthcare) using a Trans-Blot Cell (Bio-Rad), assembled 
according to manufacturer’s instructions. Transfer was performed in standard transfer buffer (25 
mM Tris-base, 200 mM glycine and 20% methanol) for 1 h 30 min at constant current of 250 mA. 
Transferred proteins in the membrane were stained with Ponceau S (Sigma-Aldrich) for 1 min and 
then the membrane was washed with PBS-Tween (PBS-T) (PBS with 0.05% Tween 20) for 5-10 
min with stirring to remove Ponceau S. 
 
8.2.13.6. Western-blot 
Following transfer, the membrane was incubated with blocking buffer (5% skimmed milk 
powder in PBS-T) for 1 h at RT on a rocking platform. The protein of interest was detected by 
incubating the membrane with the appropriate primary antibody (Table 8.1), diluted in blocking 
buffer according to manufacturer’s instructions, for 1-2 h at RT or ON at 4ºC, on a rocking platform. 
The membrane was then washed with PBS-T (three washes, each involving 5-10 min incubation on 
a rocking platform at RT) to remove unbound primary antibody. Protein-primary antibody 
interactions were detected by incubation of the membrane with a HRP-conjugated secondary 
antibody specific for the species where primary antibody was produced (Table 8.1 and section 
8.1.2.2), diluted 1:5000 in blocking buffer, for 30 min-1 h at RT on a rocking platform. The 
membrane was then washed as described above, and the protein bands were visualized by 
chemiluminescence using the SuperSignal West Pico Chemiluminescent Substrate (Thermo 
Scientific), according to the manufacturer’s recommendations. Light signal was detected on an 
autoradiography film (Fujifilm) exposed for the appropriate time and revealed using Curix 60 (Agfa).  
 
 
8.2.14. mLANA expression in insect cells using baculovirus (feasibility study) 
The feasibility study of mLANA expression in insect cells using baculovirus MultiBac system 
(Berger et al., 2004; Bieniossek et al., 2008; Trowitzsch et al., 2010; Vijayachandran et al., 2011) 
was performed by me at Eukaryotic Expression Facility at EMBL Grenoble, under the supervision 
of Dr I. Berger, Frederic Garzoni and Alice Aubert. 
8.2.14.1. Processing of samples for SDS-PAGE and YFP fluorescence 
measurement 
Samples were sonicated for 2-5 sec at medium setting and 50 µl of sonicated sample were 
removed for whole cell extract (WCE) analysis. The remaining sample was centrifuged for 3 min at 
18,000 x g and 4ºC, and 50 µl of supernatant were removed for soluble lysate (SL) analysis. The 
remaining supernatant (approximately 400 µl) was used for YFP fluorescence measurement, using 
a fluorescence spectrophotometer. WCE and SL samples were boiled in Laemmli’s sample buffer 
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at 95ºC for 10 min. Samples were then resolved by SDS-PAGE (section 8.2.13.4) and either 
stained with Coomassie Blue (section 8.2.14.2) or transferred to nitrocellulose (section 8.2.13.5) 
and immunoblotted (section 8.2.13.6) with anti-mLANA antibody to detect expression of GST-His-
mLANA and His-mLANA. 
 
8.2.14.2. Coomassie Blue staining 
To visualize proteins directly in polyacrylamide gels, gels were covered with a Coomassie Blue 
solution (0.1% Coomassie brilliant blue R-250, 40% methanol and 10% acetic acid) for 30 min to 3 
h at RT, with stirring. Staining solution was removed and gels were rinsed in destaining solution 
(30% methanol, 10% acetic acid) for 10-15 min at RT, with stirring, until excess stain was removed. 
Destaining solution was changed and left at RT, with stirring, until proper level of destaining was 
achieved. 
 
8.2.14.3. Baculovirus amplification and small-scale protein expression 
To amplify baculovirus stocks expressing GST-His-mLANA and His-mLANA, 3 ml of V0 stock 
were added to flasks containing 25 ml of Sf21 cells at 0.5x106 cells/ml. Infected suspension 
cultures were maintained at 27ºC with shaking at 90 rpm and cells were counted every 24 h using 
a hemocytometer. If cell density was lower than 1x106 cells/ml, cell culture was not diluted; if cell 
density was higher than 1x106 cells/ml, cell culture was diluted at 0.5-1x106 cells/ml in fresh 
HyClone medium, filling cell culture flasks with no more than 10% of the total volume of the flask to 
allow sufficient aeration for optimal cell growth. One day after cell proliferation arrest occurred, 
1x106 cells were harvested and centrifuged for 2 min at 18,000 x g and 4ºC. Supernatant was 
discarded and cell pellet was resuspended in 500 µl of PBS by pipetting up and down. Samples 
were processed for YFP fluorescence measurement as described in section 8.2.14.1. 48 h after 
proliferation arrest, cell culture was centrifuged at 120 x g for 3 min at 27ºC and supernatant was 
harvested, constituting the V1 amplified virus stock. V1 stock was stored at 4ºC protected from light 
and cell pellet was gently resuspended in 50 ml of fresh medium. Cells were kept in culture at 27ºC 
with shaking at 90 rpm and 1x106 cells were sampled every 24 h until YFP fluorescence reached a 
plateau (typically after 3-4 days). At that point, cell culture was centrifuged at 120 x g for 3 min, 
supernatant was discarded and cell pellet was stored at -20ºC. mLANA expression was then 
analysed by SDS-PAGE, followed by Coomassie Blue staining and Western-blot (section 8.2.14.1). 
A schematic diagram of this small-scale protein expression protocol is shown in Figure 6.2. 
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